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Abstract 
Diabetes mellitus (DM) is an established cause of increased mortality. Most deaths linked 
to DM are attributable to cardiovascular disease, and hyperglycaemia alone is not 
sufficient to explain the increased cardiovascular risk associated with DM. It is accepted 
that insulin resistance, the principal underlying cause of the most common form of DM, is 
independently linked to CVD. Prior research demonstrates insulin resistance is associated 
with excessive production of reactive oxygen species (ROS), in part via the enzyme NADPH 
oxidase 2 (NOX2). We hypothesised that reduction of NOX2-derived ROS represents a 
translationally promising strategy to improve the diminished vascular repair and 
regeneration observed in insulin resistance. This project explores the effect of NOX2 
inhibition on angiogenesis and vascular repair in murine models of whole-body and 
endothelial-specific insulin resistance. 
Mice with haploinsufficiency of the insulin receptor (IRKO), and those expressing a kinase 
dead human insulin receptor transgene in the endothelium (ESMIRO), were bred with 
NOX2 deficient mice. NOX2 knockdown was associated with significant improvement in 
vascular repair following arterial injury in ESMIRO mice. Subsequent work provided two 
potential explanations: improved endothelial cell migration, and an increased abundance 
of circulating progenitor cells. Pharmacological NOX2 inhibition partly recapitulated these 
findings in vitro, as treatment of insulin resistant human umbilical vein endothelial cells 
with the NOX2 inhibitor GP91-ds tat was associated with improved cell migration. 
Whilst this project yielded a number of promising findings, it also highlighted pitfalls 
associated with manipulation of ROS. We corroborated two existing concerns relating to 
NOX2 inhibition: the potential to compromise immune function, and the risk of inciting a 
pro-inflammatory state. Although NOX2 remains a potentially suitable target for 
therapeutic intervention, greater understanding of NOX2 biology is required. We hope the 
work carried out in this project can be built upon to facilitate that understanding, 
ultimately generating novel therapeutic agents. 
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Chapter 1 Introduction 
Due to an alarming growth in prevalence, Diabetes Mellitus (DM) has attained the status of 
a global epidemic, with an estimated 382 million sufferers in the year 2013. Various 
factors, including the increasing prevalence of obesity and the ageing of the population, 
mean that this figure is forecast to continue its inexorable rise, with a current projection of 
592 million by the year 2035 [1]. 
As well as being a cause of significant morbidity, DM is also an established cause of 
increased mortality and reduced life expectancy [2]. The Framingham Study [3] was one of 
the first to highlight the relationship between DM and an increased risk of cardiovascular 
disease (CVD), and it is now recognised that most deaths linked to DM are attributable to 
CVD. Whilst great advances have been made in CVD prevention amongst the general 
population, outcomes remain poor for patients with DM [4]. Sufferers of the disease are 
twice as likely as healthy individuals to experience complications of CVD such as 
myocardial infarction (MI) or stroke [5], and they tend to do so approximately 15 years 
prematurely [6].  
Whilst DM is usually diagnosed on the basis of elevated blood glucose, hyperglycaemia 
alone is not sufficient to explain the increased cardiovascular (CV) risk associated with the 
disease [7]. Type 2 diabetes mellitus (T2DM), by far the predominant form of the disease, 
is preceded by a prolonged pre-diabetic stage, when in spite of subclinically abnormal 
blood glucose metabolism, CV risk is still significantly elevated [8]. This is thought to be due 
to an aggregation of cardiovascular risk factors, referred to as the metabolic syndrome, 
which may be underpinned by resistance to the vascular and metabolic effects of insulin. 
Insulin resistance is implicated in both the initiation and progression of atherosclerosis, the 
key pathological process responsible for CVD. Whereas previously atherosclerosis was 
thought to result simply from lipid accumulation in arterial walls, it is now recognised as a 
much more complex and nuanced process, better characterised as a chronic inflammatory 
disease of blood vessels [9]. The earliest manifestation of atherosclerosis is endothelial 
dysfunction [10], and insulin resistance has been demonstrated to be instrumental in its 
development via disruption of endothelial nitric oxide (NO) production [11]. Insulin 
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resistance may also facilitate the progression of atherosclerosis by impairing endogenous 
vascular repair processes, which can retard atherogenesis and promote recovery of 
damaged endothelium in the context of vascular injury [12, 13]. 
One of the characteristics of insulin resistant states is excessive production of reactive 
oxygen species (ROS) [14], which has been demonstrated to be a key pathogenic process in 
endothelial dysfunction [15]. Recent work has also highlighted the critical role of ROS as 
signalling molecules in the process vascular repair [16]. ROS could therefore form a target 
for the prevention and treatment of insulin resistance-associated cardiovascular disease, a 
concept which forms the basis of this thesis. 
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1.1 Insulin signalling  
Insulin is a peptide hormone whose amino acid sequence was first identified in 1952. Its 
structure comprises A & B peptide chains of 21 and 30 amino acids respectively, linked by 
disulphide bonds. Its synthesis takes place in the β cells situated within the pancreatic 
islets of Langerhans, and the first step is the formation of the precursor molecule 
preproinsulin. Removal of a signal peptide results in the formation of proinsulin, which is 
stored in secretory vesicles until enzymatic action facilitates a further cleavage into insulin 
and C peptide [17].  
Insulin secretion via exocytosis into the circulation is triggered by multiple stimuli, the 
principal being elevated circulating concentrations of glucose. Exposure of the β cells to 
glucose results in intracellular glucose transport via GLUT1 and 2, leading to the generation 
of ATP. The increased intracellular ATP/ADP ratio causes closure of plasma membrane ATP-
dependant K+ channels and therefore membrane depolarisation. This depolarisation 
results in opening of voltage-gated Ca2+ channels, allowing an influx of calcium and thereby 
triggering insulin secretion [18].  
1.1.1 Physiological insulin signalling 
Insulin mediates its actions via binding to its cognate tyrosine kinase receptor (IR). The IR is 
a transmembrane structure which consists of two α and two β glycoprotein subunits linked 
together by disulphide bonds. Insulin binds to the receptor’s extracellular α subunit, 
resulting in a conformational change which allows ATP to bind to the β subunit’s 
intracellular domain [19]. The binding of ATP triggers receptor autophosphorylation, 
enabling the receptor’s kinase activity toward intracellular protein substrates [20]. This 
results in tyrosine phosphorylation of various docking proteins, including the insulin 
receptor substrates (IRS) 1 and 2. Multiple downstream signalling cascades are 
subsequently activated, the principal two being the phosphoinositide 3-kinase (PI3K)/ Akt 
and mitogen-activated protein kinase (MAPK) pathways (figure 1).  
PI3K/Akt pathway 
Phosphorylated IRS binds and activates PI3K, which then generates phosphatidylinositol 
triphosphate (PIP3). PIP3 stimulates membrane localisation of phosphoinositide dependant 
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kinase-1 (PDK-1), which phosphorylates Akt at threonine 308, resulting in its partial 
activation. Completion of Akt activation is achieved by phosphorylation at serine 473, 
mediated by the mammalian target of rapamycin-2 complex (mTorc2). The resulting 
effects of this cascade depend on the tissue within which it takes place; in metabolic 
tissues, Akt activation promotes GLUT4 translocation to the cell membrane and 
intracellular glucose uptake. In vascular endothelial cells (ECs), a major effect is to activate 
the enzyme endothelial nitric oxide synthase (eNOS) which catalyses NO production [21].  
MAPK pathway 
The MAPK pathway is dependent on Ras interaction with the Src-homology domain 2 (SH2) 
of the Shc adaptor protein. Activation of this pathway is responsible for the mitogenic 
effects of insulin, such as vascular smooth muscle cell (VSMC) proliferation and migration, 
as well as production of the vasoconstrictor peptide endothelin 1 (ET-1) [22]. 
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Figure 1. Insulin signalling cascade 
Binding of insulin to its receptor triggers a series of intracellular signalling cascades resulting in activation of Akt 
and MAPK. The Akt pathway stimulates GLUT4 translocation in metabolic tissue and eNOS phosphorylation in 
vascular ECs, whilst the MAPK pathway mediates the mitogenic effects of insulin and the production of ET-1.  
IRS: Insulin receptor substrate; PI3K: phosphoinositide 3-kinase; PDK1: phosphoinositide dependant kinase-1; 
mTorC2: mammalian target of rapamycin-2 complex; Grb2: growth factor receptor-bound protein 2; MAPK: 
mitogen-activated protein kinase; eNOS: endothelial nitric oxide synthase; EC: endothelial cell; VSMC: vascular 
smooth muscle cell; ET-1: endothelin 1. Adapted from Cubbon et al [21].  
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1.1.2 Insulin resistance 
The term insulin resistance can denote an impairment of downstream signal transduction 
when insulin binds to its receptor, which culminates in reduced glucose uptake in 
metabolic tissues. However the deleterious effects of insulin resistance go beyond glucose 
homeostasis and also include dyslipidaemia, inflammation and a pro-thrombotic tendency 
[23]. A number of studies have demonstrated insulin resistance to be an independent risk 
factor for CVD [24, 25] and this has generated significant interest in elucidating the 
mechanisms by which it develops. The initiation and progression of insulin resistance is 
now understood to be a multi factorial phenomenon, with contributions from both genetic 
and modifiable environmental factors. The following section is a brief synopsis of a few of 
the putative contributory facets.  
Naturally occurring mutations of the IR rare and usually result in a syndrome of extreme 
insulin resistance such as leprechaunism. Genomic analysis has demonstrated that 
mutations of the IR do not significantly contribute to the pathophysiology of T2DM or 
obesity [26]. Diminution of IR abundance would seem to be a more important contributing 
factor in the development of insulin resistance and has been noted in muscle and liver 
tissue from patients with T2DM as well as muscle and adipocyte tissue from obese subjects 
[26]. Murine models of reduced IR expression have proved useful in examining the 
sequelae of insulin resistance and will be discussed shortly. 
Aberrances downstream from the IR are a recognised contributor to insulin resistance, an 
example being polymorphisms of IRS-1, a crucial mediating protein in the insulin signalling 
cascade. The most commonly occurring of these is G972R, which is found in Caucasian 
populations with a prevalence of 5.8%. Interestingly the prevalence amongst patients with 
T2DM is significantly higher, at 10.7% [27, 28]. Studies exploring the molecular effects of 
this sequence change in IRS-1 have demonstrated a defect in binding of the p85 subunit of 
PI3K to IRS-1 and a 36% decrease in IRS-1–associated PI3-kinase activity [29]. 
Polymorphisms have also been identified of PI3K, a common example of which involves the 
p85α subunit. The mutation has been identified in 31% of Caucasians in heterozygous 
form, and 2% in homozygous form where it results in a 32% decrease in insulin sensitivity 
in an intravenous glucose tolerance test [30]. 
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Whilst genetic aberrations, such as those outlined above, can be important in the 
development of insulin resistance, there is little doubt that on a population level 
environmental factors such as obesity and ageing are the most significant contributors. 
Adipose tissue is understood to play an important role in the initiation of insulin resistance 
via alterations in levels of circulating free fatty acids (FFAs), promotion of inflammation 
and perturbation of the balance of adipokine secretion.  Expansion of adipose tissue 
secondary to nutrient excess leads to increased levels of circulating free fatty acids (FFAs) 
which can directly impair insulin signalling. In human volunteers, intravenous infusion of a 
lipid emulsion causes a 10-fold rise in plasma FFAs, resulting in a 22% decrease in 
peripheral glucose uptake in the setting of hyperinsulinaemia [31]. The mechanism by 
which FFAs can impair insulin signalling remains incompletely understood, but members of 
the protein kinase C (PKC) family appear to play an important role by acting as lipid-sensing 
molecules which can then respond by using their kinase activity to alter cellular events 
[32]. Studies carried out in the 1980s demonstrated that activation of PKC using phorbol 
acetate could induce insulin resistance [33, 34]. Subsequent work in rodents found that 
elevated FFA levels via an infusion of intralipid/heparin was associated with activation of 
PKCθ as well as development of skeletal muscle insulin resistance [34]. Yu et al 
demonstrated PKCθ activation to be associated with impaired insulin signalling via 
decreased insulin-stimulated IRS-1 tyrosine phosphorylation [35]. More recent work has 
provided an explanation for this by highlighting the ability of PKCθ to phosphorylate IRS-1 
on Ser 1101, blocking insulin-stimulated IRS-1 tyrosine phosphorylation [36] and therefore 
impeding downstream insulin signalling.  
In addition to increasing FFA levels, expanded adipose tissue has a tendency to develop 
areas of micro-hypoxia and stress of the endoplasmic reticulum, resulting in inflammation 
and the release of cytokines such as TNFα [37, 38]. The release of inflammatory cytokines 
activate stress kinases, which also impair downstream signalling via the Akt pathway as a 
result of inhibitory phosphorylation of serine residues within IRS-1 [39, 40]. Adipose tissue 
can also influence insulin sensitivity via the secretion of its own endogenous cytokines, 
termed adipokines. In the setting of hypoxic adipose tissue, the balance of secreted 
adipokines is shifted in favour of those which promote insulin resistance rather than those 
which enhance insulin sensitivity [41]. 
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The combination of inflammatory cytokines, activated macrophages and adipokines 
promotes ectopic accumulation of lipids in skeletal muscle [42] and of hepatic steatosis 
[43]. These effects contribute to insulin resistance within these tissues as well as release of 
further FFAs and cytokines to propagate the cycle. 
Prolonged resistance to the effects of insulin results in compensatory hyperinsulinaemia in 
order to maintain glucose homeostasis. However, this attempt to overcome the effects of 
insulin resistance may further exacerbate the problem. Ueno et al observed impairment of 
signalling via the Akt pathway in liver and muscle tissue from healthy rats during extended 
hyperinsulinaemic-euglycaemic clamp studies [44]. In time, compensatory mechanisms 
become overwhelmed and hyperglycaemia manifests, heralding the onset of frank 
diabetes. Sustained hyperglycaemia itself can also promote progression of insulin 
resistance via generation of oxidative stress and advanced glycation end products (AGEs) 
[45, 46]. Both of these phenomena have been shown to impair insulin signalling via 
inhibitory phosphorylation of IRS-1 [47-49]. 
Studies published at the turn of the century identified a phenomenon termed ‘pathway 
specific insulin resistance’ whereby activation of the Akt pathway is impaired, whilst MAPK 
activity remains unaffected [50]. The net effect of this imbalance is to promote the 
mitogenic effects of insulin whilst hindering its ability to stimulate NO production. As well 
as classical insulin sensitive tissues such as muscle, this observation has also been noted in 
the vasculature [51], where the combination of VSMC proliferation and reduced NO 
bioavailability results in a pro-atherogenic state. Whilst the significance of this pathway 
specific model of insulin resistance in human disease remains unconfirmed, it does provide 
a link between the metabolic and vascular abnormalities noted in insulin resistant patients. 
Murine models of insulin resistance 
Examining the role of insulin resistance per se in human CVD is difficult due to the complex 
nature of measurement of insulin sensitivity by euglycaemic clamp techniques, as well as 
the confounding effect of other factors such as obesity, dyslipidaemia, hypertension and 
hyperglycaemia which often co-exist with insulin resistance. As such, murine models have 
also proven to be a very useful tool in exploring the impact of insulin resistance. 
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Mice with homozygous insufficiency of the IR have been demonstrated to have a lethal 
phenotype despite normal in utero development. The mice develop profound 
hyperglycaemia and diabetic ketoacidosis (DKA), resulting in death within 72 hours [52, 
53]. However mice with haploinsufficiency for the IR (IRKO) are viable and have been 
extensively studied by our laboratory. IRKO mice have proven to be a good model of 
human metabolic syndrome due to a combination of preserved glucose regulation, post-
prandial hyperinsulinaemia and hypertension [54]. Investigation into the downstream 
signalling defects in IRKO mice demonstrated normal vascular levels of eNOS mRNA but 
reduced insulin-induced eNOS phosphorylation relative to wild-type. 
Murine models have also been used in order to isolate and examine the role of the 
endothelium in insulin resistance. The first murine model of endothelial-specific insulin 
resistance was VENIRKO, where Cre-lox recombination was used in order to knockout the 
insulin receptor in the endothelium [55]. As with IRKO counterparts, VENIRKO mice were 
found to have preserved glucose regulation. However in contrast to IRKO mice, VENIRKO 
mice display reduced levels of eNOS mRNA in aortic and cardiac tissue. Our group have 
developed and characterised an alternative transgenic murine model with endothelium-
specific mutant dominant negative insulin receptor overexpression (ESMIRO). Whilst these 
mice behave similarly to IRKO mice with respect to preserved glucose regulation and 
diminished insulin-induced eNOS phosphorylation, they appear to have a milder 
phenotypic derangement than IRKO counterparts as evidenced by their normal blood 
pressure [56]. The effects of altered insulin signalling in murine models with respect to 
vascular function will be discussed in a later section. 
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1.2 Reactive oxygen species 
The term reactive oxygen species (ROS) encompasses various molecules derived from the 
metabolism of oxygen which can be divided into free radicals (superoxide anion, 
peroxynitrite) and non-radicals (hydrogen peroxide, ozone). ROS have traditionally been 
seen as toxic byproducts of metabolism, a view first put forward by Denham Harman’s 
‘free radical theory’ in 1956 [57]. In the decades following this, ROS have been the subject 
of intense research and their accumulation has been implicated in the initiation and 
development of a range of cardiovascular diseases, including hypertension, 
hyperlipidaemia, ischaemic heart disease, congestive cardiac failure and diabetes mellitus 
[58]. However, in more recent years gathering evidence has shown that ROS have a role as 
intracellular signalling molecules. Signal transduction mediated by ROS, known as ‘redox 
signalling’, has been demonstrated to be crucial to numerous developmental and 
physiological processes [59]. 
1.2.1 Production and breakdown of ROS 
ROS levels within cells are governed by the relative rates of their production and 
breakdown. The most significant producers of ROS are mitochondria and various enzyme 
groups including xanthine oxidase, lipoxygenase, uncoupled endothelial nitric oxide 
synthase (eNOS) and the NADPH oxidases (NOX). The lattermost of these is the principal 
source of ROS within the vasculature and will be discussed in more detail in the following 
section. Breakdown of ROS is also attributable to the actions of a selection of enzymes. 
Superoxide anion is dismuted into hydrogen peroxide and oxygen via the action of 
superoxide dismutase, whilst hydrogen peroxide breakdown into water and oxygen is 
facilitated by catalase, glutathione peroxidise and the thioredoxin enzyme system [60] (see 
figure 2). 
In health, production and breakdown is balanced and a physiological level of ROS is 
therefore maintained. In situations where there is excessive production or insufficient 
breakdown of ROS, accumulation occurs and this is termed ‘oxidative stress’. The excess 
ROS cause damage to cell constituents such as lipids, proteins, DNA and membranes due to 
free-radical mediated chain reactions [59]. 
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Oxidative stress has been implicated in multiple forms of vascular disease and 
interestingly, NADPH oxidases have been demonstrated to be the predominant source of 
superoxide anion in patients with T2DM and advanced coronary artery disease [61] as well 
as those with metabolic syndrome [62] and obesity [63]. 
1.2.2 NADPH oxidases 
In contrast to all other ROS producing enzymes, the NOXs produce ROS as their primary 
function, rather than as a by-product [64]. NOX2 is the prototypic NADPH oxidase, and was 
first discovered in phagocytes, where it aids in antimicrobial defence by producing a 
‘respiratory burst’ of ROS to kill internalised bacteria [59]. Subsequent work found NOXs to 
also be present in non-phagocytic cells, leading to the discovery of a family of NOXs. We 
now recognise there to be 5 NOX homologues (NOX 1-5) and 2 dual oxidases (DUOX 1-2) 
[65]. 
Whilst all NOX isoforms produce ROS by transferring electrons from NADPH to molecular 
oxygen, each is unique with regard to tissue distribution and mechanism of activation. NOX 
1, 2, 4 and 5 are most commonly expressed in vascular cells whilst the other homologues 
either have not been found, or are expressed at very low levels [66]. Interestingly, 
although NOX5 is expressed in human vasculature it has been found to be entirely absent 
in rodents [67]. 
NOX2 
NOX2 is the most widely expressed NADPH isoform within the vasculature [66], and has 
also been identified in stem/progenitor cells [65]. Structurally it consists of a membrane 
spanning catalytic subunit termed gp91phox, which in order to function requires binding of 
the membrane bound p22phox subunit as well as further cytosolic components (p47phox, 
p67phox, p40phox and Rac) [15]. 
The requirement of binding of various cytosolic components in order to activate NOX2 
means that multiple stimuli can trigger ROS production. The translocation and binding of 
p47phox to NOX2 is facilitated by phosphorylation, which can be triggered by vascular 
endothelial growth factor (VEGF), angiotensin 2, tumour necrosis factor α (TNFα) and 
oscillatory shear stress.  Isoprenylation of Rac is also necessary for NOX2 activation and 
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this is triggered by cytokines, shear-stress and ischaemia-reperfusion [15]. Taking this into 
account, it can be seen why stimuli such as VEGF and ischaemia can result in ROS 
production. The predominant ROS produced by NOX2 is superoxide anion [68]. 
NOX1 
NOX1 is most highly expressed in colon epithelium [68], but has also been found in ECs, 
smooth muscle cells (SMCs) and adventitial cells within the vasculature [66]. Similarities 
with NOX2 include structural homology (60% shared amino-acid identity), the fact that its 
primary product is superoxide anion, and its activity’s dependence on binding with other 
subunits [68]. 
NOX4 
In contrast to NOXs 1 and 2, NOX4 is constitutively active and does not require cytosolic 
activator subunits [15]. This suggests that ROS production by NOX4 is dependent on 
enzyme abundance and is thus regulated predominantly by level of expression [69]. A 
study performed by Craige et al [70] showed that endothelial NOX4 expression can be 
upregulated in response to hypoxia. A further difference between NOX4 and NOXs 1 and 2 
is that NOX4 appears to generate predominantly hydrogen peroxide, rather than 
superoxide anion [69]. This notion is supported by studies which showed that peroxynitrite 
(ONOO-) was not generated when NOX4 was overexpressed in the presence of NO [71, 72]. 
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Figure 2. Production and breakdown of ROS 
Membrane-bound NADPH oxidase enzymes (NOXs 1 and 2) as well as mitochondria and uncoupled eNOS are 
responsible for the majority of superoxide anion generation. Superoxide anion is dismuted to form hydrogen 
peroxide by the action of the enzyme superoxide dismutase. NADPH oxidase NOX4 also contributes to 
hydrogen peroxide generation, which is then itself broken down into water and oxygen by the actions of 
catalase or glutathione peroxidase. Taken with permission from Ali et al [73]. 
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1.2.3 Redox signalling 
Signal transduction by electron transfer, termed redox signalling, is an emerging area of 
investigation within cardiovascular research, and one in which ROS play the major role. In 
order to be able to function as signalling molecules, ROS need to demonstrate three 
specific characteristics [74]: 
 1. Reversibility of the signalling effect 
 2. Control of their concentration at the level of synthesis and removal 
 3. Existence of specific receptors 
Superoxide anion and hydrogen peroxide are able to reversibly modify proteins in a 
manner which is comparable to the process of phosphorylation [75]. As discussed in the 
preceding section, their synthesis and removal are facilitated by groups of enzymes, thus 
allowing regulation of their concentration. Whilst they do not act on specific receptors to 
achieve their effect, specificity of action is achieved by two other mechanisms. Unlike 
other ROS, which are highly reactive and can irreversibly damage molecules, superoxide 
anion and hydrogen peroxide are relatively mild oxidants. This fact ensures that only 
certain molecules are susceptible to their modification, granting these ROS a degree of 
selectivity [74]. In addition, their specificity is aided by spatial regulation whereby these 
ROS are compartmentalised within cells. This is achieved by discrete localisation of NOX 
enzymes and the relative ubiquity of scavenging enzymes within the cytoplasm, which 
work to limit the escape and accumulation of ROS.  
There are various proteins which form targets for redox regulation. The most widely 
studied of these are kinases, which can be regulated in a redox-sensitive manner, both 
directly and indirectly. Oxidation of protein tyrosine phosphatases (PTPs), which reverse 
the action of kinases, leads to their inhibition, thus providing indirect kinase regulation 
[76].  An important example of this in the context of angiogenesis is the relationship 
between the receptor tyrosine kinase VEGFR2 and the protein tyrosine phosphatases SHP-
1, SHP-2 and low-molecular weight PTP (HCPTPA). As will be described later, signalling by 
VEGFR2 is crucial to angiogenesis and the aforementioned PTPs inducibly associate with it 
following VEGF binding [77], [78], [79]. These PTPs have an inhibitory effect on VEGFR2 
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autophosphorylation [80], [81] and therefore attenuate signal transduction. Thus VEGFR2-
directed ROS production inactivates these PTPs in a positive feedback loop necessary for 
normal VEGF-induced angiogenesis.  
With regard to direct redox-regulation of kinases, it is becoming apparent that oxidation by 
ROS can both activate and inactivate certain kinases (drawing another parallel between 
redox signalling and phosphorylation). This phenomenon is best recognised with Src 
tyrosine kinase; its activation by oxidation is well established [82], but recent work by 
Kemble et al [83] has found that oxidation can also result in formation of inactive dimers. 
Other redox sensitive kinases include receptor tyrosine kinases (e.g. insulin receptor, PDGF 
receptor) [84], AKT and MAP kinases [85], [86]. 
In addition to PTPs and kinases, transcription factors such as HIF-1, and proteinases such as 
matrix metalloproteinase (MMP), are also redox sensitive [74]. The importance of this to 
the processes of angiogenesis and vascular repair will be discussed later. 
1.2.4 Oxidative stress and insulin resistance 
A significant body of research has highlighted a link between oxidative stress and insulin 
resistance, and in 2006 Houstis et al demonstrated a causal relationship [87]. Whilst a 
number of putative mechanisms exist to explain how ROS may contribute to insulin 
resistance, the precise nature is likely to vary depending on the tissue in question [88]. This 
section will therefore focus on general principles based on our current understanding (See 
figure 3). 
ROS can activate a specific group of MAPKs termed ‘stress-activated protein kinases’ 
(SAPKs), such as c-Jun N-terminal kinases (JNKs) and IκB kinase (IKK) [87], via two 
mechanisms; firstly, by inactivating molecules which would otherwise inhibit the SAPKs, 
such as MAPK phosphatases. Additionally, ROS are able to increase the expression of pro-
inflammatory cytokines such as interleukin-6 (IL-6) and TNFα, which directly activate the 
MAPKs [89]. Once activated, these SAPKs induce phosphorylation of IRS-1 on serines 302, 
307 and 612, which results in suppression of IRS-1 binding to the IR and PI3K as well as 
promoting IRS-1 breakdown [90]. This interference with the PI3K/Akt signalling cascade is a 
mechanism whereby ROS can contribute to the ‘pathway-specific insulin resistance’ 
discussed in section 1.1.2. 
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As well as inducing inhibitory phosphorylation of IRS-1 via activation of SAPKs, TNFα and IL-
6 have been shown to exert a long term inhibitory effect on the gene transcription of IRS-1 
and GLUT-4 [91]. Furthermore, it has been proposed that TNFα can interfere with IR 
function, as neutralisation of TNFα with a soluble TNF receptor-IgG fusion protein 
increases insulin-stimulated phosphorylation of the IR [40]. 
Interestingly, whilst the consensus of current understanding is of insulin resistance and 
oxidative stress being pathological phenomena closely intertwined with the development 
of CVD, there is some evidence which suggests that insulin resistance could in fact be a 
defence mechanism against nutrient excess [92]. Hoehn et al demonstrated that 
mitochondrial superoxide production is a common feature in various models of insulin 
resistance, and also that insulin resistance is rapidly reversible upon exposure to 
mitochondrial uncoupling agents. Furthermore, acute induction of mitochondrial 
superoxide production causes rapid attenuation of insulin action independent of the 
PI3K/Akt pathway. The group went on to demonstrate that mice over-expressing 
mitochondrial superoxide dismutase (MnSOD) are protected from high-fat diet (HFD) 
induced insulin resistance, and that MnSOD+/- mice become glucose intolerant on a 
standard chow diet. In their conclusion, the authors suggested that insulin resistance may 
be part of the antioxidant defence mechanism to protect cells from oxidative damage and 
therefore be an appropriate response to increased nutrient accumulation. 
Whilst there are a number of proposed mechanisms which lead to the development of 
insulin resistance (some of which are outlined in section 1.1.2), oxidative stress appears to 
be one of the overarching phenomena that are implicated within these disparate 
pathological processes. Furthermore, as will be discussed in following sections, oxidative 
stress is also understood to be a critical link between established insulin resistance and the 
development of CVD.  
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Figure 3. Oxidative stress and insulin resistance 
Oxidative stress can induce increased expression of pro-inflammatory cytokines such as IL-6 and TNFα, which 
results in impaired IR phosphorylation and reduced transcription of IRS-1 and GLUT-4.  In addition oxidative 
stress can activate stress-activated MAPKs such as JNKs and IKK which serve to phosphorylate IRS-1 on serines 
302, 307 and 612, leading to impaired binding to the IR and PI3K. The net result of all of these actions 
contributes to the development of insulin resistance. 
IL-6: interleukin-6; TNFα: tumour necrosis factor α; IR: insulin receptor; IRS-1: insulin receptor substrate-1; 
MAPK: mitogen activated protein kinase; JNK: c-Jun N-terminal kinases; IKK: IκB kinase; PI3K: phosphoinositide 
3-kinase 
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1.3 Endothelial physiology and atherogenesis 
1.3.1 Physiological role of the endothelium 
The endothelium is a monocellular lining that covers the inner surface of the entire 
vascular system. Once thought of as an inert barrier with a purely protective function, our 
understanding has developed to the point where we now recognise the endothelium to be 
a complex and dynamic organ in its own right. Endothelial cells (ECs) have the capability to 
behave as both receptors and effectors, allowing them to sense different physical or 
chemical stimuli and then modify vessel function or release various substances in order to 
maintain physiological homeostasis [93]. One of the most important examples of this is the 
process of maintaining vascular tone. In order to achieve this, ECs produce and secrete a 
fine balance of substances that promote either vasoconstriction (ET-1, angiotensin 2 and 
various ROS) or vasodilation (NO, prostacyclin, hydrogen peroxide). By secretion of these 
mediators and others, the endothelium also plays an important role in platelet function, 
inflammation and coagulation. 
1.3.2 Nitric oxide 
Nitric oxide (NO) is one of the most important and widely studied mediators of vascular 
health. It is a biologically active, volatile gas which easily diffuses across plasma 
membranes due to its low molecular weight and lipophilicity [94]. NO is generated by the 
action of the enzyme nitric oxide synthase (NOS), of which there are three isoforms: 
endothelial (e)NOS, neuronal (n)NOS and inducible (i)NOS. All three isoforms share a 
dimeric structure, with a C-terminal reductase domain that binds nicotinamide adenine 
dinucleotide phosphate (NADPH) and an N-terminal oxygenase domain which binds L-
arginine, tetrahydrobiopterin and a heme group [95]. Electron transfer from NADPH to the 
heme group leads to the reduction and activation of O2, which facilitates hydroxylation of 
L-arginine to N-hydroxy-L-arginine. This is then oxidised to form NO and L-citrulline [96]. 
Whilst endothelial cells express both eNOS and iNOS, the predominant isoform found 
within the vasculature is eNOS. Of particular significance to its role within the 
cardiovascular system is the fact that both the expression and activity of eNOS can be 
regulated by specific stimuli; vascular endothelial growth factor (VEGF), shear stress and 
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insulin have all been shown to upregulate eNOS expression [97, 98], and can also trigger its 
activation via phosphorylation of serine 1177 [99]. This ability of eNOS expression and 
activation to change in response to pertinent stimuli is crucial in allowing the 
cardiovascular system to adapt and maintain homeostasis. Modulation of eNOS activity 
can also be achieved via phosphorylation of multiple other residues, and in response to 
elevated levels of intracellular calcium. 
NO has a multitude of functions within the vasculature, the most studied of which is its 
role in maintaining vascular tone. This is achieved via mediation of vasodilation and has 
been demonstrated experimentally using levo-N-monomethyl arginine (L-NMMA), a 
specific inhibitor of NOS. Infusion of L-NMMA into rabbit models causes a marked increase 
in systolic blood pressure, whilst ex-vivo exposure of aortic rings to L-NMMA can reverse L-
arginine mediated vasodilatation [100]. In human studies, infusion of L-NMMA into the 
brachial artery of healthy volunteers results in blunted flow-mediated vasodilation [101]. 
In order to exert its vasodilatory effect, NO crosses through ECs to reach VSMCs where 
activation of soluble guanylate cyclase results in production of cyclic guanosine 
monophosphate (cGMP). This sequence of events regulates cytoplasmic calcium 
concentrations, encouraging VSMC relaxation and therefore vasodilatation [102]. 
NO also has an important role in protecting against development and progression of 
atheroma. It has an anti-proliferative effect on VSMCs [103, 104], whilst also negatively 
regulating the expression of adhesion molecules such as P-selectin, vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on the surface of ECs 
[105]. Furthermore, an ability to interfere with leucocyte adhesion to ECs imbues NO with 
anti-inflammatory properties [106]. Taken together, these characteristics highlight NO to 
be an anti-atherogenic molecule, and its ability to inhibit platelet aggregation [107, 108] 
and thrombin-induced platelet adhesion to the vascular endothelium [109] means that it is 
also anti-thrombotic, reducing the risk of thrombus formation on vulnerable plaques. 
Given that the majority of CVD is atherosclerosis-mediated, the importance of NO to the 
maintenance of cardiovascular health can scarcely be overstated. The mechanism whereby 
insulin resistance can impair NO production has been discussed earlier, but NO 
bioavailability can also be reduced via sequestration by an excess of ROS and this will be 
discussed in section 1.3.4. 
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1.3.3 Endothelial dysfunction 
Endothelial dysfunction can be defined as the pathological state resulting from an 
imbalance of vasodilating and vasoconstricting substances produced by or acting on ECs 
[110]. A hallmark of the condition is impairment of NO-mediated vasodilation due to either 
reduced production or increased breakdown/inactivation of NO. 
Endothelial dysfunction is recognised as one of the initiating steps in the development of 
atherosclerosis [111]. Invasive assessment of endothelial function can be performed using 
acetylcholine (ACh), which induces endothelium-dependant dilation and smooth muscle-
mediated constriction. In the coronary arteries of healthy individuals, the predominant 
response to ACh is endothelial-dependant dilation. However, when the endothelium is 
damaged the balance is shifted towards smooth muscle-mediated vasoconstriction. 
Comparison of coronary artery diameter before and after ACh infusion can thus be used to 
identify endothelial dysfunction. Non-invasive techniques to identify and quantify 
endothelial dysfunction have subsequently been developed, an example of which is 
ultrasound detected flow-mediated dilation (FMD) in the brachial artery in response to 
reactive hyperaemia. The increased blood flow and shear stress induced by the reactive 
hyperaemia stimulates NO release and FMD, which can be used as measure of vasomotor 
function [112]. 
Coronary angiography pre- and post-ACh infusion was used to provide the first human 
evidence of endothelial dysfunction in the presence of atherosclerosis, where paradoxical 
vasoconstriction was observed in the arteries of patients with both advanced and mild 
coronary artery disease (CAD) [113]. Ultrasonic detection of FMD has since been used to 
demonstrate endothelial dysfunction in the preclinical stage of atherosclerosis, prior to 
angiographic or ultrasonic evidence of atherosclerotic plaque, and it is now accepted that 
endothelial dysfunction is itself an independent predictor for the development of CVD 
[114]. 
1.3.4 Oxidative stress and endothelial dysfunction 
At physiological levels, ROS play an important role in maintaining endothelial health. 
Hydrogen peroxide promotes calcium-dependant eNOS activity, allowing appropriate 
concentrations of NO to be produced [115]. However, when their concentration becomes 
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excessive, ROS can lead to a reduction in the bioavailability of NO, and so oxidative stress 
can promote endothelial dysfunction.  
In conditions of oxidative stress, the excess of superoxide anion can sequester NO by 
reacting with it to form peroxynitrite (ONOO-). Peroxynitrite can then oxidise the eNOS 
cofactor tetrahydrobiopterin (BH4) to form the inactive molecule BH2. This reaction leads 
to the uncoupling of eNOS, resulting in the production of further superoxide anion instead 
of NO, and thus propagating the cycle [116] (see figure 4).  
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Figure 4. Oxidative stress and endothelial dysfunction 
In health NADPH oxidase produces superoxide anion (O2-), which is dismuted into hydrogen peroxide (H2O2) by 
the action of superoxide dismutase (SOD). H2O2 can promote activation of eNOS, increasing nitric oxide (NO) 
bioavailability, which maintains endothelial function. In the setting of oxidative stress, excess production of O2- 
results in sequestration of NO via a reaction to produce peroxynitrite (ONOO-). ONOO- oxidizes the eNOS 
cofactor BH4, uncoupling eNOS to then produce further O2-. The reduction in NO bioavailability leads to 
impaired vasodilation as well as inflammation, platelet aggregation and cell proliferation, all of which are 
contributory factors to atherogenesis. The excess ROS can also react with cellular macromolecules such as 
lipids and nucleic acids resulting in damage to membranes and DNA. Taken with permission from Ali et al [73].   
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1.3.5 Atherosclerosis 
Atherosclerosis is a disease whose insidious onset and progression belies the fact that it is 
thought to underpin up to half of all deaths in Western societies [117]. The enormous 
burden of morbidity and mortality resulting from atherosclerosis-related diseases mean 
that it has been an area of intense research for almost two centuries. In 1856 Rudolph 
Virchow challenged the contemporary dogma that atherosclerosis was purely a result of 
lipid accumulation within arterial walls, and hypothesised an important role for 
inflammatory changes in the development of the disease [118]. Over subsequent decades 
his theory has been expanded and refined to the point where we now appreciate 
atherosclerosis to be an inflammatory condition [10]. 
The earliest lesions associated with atherosclerosis can be identified in the first decade of 
life and are termed ‘fatty streaks’. These tend to form preferentially at specific points 
within arteries such as bifurcations, or areas of curvature due to perturbations in blood 
flow dynamics. The turbulent flow in these areas generates shear stress that acts on the 
ECs and affects their morphology. Whereas in areas of laminar blood flow ECs are ellipsoid 
in shape and aligned in the direction of flow, in areas of disturbed flow the ECs have a 
polygonal shape and a disordered orientation [117]. These changes in the EC monolayer 
result in increased permeability to macromolecules such as low-density lipoprotein (LDL), 
allowing for the initiation of fatty streak formation. The abnormal shear stress also 
stimulates EC expression of cell surface molecules such as ICAM-1 [10],  and release of 
mitogens such as platelet derived growth factor (PDGF)-B [119]. These modulate local 
immune response by encouraging recruitment of inflammatory cells, such as rolling and 
adhesion of monocytes. These monocytes can then migrate into the sub-endothelium 
where they can become activated and differentiate into macrophages [10]. Activated 
macrophages produce ROS which oxidise LDL to form oxidised LDL (ox-LDL), stimulating 
overlying ECs to produce pro-inflammatory molecules such as macrophage-colony 
stimulating factor (M-CSF) and monocyte chemoattractant protein (MCP), thus 
perpetuating the inflammatory infiltration cycle. Ox-LDL is also able to inhibit production of 
the anti-atherogenic molecule NO [117]. 
Macrophages within the fatty streak internalise and accumulate LDL, transforming into 
foam cells in a process mediated by cell-surface scavenger receptors. Expression of 
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scavenger receptors is regulated by cytokines such as TNFα and peroxisome proliferator-
activated receptor-γ (PPAR γ), a transcription factor whose ligands include oxidized fatty 
acids [117]. Foam cells eventually undergo necrosis, releasing pro-inflammatory cytokines 
into the circulation. In conjunction with the cytokines and growth factors secreted by 
macrophages and T-cells, the effect is to stimulate migration and proliferation of SMCs as 
well as production of extra-cellular matrix. The resulting fibrosis allows a ‘fibrous cap’ to 
from, shielding the circulation from the thrombogenic core of the atherosclerotic lesion 
[117]. Whilst a plaque may remain stable for many years with a fibrous cap in place, a 
patient may experience symptoms based on the level of luminal obstruction caused by the 
lesion. If the vessel calibre is narrowed to the extent that adequate tissue perfusion during 
stress is impeded, conditions such as angina pectoris and intermittent claudication may 
develop.  
The culminating event in the natural history of some atherosclerotic plaques is ulceration 
and rupture, triggering a sequence of events which result in thrombosis within the vessel. 
Pathological studies have shown that the likelihood of this cascade occurring is principally 
dependent upon the composition and vulnerability of the plaque, rather than degree of 
stenosis [117]. The main features thought to influence plaque vulnerability are the 
thickness of its fibrous cap, as well as the abundance of inflammatory cells within it, since 
macrophages produce various proteases that contribute to degradation of the cap. 
Additional factors which influence the stability of advanced lesions are intimal calcification 
and neovascularisation, which provides a route for inflammatory cells into the plaque 
[117]. Following rupture of the plaque, the thrombogenic core of the lesion is exposed to 
the platelets and coagulation factors within the circulation, resulting in thrombus 
formation, which can lead to acute vascular occlusion and downstream tissue infarction.  
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1.4 The role of ROS in insulin resistance-associated vascular disease 
In order to dissect the role of ROS in the link between insulin resistance and vascular 
disease, our group has studied a number of murine models which aim to represent the 
pre-diabetic phenotype. In 2007 we published a study [120] demonstrating that IRKO mice 
displayed accelerated endothelial dysfunction relative to wild-type (WT) controls, in spite 
of preserved glucose regulation. The study also found that use of a SOD mimetic could 
restore endothelial function in IRKO mice, which were shown to generate greater 
quantities of ROS than WT counterparts. As well as the genetically induced insulin 
resistance examined in this study, there is also evidence to show that ROS have a role to 
play in the insulin resistance and endothelial dysfunction that is observed secondary to 
diet-induced obesity [121]. This paper demonstrated that middle-aged mice fed with a high 
fat diet (HFD) developed obesity, dyslipidaemia, hypertension, insulin resistance and 
endothelial dysfunction associated with increased NOX2 expression and ROS production. 
Inhibition of NOX2, either pharmacologically or genetically, reversed all of the HFD induced 
abnormalities except for hyperinsulinaemia. The conclusion from this study was that 
NOX2-derived ROS play a key role in damaging insulin signalling and endothelial function in 
dietary obesity after middle age.   
Given the close relationship between insulin resistance and endothelial dysfunction, we 
have undertaken further work focussing on the effect of endothelial specific insulin 
resistance using ESMIRO mice. ESMIRO mice, which display normal glucose regulation, 
have impaired endothelial function associated with reduced NO bioavailability, which 
could be rescued in vitro with a SOD mimetic [56]. Furthermore, when ESMIRO mice were 
cross-bred with atherosclerosis-prone ApoE deficient mice, the resulting ApoE-/-/ESMIRO 
mice exhibited accelerated atherosclerosis [13]. This finding has been independently 
corroborated by Rask-Madsen et al, who demonstrated that ApoE-/- mice with endothelial 
insulin receptor knockout had increased atherosclerosis relative to ApoE-/- mice [122]. 
In the aforementioned endothelium-specific insulin resistance studies performed by our 
group, the combination of elevated levels of ROS, and the ability of pharmacological 
superoxide diminution to reverse the observed endothelial dysfunction, implicates 
oxidative stress as an underlying mechanism. This suggests that NOX2, the primary 
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generator of superoxide anion within the vasculature, could form a target for reducing 
oxidative stress and the associated endothelial dysfunction in insulin resistance. To this 
end, our group has generated transgenic ESMIRO mice with global NOX2 knockout 
(ESMIRO/NOX2y/-) and demonstrated that genetic NOX2 inhibition could reduce superoxide 
levels and improve vascular function [123]. These findings were replicated with use of 
either acute or chronic pharmacological inhibition using the NOX inhibitor GP91ds-tat. This 
study established NOX2 inhibition as a novel therapeutic target in insulin resistance-
associated vascular dysfunction. 
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1.5 Vascular regeneration and repair 
As discussed in section 1.3.5, the culminating event in atherosclerotic disease such as MI or 
stroke is the rupture of a plaque, triggering thrombus formation and acute vascular 
occlusion. Endogenous vascular repair mechanisms are responsible for re-
endothelialisation of the blood vessels injured by the formation and rupture of plaques. 
Meanwhile, downstream tissues rendered ischaemic by vascular occlusion depend on the 
formation of neovessels for their reperfusion. There are three recognised forms of 
neovascularisation: angiogenesis, arteriogenesis and vasculogenesis.  
1.5.1 Angiogenesis 
Angiogenesis is the term given to the sprouting or intussusception of neovessels from pre-
existing vasculature and is the predominant means of generating capillary beds in 
adulthood [124], as well as the key process involved in post-ischaemic neovascularisation 
[125]. The vascular endothelium is crucial to this process and ECs are required to 
proliferate, migrate and form capillary tubes [126]. This complex process is initiated by 
pro-angiogenic factors, with VEGF being the best recognised of these.  Following exposure 
to VEGF, quiescent ECs form sprouts that comprise tip cells and stalk cells. The tip cells are 
positioned at the leading point of the sprouts and migrate along a VEGF gradient. The stalk 
cells proliferate behind the tip cells to form a column within which the capillary lumen 
forms [21]. Vessel loops are formed when tip cells anastomose with cells from 
neighbouring sprouts [126]. 
The initial hypothesis that insulin resistance can disturb angiogenesis came from 
extrapolation of data showing diminished vascular regeneration in a range of disorders 
underpinned by the phenomenon. Diabetes is known to impair collateral artery formation 
in the setting of coronary and peripheral arterial disease [127], and has been shown to be 
associated with impaired angiogenesis in chronic wounds [128]. Furthermore, obesity has 
been demonstrated to be associated with reduced angiogenesis following hind-limb 
ischaemia [129]. Following on from these and other similar studies, our group has provided 
direct evidence that insulin resistance per se can impede vascular regeneration, as IRKO 
mice were shown to display impaired post-ischaemic neovascularisation as well as in vitro 
indices of angiogenesis [130]. 
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1.5.2 Vascular repair 
Vascular repair is the process whereby injured, established conduit vessels are re-
endothelialised in order to re-establish vessel integrity. There are currently two proposed 
mechanisms by which this occurs; proliferation and migration of ECs adjacent to the 
injured vessel segment which replace lost and damaged cells, and the recruitment of bone 
marrow derived progenitor cells which home to the site of injury and assist in repair by 
either direct incorporation or paracrine stimulation of resident ECs [131]. Debate is 
ongoing around the latter of these theories, and this will be discussed in more detail in 
section 1.5.3. 
As well as impairing angiogenesis, insulin resistance has also been demonstrated to 
impede vascular repair, either in the context of diabetes, or in isolation. Diabetes has been 
shown to be associated with impaired coronary re-endothelialisation after percutaneous 
intervention [132], and further work on the IRKO mouse model by our group has 
demonstrated diminished femoral arterial repair following injury in the setting of insulin 
resistance [12]. 
1.5.3 Endothelial progenitor cells 
Vasculogenesis, which is the de novo formation of blood vessels, was previously thought to 
be exclusively limited to embryonic development. However work done by Asahara et al 
[133] challenged this notion with the discovery of ‘putative progenitor endothelial cells’ in 
adults. The premise for this work was the hypothesis that peripheral blood contained stem 
cells which could differentiate into ECs. In order to examine this, the authors identified 
CD34 and VEGFR-2 as cell surface markers which are expressed by both ECs and 
haematopoietic stem cells (HSCs), but which are lost during maturation of the latter. Cells 
expressing either of these markers were isolated from human blood mononuclear cells by 
magnetic separation and were found to display an endothelial-like phenotype during in 
vitro culture-expansion, and augment angiogenesis when re-infused into mice with hind 
limb ischaemia. 
This work has led to a great deal of subsequent research aimed at further characterising 
the nature of these cells, as well as their potential role in post-natal vasculogenesis. The 
cell surface selection markers used in the seminal Asahara et al paper have since been 
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extrapolated by other groups, with most studies using a combination of the 
haematopoietic cell markers CD133 and CD34, as well as the endothelial cell marker 
VEGFR-2. Cells which co-express these markers are identified by use of fluorescently 
labelled antibodies and flow cytometry and have been loosely termed ‘endothelial 
progenitor cells’ (EPCs) [134]. EPCs are postulated to be capable of contributing to vascular 
repair [135], and their abundance has been shown to independently predict future major 
cardiovascular events [136].  
An alternative method for obtaining EPCs involves utilising cell culture techniques in order 
to manipulate circulating peripheral blood mononuclear cells (PBMCs), as originally 
demonstrated by Asahara et al [137]. These techniques have led to the discovery of two 
subsets of EPCs based on the duration of their culture in endothelial growth medium; 
‘early outgrowth EPCs’ (EEPCs) following 4-7 days’ culture, and ‘late outgrowth EPCs’ 
(LEPCs) following sustained culture over a period of weeks. These two groups of EPCs are 
disparate, both morphologically and functionally. EEPCs have a spindle-shaped 
appearance, similar to the cells seen by Asahara et al [133], have only a limited capacity for 
proliferation, and retain functional and surface marker characteristics of myeloid cells. In 
vivo studies have shown that EEPCs appear unable to incorporate directly into the 
endothelium but can augment angiogenesis and vascular repair in a paracrine fashion 
[138]. In contrast, LEPCs have an appearance akin to endothelial cells [137], are rapidly 
proliferative in vitro where they can form capillary-like structures [138], and display a true 
progenitor population hierarchy.   
Further insights into EPC biology have been facilitated by the identification of murine 
equivalents of these cells. Murine EPCs are marked by co-expression of stem cell antigen 1 
(Sca1) and VEGFR-2/Kinase insert domain receptor (KDR) [139]. Interestingly, whilst murine 
EEPCs have been consistently derived from blood as well as homogenised marrow and 
spleen tissue, sustained culture of murine LEPCs have proved to be much more challenging 
to establish [140].  
The relationship between circulating EPCs and those derived by cell culture remains 
unclear. Whilst there have been in vivo studies to show that LEPCs are able to contribute 
directly to vascular regeneration [138], a study performed by Hagensen et al suggested 
that vascular repair following carotid artery wire injury is solely mediated by the migration 
53 
 
of ECs from adjacent healthy endothelium [141]. Nevertheless, whilst there remains 
significant debate regarding the existence and role of EPCs in vivo, there is a general 
acceptance that such cells represent a potential autologous cell-therapy to promote 
vascular repair and neovascularisation [135]. For the purpose of clarity, for the remainder 
of this thesis endothelial progenitor cells derived from cell culture techniques will be 
referred to as ‘EPCs’, whilst circulating progenitor cells will be referred to as ‘CPCs’, 
reflecting our ongoing uncertainty as to their role in vivo.   
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1.6 Redox signalling in angiogenesis and vascular repair 
Having outlined the mechanisms involved in angiogenesis and vascular repair, the 
following section describes the role of ROS as signalling molecules within these pathways 
by highlighting a few key relationships (simplified schematic shown in figure 5). 
1.6.1 ROS and VEGF 
VEGF is the most widely studied pro-angiogenic factor and its signalling is achieved through 
interaction with three receptors; VEGFR1, VEGFR2 and VEGFR3 [142]. Its mitogenic and 
chemotactic effects in ECs are mediated principally through VEGFR2. Binding of VEGF to 
VEGFR2 promotes ROS production from two sources; firstly, by activation and 
translocation of Rac1 to the plasma membrane, thus completing the NOX2 NADPH oxidase 
complex. Secondly, it increases production of mitochondria derived ROS [143]. The 
resultant higher levels of ROS inactivate PTPs, removing their negative regulation of 
VEGFR2. This has the effect of enhancing VEGFR2 autophosphorylation, thereby activating 
downstream signalling pathways essential for EC proliferation and migration such as eNOS, 
MAPK and Akt [144].  
Whilst VEGF can stimulate increased ROS production, the reverse is also true. ROS, 
produced either by NADPH oxidase or mitochondria, can induce the expression of redox-
sensitive genes, such as VEGF, via induction of redox sensitive transcription factors 
including HIF-1 [144]. Thus a cyclical relationship exists between ROS and VEGF whereby 
increasing concentrations of one can promote production of the other.  
It is important to note that whilst increasing ROS levels will increase VEGF-induced 
angiogenesis, this effect can be mitigated by VEGF-independent mechanisms above a 
certain ROS threshold. A study performed by Okuno et al [145] on the topic of pathological 
angiogenesis provided a novel explanation for the mechanism by which an excess of ROS 
could retard angiogenesis. The protein kinase ataxia telangiectasia mutated (ATM) is 
mutated in patients with the condition ataxia telangiectasia, which is characterised by 
blood vessel instability. The cited study found that inhibiting wild-type ATM in ECs led to an 
increased ROS level, thereby activating p38α which induces growth arrest and attenuates 
angiogenesis.  Taking this into account, it appears that in the context of angiogenesis ROS 
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could be viewed as a double-edged sword depending on their prevailing level, and this is a 
theme which will be discussed later. 
1.6.2 ROS and HIF-1  
Hypoxia is a crucial stimulus for angiogenesis, and its effects are mediated by a group of 3 
transcription factors called Hypoxia Inducible Factors (HIFs 1-3). ROS are involved in the 
regulation of HIF-1 levels by exerting a level of control on both its production and 
degradation [143]. ROS can increase HIF-1 production by activating the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) and PI3K/Akt/4E-BP1 pathways 
[146] and [147]. HIF degradation can also be suppressed by depletion of cellular ascorbate, 
which is a cofactor for prolyl hydroxylate proteins (PHDs). This inhibits HIFα hydroxylation, 
and therefore Von Hipel-Lindau (VHL) complex mediated ubiquitination of HIF [143].  
1.6.3 ROS and CPCs 
Current evidence suggests that CPCs are mobilised from the BM into peripheral blood in 
response to tissue injury or ischaemia [148], and then migrate to damaged endothelium. 
They may then contribute to neovascularisation or vascular repair by either differentiating 
into ECs or by secreting pro-angiogenic factors and cytokines [138]. 
Mobilisation 
CPC mobilisation can be modulated by endogenous and pharmacological agents. Examples 
of endogenous cytokines which trigger CPC mobilisation include VEGF and stromal cell-
derived factor 1 (SDF-1), both of which are produced by ischaemic tissues. Additionally, 
granulocyte monocyte colony-stimulating factor (GM-CSF), granulocyte colony-stimulating 
factor (G-CSF) and erythropoietin (EPO) have been found to be potent CPC mobilising 
agents. Pharmacological agents known to induce CPC mobilisation include statins and 
PPAR agonists [148]. 
The local bone marrow environment, termed the ‘stem-cell niche’, governs the 
maintenance and mobilisation of CPCs [148]. Cytokines which induce release of CPCs from 
BM interfere with the interactions between stem cells and BM stromal cells, allowing them 
to pass into the bloodstream. This process is mediated by proteinases such as elastase and 
MMPs [149]. MMP-9 cleaves membrane bound Kit ligand and releases soluble Kit ligand 
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(sKitL) which facilitates the mobilisation of CPCs from the stem cell niche [65]. Since MMP 
is a redox sensitive protein whose expression is upregulated by ROS, this imbues ROS with 
the ability promote CPC mobilisation. 
 
Homing 
Once released into the bloodstream, CPCs home to the area in need of neovascularisation 
or re-endothelialisation. This process appears to share common features with the homing 
of leucocytes to areas of inflammation and involves cytokines, adhesion molecules and 
proteases [150]. 
The cytokine SDF-1, noted earlier for its ability to trigger CPC mobilisation, is also involved 
in the recruitment of CPCs to target tissue. SDF-1 expression has been found to be up-
regulated in ischaemia [151], and its over-expression has been shown to enhance stem cell 
homing and incorporation into ischaemic tissue [152]. A study by Urao et al [153] 
demonstrated the influence of ROS in this process. In a model of hind limb ischaemia, 
NOX2 knockout (NOX2y/-) mice displayed impaired ischaemia-induced flow recovery and 
CPC mobilisation from BM. In vitro experiments showed progenitor cells from NOX2y/- BM 
to have impaired chemotaxis and invasion in response to SDF, associated with blunted 
SDF-1 mediated phosphorylation of Akt. 
The homing capacity of CPCs also involves various adhesion molecules [150]. One of the 
crucial steps in the homing process is thought to be the rolling of the cells on the vascular 
endothelium, mediated by the selectin family of adhesion molecules. E-selectin is 
expressed exclusively on ECs, whilst P-selectin is expressed on both ECs and platelets [150]. 
NADPH oxidase-derived ROS have been found to be involved in the expression of both on 
the endothelial cell surface [154], [155] and [156]. Other adhesion molecules known to be 
of importance to EPC homing are ICAM-1 and VCAM-1, both of whose expression is known 
to be mediated by ROS [157].  
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1.6.4 ROS and Nitric Oxide 
Nitric oxide is well established as being a critical molecule for maintenance of endothelial 
health, and it is also understood to be of importance in facilitating angiogenesis and 
vascular repair. Physiological concentrations of NO have been demonstrated to exert a 
direct effect on EC proliferation and survival [158], whilst CPC mobilisation also appears to 
be dependent upon NO [159]. Given these observations, it is perhaps unsurprising that 
eNOS deficient mice display impaired revascularisation [160]. 
As outlined in section 1.3.4, at physiological concentrations ROS (specifically hydrogen 
peroxide) activate eNOS, promoting production of NO. Conversely, at supra-physiological 
concentrations ROS can sequester NO resulting in the formation of ONOO-, which 
ultimately causes uncoupling of eNOS.  
Whilst the scavenging of NO in order to produce ONOO- clearly has detrimental effects on 
vascular function, it is important to note that ONOO- itself can be directly damaging. 
Ballinger et al demonstrated that mitochondrial protein synthesis is inhibited in a dose-
dependent manner by ONOO-, resulting in reduced cellular ATP levels and mitochondrial 
redox function [161]. In addition to direct cellular toxicity, ONOO- can also cause oxidative 
damage to cellular proteins and lipids [162]. 
1.6.5 ROS and ECs  
ECs are instrumental in orchestrating the multiple events involved in angiogenesis and 
vascular repair. Peshavariya et al demonstrated that ROS play a role in regulating their 
proliferation and apoptosis [163]. This paper found that NOX4-derived hydrogen peroxide 
promotes EC proliferation via activation of ERK 1/2, whilst NOX2-derived ROS support cell 
survival by maintaining cytoskeletal integrity and preventing apoptosis. 
EC migration is crucial to the process of vascular regeneration, and disruption of 
intercellular connections is required in order to facilitate this [164]. Vascular endothelial- 
(VE-) cadherin is the main adhesion component of these connections and is linked to the 
actin cytoskeleton by α and β catenins and p120. ROS-dependant phosphorylation is 
responsible for disassembly of the VE-cadherin-catenins complex and leads to EC 
junctional breakdown [143]. 
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As well as assisting in breaking intercellular connections, ROS have a role in modulating the 
motility of migrating ECs. The process of actin network remodelling, which modulates cell 
shape and motility, is dependent on ROS for its regulation [165]. ECs also use ROS to direct 
their mobility by localising NADPH oxidase (and thus ROS production) to focal complexes in 
lamellipodia and membrane ruffles [166].
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Figure 5. Redox signalling in angiogenesis and vascular repair 
NOX2-derived superoxide anion (O2-) activates redox sensitive transcription factors, resulting in increased production of MMP and VEGF. MMP and VEGF are involved in CPC mobilisation, whilst VEGF is also important for EC proliferation/migration as 
well as stimulating further O2- production.  Hydrogen peroxide (H2O2) is produced by NOX4 and via the action of superoxide dismutase (SOD) on O2-.  H2O2 activates redox sensitive transcription factors as well as eNOS and MAPK1/2; eNOS produces 
NO which facilitates CPC mobilisation and EC migration, whilst MAPK1/2 are involved in EC proliferation and migration.
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1.7 Manipulation of ROS in the context of angiogenesis and vascular 
repair 
1.7.1 Angiogenesis 
The preceding section of this chapter has explored the role of ROS on some of the 
individual components involved in the process of angiogenesis; numerous in vivo 
experiments have also been conducted which bring these together in order to provide a 
more holistic view. The research in this area has focussed mainly on angiogenesis in the 
setting of ischaemic revascularisation, tumour development and proliferative 
retinopathies.  
Angiogenesis in ischaemic revascularisation 
The term ‘ischaemic revascularisation’ refers to the process of collateral blood vessel 
formation which occurs following an MI, stroke or in the context of critical limb ischaemia 
in order to re-perfuse tissue which has been rendered ischaemic. The hindlimb ischaemia 
model, whereby femoral artery ligation is followed by assessment of ischaemia-mediated 
flow recovery, is a commonly used method to study this process and was used by Tojo et al 
[167] to investigate the role of NOX2 derived ROS on angiogenesis. The study found that 
NOX2 expression and ROS levels are increased in response to hindlimb ischaemia. 
Furthermore NOX2y/- mice were found to have impaired angiogenesis relative to WT 
controls. These findings were corroborated by Urao et al [153], who went on to show that 
the impaired angiogenesis seen in NOX2y/- mice could be ameliorated by the 
transplantation of WT BM. The conclusion from this study was that the effect of NOX2-
derived ROS on angiogenesis is mediated via BM derived CPCs. 
The same group then went on to investigate the role of endothelial-derived ROS in 
angiogenesis, looking specifically at H2O2 by using transgenic mice over-expressing 
endothelial catalase [168]. These transgenic mice were shown to have delayed blood flow 
recovery as well as reduced capillary formation and collateral remodelling in comparison to 
WT littermates. This led to the conclusion that endogenous EC-derived H2O2 is critical to 
post-ischaemic neovascularisation. These findings were in keeping with previous research 
done on endothelial-specific NOX4-derived ROS and angiogenesis. Craige et al [70] found 
61 
 
NOX4 to be expressed in response to hypoxia, both in vitro and in vivo, and that mice over-
expressing NOX4 had augmented angiogenesis relative to WT following hindlimb 
ischaemia. Cultured ECs over-expressing NOX4 displayed increased eNOS expression and 
activity, leading to the conclusion that NOX4 promotes hypoxia-induced angiogenesis in an 
eNOS-dependant manner.  
The previous study focussed on endothelial-specific NOX4, and research has also been 
done looking at the effect of global NOX4 knockout on angiogenesis. Schroder et al [69] 
found that NOX4-/- mice had attenuated angiogenesis relative to WT controls, and a link 
between NOX4 and eNOS expression was once again put forward. Zhang et al [169] found 
that myocardial angiogenesis is impaired in NOX4-/- mice compared to WT in the setting of 
pressure overload-induced cardiac hypertrophy, due to attenuation of HIF-1 activation, 
and therefore VEGF production. 
This multitude of studies confirm the fact that ROS play an integral part in the process of 
angiogenesis, and that deletion of NADPH oxidases 2 or 4 in a physiological setting is 
detrimental. However, when considering human disease states and potential therapeutic 
strategies, manipulation of ROS levels in models better reflecting clinical disease is also 
important. To this end, studies have been performed assessing the impact of NADPH 
oxidase deletion on angiogenesis in situations of oxidative stress.  
In 2006 Ebrahimian et al [170] published a paper exploring the effect of diabetes-induced 
oxidative stress on post-ischaemic angiogenesis. Using the previously described hindlimb 
ischaemia model, this study found type-1 diabetic mice to have impaired post-ischaemic 
neovascularisation relative to wild-type littermates. The study went on to show that 
reduction of ROS levels in the setting of diabetes, using NOX2y/- type-1 diabetic mice, could 
restore the angiogenic capacity back to WT levels. The finding that NOX2 deletion has a 
protective effect on angiogenesis in the context of oxidative stress has been corroborated 
by Haddad et al in two recent studies. In the first [171], the pathological state was 
exposure to cigarette smoke. WT and NOX2y/- mice were exposed to one cigarette twice a 
day for 14 days prior to unilateral femoral artery removal and their recovery from hindlimb 
ischaemia compared. The second study [172] used hypercholesterolaemia as the disease 
state, whereby wild-type and NOX2y/- mice were rendered hypercholesterolaemic by a 15 
week high cholesterol diet, and once again compared with respect to their post-ischaemic 
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neovascularisation.  In both studies NOX2 deletion, and the resultant reduction in ROS 
production, was shown to be beneficial to angiogenesis with the proposed mechanism 
being preservation of the VEGF/NO signalling pathway.  
Tumour angiogenesis 
Angiogenesis is crucial to tumour growth and development, reflected by the fact that it is 
recognised as one of the six hallmarks of cancer [173]. NOX1 derived ROS have been 
demonstrated to play a pivotal role in tumour angiogenesis [174], and Garrido-Urbani et al 
[175] went on to study the effect of NOX1 inhibition on tumour vasculogenesis. Using an in 
vivo matrigel angiogenesis assay, this study showed that NOX1-/- mice exhibit impaired 
angiogenesis and that tumour vascularisation is inhibited by genetic or pharmacological 
NOX1 inhibition. The authors’ conclusion was that NOX1 is a mediator of tumour 
angiogenesis and exerts its effects via inhibition of the anti-angiogenic factor PPARα. 
Interestingly, the same study found genetic inhibition of NOX2 and NOX4 to have no effect 
on angiogenesis, which contrasts to the findings of previously mentioned studies in this 
chapter. This apparent contradiction is not yet fully understood, but may be a reflection of 
the mechanistic differences that exist between ischaemic revascularisation and tumour 
angiogenesis. 
Angiogenesis in proliferative retinopathies 
Pathological angiogenesis is a hallmark feature both diabetic retinopathy (DR) and 
retinopathy of prematurity (ROP). DR is the most common global cause of acquired 
blindness and has been divided into two stages: an early, non-proliferative stage and a 
later, proliferative stage. Oxidative stress has been recognised to play an important role in 
the development of the disease, and studies have shown that the retinas of diabetic rats 
have higher levels of NADPH oxidase and lower levels of SOD that those of their non-
diabetic counterparts [176]. Increased NOX2 within retinal vessels has been correlated 
with increased VEGF expression and vascular permeability. Rojas et al found that deletion 
of NOX2 in either bone marrow or retina could attenuate the increased VEGF and ICAM-1 
expression, as well as the leukostasis, seen in the retina of diabetic mice [177].  
The role of ROS has also been examined in the pathogenesis of ROP. A study performed by 
Saito et al [178] reported that when rats with ROP were exposed to hyperoxia (28% O2) 
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rather than room air (21% O2) in phase 2 of ROP, there was increased activation of NOX2. 
Furthermore, it was reported that administration of the NADPH oxidase inhibitor apocynin 
reduced the intra-vitreous neovascularisation (INNV) area in these rats. 
1.7.2 Vascular repair 
As well as angiogenesis, there is also evidence to support a role for NADPH oxidase-derived 
ROS in the process of vascular repair. Schroder et al [16] found that re-endothelialisation 
of injured mouse carotid artery is enhanced by hypoxia and EPO, but that this effect is 
abrogated in NOX2y/- mice. Further data from this study went on to link this finding to a 
deficiency in hypoxia-induced CPC mobilisation in the NOX2y/- mice, which could be 
restored by the transplantation of WT BM. Data also exists which suggests a role for NOX1 
in vascular repair, as shown by Lee et al [179]. In this study, NOX1-/- mice were found to 
have impaired neointimal formation following femoral artery wire injury when compared 
to WT controls. The authors’ conclusion stated that NOX1 is critical to vascular repair due 
to its mediation of VSMC migration, proliferation, and extracellular matrix production.   
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1.8 ROS, other CVD risk factors and atherosclerosis 
Beyond promoting endothelial dysfunction and impaired vascular regeneration, oxidative 
stress is also associated with risk factors for developing CVD (for a more detailed review, 
see Roberts et al [180]). A number of studies have demonstrated oxidative stress to be a 
contributory factor in the development of hypertension; in the context of angiotensin II-
infused mice, NOX2 inhibition has been shown to normalise blood pressure [181] and 
conversely, endothelial-specific NOX2 overexpression to promote hypertension [182]. 
However, NOX2 may not mediate renin and endothelin-1 induced hypertension [183, 184]. 
Conversely, endothelial NOX4 overexpression has also been shown to reduce blood 
pressure due to the vasodilatory action of hydrogen peroxide [185]. Small-scale clinical 
trial data also illustrate the potential of broad-spectrum antioxidants to improve insulin 
sensitivity, adipokine profile, and indices of leukocyte-endothelial interaction over the 
short-term in overweight young adults [186]. However, as discussed in section 1.10, these 
promising findings have not translated into reductions in ‘hard outcomes’ in large clinical 
trials.  
Whilst papers cited in this chapter have highlighted a role for ROS in atherogenesis in the 
context of insulin resistance, there is also recognition that oxidative stress can 
independently promote the development and progression of atherosclerosis. Evidence for 
this can be seen in a study published by Judkins et al, which demonstrated that 
atherosclerotic lesion area could be reduced by approximately 50% in high-fat-fed ApoE-/- 
mice via genetic inhibition of NOX2 [187]. More recently, an interesting paper has been 
published in which subclinical atherosclerosis was quantified in patients with chronic 
granulomatous disease (CGD), an immunodeficient state most often caused by defective 
gp91phox (NOX2). Despite a high prevalence of traditional cardiovascular risk factors, 
patients with CGD exhibited reduced carotid artery atherosclerosis relative to age-matched 
controls [188]. The findings of this study support a role for NOX2-derived ROS in the 
pathogenesis of atherosclerosis and although the mechanism was not explored in this 
paper, insights can be gained from previously published work. For example, oxidative 
stress is known to induce the expression of pro-inflammatory adhesion and chemotactic 
molecules such as vascular adhesion molecule 1 (VCAM-1) [189] and monocyte 
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chemoattractant protein 1 (MCP-1) [190], which in turn promote the recruitment and 
accumulation of inflammatory cells to atherosclerotic lesions [191, 192]. 
Whilst a protective effect of NOX2 inhibition on atherogenesis via diminution of pro-
inflammatory mechanisms seems to be an intuitive explanation, it is important to note that 
this remains a contentious issue in the wider literature. Indeed, some other studies 
investigating the links between CGD, ROS, inflammation and atherosclerosis have 
published seemingly conflicting data. Firstly, Deffert et al [193] simulated CGD-associated 
hyperinflammation in mice with genetic inhibition of NOX2 via an intradermal injection of 
β –glycan. The study found that these mice suffered a massive and prolonged 
hyperinflammation, with lesions characterized by persistent neutrophilic infiltration, along 
with ulceration and necrosis. Further work in this study attributed this finding to increased 
macrophage secretion of interleukin 1β (IL-1β), interleukin 6 (IL-6) and TNF-α. A similar 
upregulation of pro-inflammatory cytokines was noted in a study examining the effect of 
NOX2 deficiency in atherosclerosis prone ApoE-/- mice with angiotensin 2-induced 
abdominal aortic aneurysms (AAA) [194]. This paper concluded that systemic NOX2 
deficiency promotes AAA development due to enhanced macrophage secretion of not only 
1L-1β, but also of MMP-9, which promotes tissue remodelling in AAA. Importantly, this 
study also suggested a trend towards increased atheroma burden in these mice, although 
this was not the principal focus of the manuscript. Although the validity of NOX2 as a 
therapeutic target in atherosclerosis remains unclear, it certainly warrants further 
investigation. 
Excessive mitochondrial ROS production is also implicated in the development of 
cardiovascular disease, and a recent paper explored the role of mitochondria-derived ROS 
in the development of ischaemia-reperfusion injury [195]. Ischaemia-reperfusion injury is 
thought to be an important contributor to the damage caused by certain cardiovascular 
diseases, such as MI or stroke.  This novel study identified the citric acid cycle intermediate 
succinate to be responsible for mitochondrial ROS production during reperfusion. The 
authors noted that during ischaemia, activity of the enzyme succinate dehydrogenase 
(SDH) is reversed which resulted in accumulation of succinate. Following reperfusion, the 
direction of SDH activity is normalised and the accumulated succinate is rapidly re-
oxidised, driving extensive ROS production by reverse electron transport mitochondrial 
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complex 1. Significantly, pharmacological inhibition of succinate accumulation was 
demonstrated to ameliorate ischaemia-reperfusion injury in murine models of MI and 
stroke.  
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1.9 The ‘redox window’ hypothesis  
The ‘redox window’ hypothesis was first put forward by Yun el al [196] when studying 
redox signalling in coronary collateral growth. It states that a hypothetical window exists in 
which “redox state not only permits, but also can amplify coronary collateral growth. A 
shift in the redox state to either to an overly reductive environment or an oxidative 
environment corrupts growth factor–initiated redox-dependent signalling.”  
The studies cited in the preceding sections serve to corroborate this theory. Reducing ROS 
levels below a certain threshold (into an “overly reductive environment”) via deletion or 
inhibition of NADPH oxidase appears to be detrimental to vascular regeneration. However 
in situations of underlying oxidative stress, such as diabetes or hypercholesterolaemia, a 
reduction in ROS level has been shown to augment angiogenesis by shifting the redox state 
from an oxidative environment back into the hypothetical window. Furthermore, in 
situations where excessive and abnormal angiogenesis is pathological (tumours, 
retinopathies), reducing ROS levels via NADPH oxidase inhibition also appears to be 
beneficial in minimising disease progression (See figure 6). Support for this concept in 
human disease comes from the recent work of Ali et al [197], who showed that genetic 
variants associated with reduced expression of Gpx1 are associated with risk of arterial 
neointima formation. Surprisingly, they noted that beyond the somewhat predictable 
oxidative stress and enhanced atherosclerosis seen in Gpx1 knockout mice, glutathione 
accumulation resulted in simultaneous ‘reductive stress’, manifesting in the form of 
signalling dysregulation caused by inhibitory S-glutathionylation of the phosphatase SHP-2. 
This illustrates the complexity of redox imbalance in human disease, and supports the 
need for nuanced understanding of disease mechanisms in order to produce effective 
therapies. 
Whilst the ‘redox window hypothesis’ was initially proposed in relation to angiogenesis, 
given that certain mechanistic overlaps and redox-sensitive mediators are shared, it would 
seem intuitive for the principle to be applicable to the process of vascular repair as well. 
The concept of improving angiogenesis and vascular repair in the setting of oxidative stress 
via reduction of ROS levels forms the premise of my project and will be expanded in 
section 2.   
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Figure 6. The ‘redox window’ hypothesis 
NOX2 knockout results in impaired angiogenesis and vascular repair since insufficient levels of ROS are 
disruptive to redox signalling. However, when NOX2 is knocked down in the context of a disease process 
associated with oxidative stress, such as insulin resistance, angiogenesis and vascular repair can be augmented 
due to a shift into the optimal redox window. Taken with permission from Ali et al [116]. 
 
  
69 
 
1.10 Clinical implications and the therapeutic application of anti-oxidants 
Given the potential to prevent or treat a multitude of disease processes via manipulation 
of ROS levels, it is of no surprise that interest in the therapeutic application of anti-
oxidants has been intense. However, clinical trials have thus far been disappointing. The 
initial strategy employed involved use of SOD-mimetics with the intention of restoring 
oxidative balance. Whilst this appeared to work well in laboratory studies, clinical 
translation was found to be poor [198]. Initial promise was also seen with the anti-oxidant 
vitamin E which was found to reduce the incidence of MI in two small trials [199, 200]. 
However further research provided evidence to the contrary with a number of larger trials 
showing vitamin E to be either non-beneficial [201-203] and indeed even harmful [204]. It 
must also be noted that there is currently no convincing published evidence that anti-
oxidants can modulate pathological angiogenesis as seen in tumour development or 
proliferative retinopathies. 
The presumed reasons for the unsatisfactory results seen so far with anti-oxidants are 
multiple [205]: firstly, when anti-oxidants such as vitamin E scavenge radicals they 
themselves become radicals with the associated deleterious effects. Secondly, as discussed 
in section 1.2.3, ROS production is specifically localised within cells and it is likely that the 
anti-oxidants aren’t able to effectively reach the required sites. Finally, and most 
significantly, the anti-oxidant approaches described thus far were non-selective in their 
scavenging of ROS. Given the importance of physiological levels of ROS in redox signalling, 
the damage caused to homeostatic processes by a blanket reduction in their levels likely 
outweighs any potential benefit to the disease processes being targeted.  
Based on the issues identified with non-selective ROS level reduction, research has turned 
to explore the concept of NADPH oxidase inhibitors [206]. This area shows a great deal of 
potential, but a number of challenges remain. The most widely studied NADPH oxidase 
inhibitors are apocynin and diphenyleneiodonium (DPI), and while they have been of great 
value in research, their lack of specificity for NADPH oxidase over other enzymes limits 
their potential in clinical practice.  
Taking all of the above into account, the ideal solution appears to be a specific NOX1/2 
inhibitor which is able to maintain ROS levels within the redox window, whereby vascular 
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regeneration is augmented but homeostatic functions are not compromised. Further 
research is required in order to better characterise specific NADPH oxidase isoforms and 
the extent of enzymatic blockade required to in order to achieve the desired lowering of 
ROS levels. The necessity for further investigation into this area forms the rationale for my 
project, where I intend to assess the effect of NOX2 inhibition on angiogenesis and 
vascular repair in the context of insulin resistance. Given the importance of the specificity 
of inhibition, two complementary approaches will be used in order to curtail NOX2 activity: 
genetic knockdown of the enzyme, and NOX2-specific pharmacological inhibition using the 
synthetic peptide GP91ds-tat. The aims and objectives for the project are discussed in 
detail in the following section. 
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Chapter 2 Aims and Hypotheses 
The aim of this project was to explore the potential of manipulating ROS levels in order to 
enhance vascular repair and regeneration in the context of insulin resistance. The first part 
of the project focussed on murine models of insulin resistance, whilst the second part 
involved use of human umbilical vein endothelial cells (HUVECs) 
2.1 Murine models of insulin resistance 
IRKO and ESMIRO mice were bred with mice that have a genetic knockdown of the NOX2 
enzyme (GP91phoxy/-) in order to produce double transgenic offspring that simultaneously 
fail to express NOX2, whilst having whole-body or endothelium-specific insulin resistance 
respectively. For both colonies of mice, I intended to investigate the effect of NOX2 
inhibition in the setting of insulin resistance in the following ways: 
1. Phenotypic characterisation the double cross mice, with a comparison made to 
WT and insulin resistant (IRKO or ESMIRO) littermates. 
2. Assessing whether the double cross mice display improved endothelial repair 
following vascular injury relative to insulin resistant littermates. 
3. Assessing whether the double cross mice display improved ischaemic 
revascularisation following hind limb ischaemia relative to insulin resistant 
littermates. 
4. Comparing the abundance of CPCs and EPCs across the genotypes. 
5. Assessing the function of pulmonary-derived ECs across the genotypes. 
2.2 HUVEC model of insulin resistance 
A complementary model of insulin resistance was generated by using lentiviral 
transduction with appropriate shRNA to knock-down insulin receptor expression in 
HUVECs. These ‘insulin resistant’ HUVECs were treated with GP91ds-tat and then used in 
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functional and biochemical assays, which allowed an assessment to be made of the effects 
of pharmacological NOX2 inhibition on the function of insulin resistant ECs. 
2.3 Hypotheses 
1. Inhibition of NOX2 in the setting of insulin resistance can improve vascular repair and 
regeneration. 
2. These improvements arise from a combination of increased progenitor cell-mediated 
vascular repair and improved resident EC function. 
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Chapter 3 Materials  
3.1 Animal Husbandry  
Chow feed       B&K Universal Ltd 
3.2 Genotyping  
Sodium hydroxide       Fisher  
Tris-hydrochloric acid      Fisher  
Molecular grade H2O     BD Biosciences  
Biomix Red “Mastermix”     Bioline  
Primers (see Methods)      Invitrogen  
Tris base      Fisher  
EDTA        Sigma-Aldrich  
PCR reaction tubes/lids      Thermo Scientific  
PTC-200 Thermal Cycler     MJ Research  
Agarose       Bioline  
Glacial acetic acid      Fisher  
Ethidium bromide      Sigma-Aldrich  
100 base pair ladder      Thermo Scientific  
Syngene G-box imaging system     Syngene  
3.3 Glucocompetence Testing  
Accucheck glucometer/test strips    Aviva  
D-glucose       Sigma       
Actrapid insulin      Novo Nordisk 
Dulbecco’s phosphate-buffered Saline (PBS)   Sigma  
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Veet hair removal cream     Reckitt-Benckiser  
Vaseline® Paraffin-based ointment    Unilever  
14G needle       Terumo  
Microvette tubes (powdered lithium heparin)   Sarstedt 
Microvette (EDTA-tripotassium)    Sarstedt  
Liquid heparin sodium      Wockhardt  
Ultrasensitive mouse insulin ELISA kit (90080)  Crystal Chem  
Dynex MRX plate reader and Revelation v4.21  Dynex Technologies 
3.4 Real-time quantitative PCR  
Tissue Lyser       Qiagen  
6mm cone balls (RS.22.455.0003C)    Retsch  
RNAse Away spray      Molecular Bio Products  
TRIzol® (Tri reagent)      Sigma  
Phenol chloroform      Sigma  
Isopropanol       Sigma  
Ethanol       Fisher  
RNAse free H2O      Life Technologies  
NanoDrop® ND1000 Spectrophotometer   Thermo Scientific  
ND-1000 v3.1 software      Thermo Scientific  
High capacity cDNA reverse transcription kit  Applied Biosystems 
96 well optical reaction plate     Applied Biosystems  
ABI Prism 7900 HT PCR cycler     Applied Biosystems  
SDS v2.2 software      Applied Biosystems  
RT-PCR primers (SYBR green)     Invitrogen  
Power SYBR® green PCR Mastermix   Applied Biosystems  
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Taqman® Gene Expression Mastermix   Applied Biosystems  
RT-PCR primers (Taqman®)     Applied Biosystems  
Molecular grade H2O      BD Biosciences  
3.5 Vascular Injury  
Buprenorphine       Alsatoe Animal Health  
Isoflurane      Abbott Logistics BV  
Irripod (sterile 0.9% saline)     Unither  
Lignol (1% lignocaine + adrenaline)    Arnolds  
Dissecting microscope OPMI 1-FC    Zeiss  
Veet hair removal cream     Reckitt-Benckiser  
0.75% providone-iodine     Animal Care  
Vicryl absorbable 8.0/6.0 suture    Ethicon  
Iris Scissors and needle holder  World Precision Instruments  
Dry sterilizer #500121      World Precision Instruments  
Lubrital #31329      Dechra  
Vannas spring scissors      Fine Science Tools  
Dumont, atraumatic tipped forceps (11253-25)   Fine Science Tools  
Round handled suture tying forceps    Fine Science Tools  
Hitorque Cross-it 200XT guide wire    Abbott Vascular  
Evans Blue (195550050)     Acros Organics  
4% paraformaldehyde      Fisher  
30% hydrogen peroxide      Sigma  
Insulin syringe / 27Gx13mm needle    Terumo  
Olympus Dissecting Stereo Microscope SZ61  Olympus 
QiCam Olympus digital camera     Olympus  
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ImagePro Plus 7.2      Media Cybernetics  
Micro-osmotic pump model 1002   Alzet 
GP91-ds tat – RP21052     Genscript 
GP91-ds tat scrambled peptide – RP21051  Genscript 
3.6 Ischaemic revascularisation 
Nikon SMZ1500 Stereo microscope   Nikon 
Olympus SZ61 microscope    Olympus 
Olympus QiCam digital camera    Olympus 
Fluovac anaesthetising chamber    Harvard apparatus 
Compact anaesthesia system AN001   Vet Tech solutions 
Isofluorane key fill applicator AN003B   Vet Tech solutions 
Heating plate      Vet Tech solutions 
Thermal cage HE-011     Vet Tech solutions 
Light source 1500 LCD     Schott KL 
Guide wire 0.014” Hi-Torque Cross-IT   Abbott Vascular 
Micro serrifine curved (18055-05)    Inter Focus 
Forceps type clip applicator (18057-14)   Inter Focus 
Needle holder (14109)     World Precision Instruments 
Vannas scissors (501778)    World Precision Instruments 
Vannas scissors (91501-09)    Inter Focus    
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Fine Iris scissors (14094-11)    Inter Focus 
Tweezers Dumont #500339    World Precision Instruments 
Insulin syringe 0.3ml with 29G x 13mm needle  Terumo 
Insulin syringe 0.5ml with 27G x 13mm needle  Terumo 
Insulin syringe 1ml with 29G x 13mm needle  Terumo 
VICRYL absorbable surgical suture, 6-0   Ethicon, J&J 
VICRYL absorbable surgical suture, 8-0   Ethicon, J&J 
Microscope slide     Cell path 
Microscope slide coverslip 22mm x 22mm  SLS 
Veet hair removal cream     Reckitt-Benckiser  
Isofluorane-vet      Merial Animal Health 
Rodent No.1 maintenance diet    Specialist diet service 
Buprenorphine      Alsatoe Animal Health 
Laser Doppler analysis Moor LD12-HR   Moor systems 
3.7 Enumeration of Circulating Progenitor Cells (CPCs)  
Heparin 1000IU/mL      Wockhardt  
Microvette (EDTA-tripotassium)    Sarstedt  
Pharmlyse red cell lysis buffer     BD Biosciences  
Syringe filter (0.2μm membrane)    Pall Life Science  
Corning centrifuge tubes     Sigma  
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Foetal bovine serum (FBS)     Biosera  
Bovine serum albumin (BSA)    Sigma  
Fc block (CD16/CD32 rat anti-mouse 553142)  BD Biosciences  
FITC (rat IgG2a Isotype Control 553929)   BD Biosciences  
Sca1-FITC (rat IgG2a κ Ly6A/E 557405)    BD Biosciences  
PE rat (IgG2a κ Isotype Control 553930)    BD Biosciences  
Flk1-PE (Flk1 VEGFR2; 555308)     BD Biosciences  
APC (rat IgG2b κ Isotype Control; 553991)  BD Biosciences  
APC (rat anti-mouse CD117; 553356)    BD Biosciences  
Fortessa Flow Cytometer    BD Biosciences 
3.8 Isolation and Enumeration of Early Outgrowth EPCs  
Insulin syringe / 29G x 13mm needle    Terumo  
Sodium citrate from 4mL blood collection tubes   Greiner Bio-One  
4mL EDTA blood tube      Greiner Bio-One  
23G needle       Terumo  
70μm nylon cell strainer     Greiner Bio-one  
5cm Petri dish       BD Falcon  
Histopaque-1083     Sigma  
EGM-2 basal medium/bullet kit     Lonza  
Foetal bovine serum      Biosera  
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Antibiotic/antimycotic supplement    Invitrogen  
Trypan blue       Sigma  
Neubauer Counting Chamber     Hawksley  
24-well/6-well fibronectin coated cell culture plates  BD Biocoat  
DiI-ac-LDL       Life Technologies  
FITC-lectin       Sigma  
CKX-41 fluorescent microscope     Olympus  
Cell B software      Olympus  
Image J v1.46r       National Institutes of Health  
3.9 Isolation and Culture of Pulmonary Endothelial Cells (PECs)  
Scalpel blades size 22      Swann-Morton  
Dulbecco’s Modified Eagle’s Medium (31966-021) Life Technologies  
Hank’s Balanced Salt Solution (H9269)   Sigma  
Collagenase/Dispase (11097113001)    Roche  
Bovine skin gelatin      Sigma  
Bovine serum albumin 7.5%     Sigma  
MACSmixTM tube rotator     Miltenyi Biotec  
14G Cannula       BD Biosciences  
10mL syringe       BD Biosciences  
EC growth medium MV2 + supplements   PromoCell  
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Foetal bovine serum      Biosera  
Antibiotic/antimycotic supplement    Invitrogen  
CD146 (LSEC) microbeads, mouse   Miltenyi Biotec 
T25 Corning® cell culture flask     Sigma  
Trypsin-EDTA 0.25%      Sigma  
OctoMACS manual separator    Miltenyi Biotec 
MACS MS cell separation columns   Miltenyi Biotec 
Dulbecco’s phosphate-buffered Saline (PBS)   Sigma  
3.10 Culture of human umbilical vein endothelial cells (HUVECs) 
HUVECs cryopreserved (pooled)    Promo Cell 
100mm TC- treated culture dish    Corning 
Medium 199      Sigma Aldrich 
Foetal bovine serum      Biosera  
Antibiotic/antimycotic supplement    Invitrogen  
Endothelial growth supplement (E2759-5X15MG) Sigma Aldrich 
Sodium pyruvate (P2256-25G)    Sigma Aldrich 
Heparin 1000IU/mL      Wockhardt  
HEPES 1M solution (15630-080)    Thermo Scientific 
Dulbecco’s phosphate-buffered Saline (PBS)   Sigma  
MISSION® shRNA lentiviral particle 07101521MN Sigma 
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GP91-ds tat – RP21052     Genscript 
GP91-ds tat scrambled peptide – RP21051  Genscript 
3.11 Endothelial cell functional assays 
3.11.1 Endothelial cell proliferation assay 
Click-iT® EdU Alexa Fluor 647 flow cytometry assay kit Life technologies 
Fortessa Flow Cytometer    BD Biosciences 
3.11.2 Endothelial cell migration assay 
ImageLock 96 well plate     Essen Biosciences  
WoundmakerTM 96-pin tool     Essen Biosciences  
Integrated Cell Migration Analysis Module  Essen Biosciences  
IncuCyteTM Imaging System    Essen Biosciences  
Alconox/Vircon cleaning solutions    Sigma  
3.11.3 Superoxide assay 
Clear 96 well cell culture plate     Thermo Scientific  
Dihydroethidium D11347     Life Technologies  
HEPES sodium salt      Sigma  
Flex Station 3 Multi-mode microplate reader  Molecular Devices    
SoftMax® Pro v5.4.5      Molecular Devices  
3.12 Western blotting 
Tris-HCl       Fisher  
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Glycerol       Sigma  
EDTA        Sigma  
Sodium dodecyl sulphate     Sigma  
Phosphatase inhibitors 2&3     Sigma  
Tween®-20       Sigma  
Bovine serum albumin (BSA)     Sigma  
Pierce® BCA protein assay kit     Thermo Scientific  
96 well clear microplate     Greiner Bio-One  
Micro-amp® optical adhesive film    Life Technologies  
NuPAGE® LDS sample buffer     Invitrogen  
NuPAGE® sample reducing agent    Invitrogen  
NuPAGE® MES SDS running buffer    Invitrogen  
NiPAGE® 4-12% Bis-Tris Gel     Invitrogen  
XCell SureLock Electrophoresis cell    Thermo Scientific   
Amersham Tracker Tape (#RPN2050)    GE Healthcare 
Primary antibodies (see table 10)   Cell Signaling 
Secondary antibodies (see table 10)   Dako 
Immobilon Western Chemiluminescent HRP Substrate  Merck Millipore  
Immobilon®-P transfer membrane    Merck Millipore  
Syngene G-box imaging system     Syngene  
Dynex MRX plate reader and Revelation v4.21  Dynex Technologies  
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Image J v1.46r       National Institutes of Health 
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Chapter 4 Methods  
4.1 Animal husbandry 
4.1.1 Housing and experimental conditions 
All experiments were performed under the Experimental Animals (Scientific Procedures) 
Act 1988. Mice were housed in the animal facility at the University of Leeds under standard 
laboratory conditions and were fed a standard chow diet and normal drinking water. In 
order to allow identification, the mice underwent ear notching at the age of 3-4 weeks, 
and the notched tissue was used for genotyping. Only male animals were used in order to 
exclude cardiovascular effects of cyclically varying oestrogen levels and lyonisation of the 
mutant NOX2 allele expressed on one of the X chromosomes.       
4.1.2 ESMIRO mice 
ESMIRO mice display endothelium-targeted over-expression of a dominant-negative 
mutant human insulin receptor (hIR). The IR is rendered less catalytically active in response 
to insulin binding due to an amino acid substitution in the kinase domain. To achieve this, a 
Thr1134 mutation was introduced into the cDNA encoding hIR by site-directed mutagenesis. 
In order to target the expression of the mutant hIR to the endothelium, a murine Tie2 
promoter and intronic enhancer was used. The mutant hIR cDNA was cloned into a pHHNS 
plasmid following excision of the LacZ sequence with Sbf1 and Mlu1. The transgene Tie2-
hIR was then microinjected into fertilised eggs from C57 black 6 (C57BL/6) x CBA mice, and 
the offspring backcrossed eight times onto a C57BL/6 background.  
ESMIRO mice used for this project were obtained from established local colonies, having 
been originally generated by Duncan et al [56].  
4.1.3 IRKO mice 
IRKO mice, which are haploinsufficient for the IR, were originally developed at the National 
Institutes of Health (USA). Their generation was achieved by targeting the IR gene using a 
vector which incorporates a premature chain termination at exon 4, as well as a cassette 
encoding neomycin resistance. Using electroporation, this vector was used to transfect 
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embryonic stem cells, into which the gene could then be incorporated via homologous 
recombination. These embryonic stem cells were then grown in the presence of neomycin, 
allowing selection for the mutated allele. The surviving cells were expanded prior to being 
injected into murine embryos at day 3.5. These embryos were implanted into dark-coated 
female C57BL/6 mice, resulting in chimeric offspring identifiable by coat colour. The male 
offspring were bred with C57BL/6 females, and the resulting progeny used to establish 
colonies. 
IRKO mice were purchased from Jackson laboratories and bred with female C57BL/6 mice 
for 12 generations in order to generate local colonies. The IRKO mice used in this project 
were obtained from these established local colonies, thus obviating the need for genetic 
manipulation at our site.  
4.1.4 GP91phox y/- mice 
GP91phox y/- mice display whole-body knockdown of the NOX2 enzyme, and the original 
generation of this model is described in detail by Pollock et al [207]. The gene for NOX2 is 
located on the X chromosome at a locus designated Cybb. A 4.8kb NcoI genomic fragment 
containing the second and third exons of the Cybb gene was used to construct a targeting 
vector by placing the expression cassette for neomycin-resistance into the third exon and 
attaching a flanking herpes thymidine kinase gene. Using electroporation, this vector was 
used to transfect embryonic stem cells which were then grown in the presence of 
neomycin, allowing selection for the mutated allele. A correctly targeted selected clone 
from the electroporated embryonic stem produced chimeric males, hemizygous for the 
disrupted gene. These were subsequently backcrossed to C57BL/6 in order to generate 
colonies.  
The GP91phox y/- mice used in this project were obtained from established local colonies, 
having been originally purchased from the Jackson Laboratory. 
4.1.5 ESMIROxGP91phox y/- mice 
Male ESMIRO mice were bred with female GP91phox heterozygous mice, resulting in litter 
containing the ESMIRO x GP91phox y/- genotype. The other genotypes from this litter were 
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wild type (WT), ESMIRO and GP91phox y/-. Experimental work was carried out on all 
genotypes except GP91phox y/-. 
4.1.6 IRKOxGP91phox y/- mice 
Male IRKO mice were bred with female GP91phox heterozygous mice, resulting in litter 
containing the IRKO x GP91phox y/- genotype. The other genotypes from this litter were 
WT, IRKO and GP91phox y/-. Experimental work was carried out on all genotypes except 
GP91phox y/-. 
4.1.5 Animal euthanasia 
Animals were sacrificed in two ways depending on requirements. Prior to obtaining organs, 
mice were exposed to rising concentrations of carbon dioxide in a 12 minute cycle. After 
confirming death using cervical dislocation, the required tissue was dissected. For EPC 
isolation 1mL of blood was required, and since the 12 minute cycle resulted in 
intravascular thrombosis, these mice underwent terminal isoflurane anaesthesia. 
Following this, a caval bleed was performed and any other tissue was obtained by 
dissection. 
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4.2 Genotyping 
4.2.1 DNA extraction 
Ear notches were incubated in 100µL of 25mM NaOH/EDTA for 25 minutes at 95°C. 
Following this, 100µL of 40mM Tris-HCl was added and the sample vortexed thoroughly in 
order to disperse the DNA.  
4.2.2 Polymerase chain reaction (PCR) 
For each PCR reaction, a stock solution was prepared in a laminar flow hood. The stock 
solution comprised primers, distilled water and a commercially obtained pre-made 
‘Mastermix’ which contained PCR buffer, magnesium chloride, deoxynucleotide 
triphosphate (dNTP) mixture and Thermophilus aquaticus (Taq)-derived DNA 
polymerase. The volume of each constituent within the stock solution per sample is listed 
in table 1. 
 ESMIRO IRKO GP91y/- 
Mastermix (μL) 10 10 10 
Primer 1 (μL) 0.5 0.5 0.5 
Primer 2 (μL) 0.5 0.5 0.5 
Primer 3 (μL) N/A 0.5 1 
Water (μL) 13 12.5 12 
Table 1 Constituents of genotyping stock solution 
Stocks of the primers were obtained commercially and reconstituted in TE buffer (10mM 
Tris, 1mM EDTA at pH 8) and then subsequently diluted 1:10 in distilled water.  
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All components were mixed and 24µL reaction volumes were measured into PCR tubes. 
1µL of either DNA or controls were added to each tube and PCR was carried out by thermal 
cyclers with heated lids using a specific programme for the IRKO, ESMIRO and GP91phoxy/- 
DNA. 
4.2.3 ESMIRO PCR 
Two primer sequences specific for the gene targeting cassette were used:  
 Forward – TGG CAG CTT TCC CCA ACA CT 
 Reverse – CCG TTC CTC AGG GGT GTCC 
The PCR comprised the following cycles: 
 1. 94°C for 4 minutes 
 2. 94°C for 1 minute 
 3. 55°C for 1 minute 
 4. 72°C for 1 minute 
  Repeat steps 2-4 for 32 cycles 
 5. 72°C for 15 minutes 
 6. 4°C on hold 
On UV imaging following gel electrophoresis, WT DNA showed no bands whilst ESMIRO 
DNA displayed a band at 172bp. 
4.2.4 IRKO PCR 
Three primer sequences specific for the gene targeting cassette were used:  
Forward - TTA AGG GCC AGC TCA TTC CTCC  
Forward - AGC TGT GCA CTT CCC TGC TCAC  
Reverse - TCT TTG CCT GTG CTC CAC TCT CA  
The PCR comprised the following cycles:  
1. 94°C for 4 minutes  
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2. 94°C for 1 minute  
3. 62°C for 1 minute  
4. 72°C for 1 minute  
 Repeat steps 2-4 for 31 cycles 
 5. 72°C for 4 minutes 
On UV imaging following gel electrophoresis, WT DNA fluoresced as a single band at 232bp 
whilst IRKO DNA displayed a double band at 232bp and 255bp. 
4.2.5 GP91phox PCR 
Three primer sequences specific for the gene targeting cassette were used:  
 517 - AAG AGA AAC TCC TCT GCT GTG AA 
 518 – CGC ACT GGA ACC CCT GAG AAA GG  
 519 – GTT CTA ATT CCA TCA GAA GCT TAT CG 
The PCR comprised the following cycles: 
 1. 94°C for 3 minutes 
 2. 94°C for 20 seconds 
 3. 64°C for 30 seconds 
 4. 72°C for 35 seconds 
  Repeat steps 2-4 for 12 cycles 
 5. 94°C for 20 seconds 
 6. 58°C for 30 seconds 
 7. 72°C for 35 seconds 
  Repeat steps 5-7 for 25 cycles 
 8. 72°C for 2 minutes 
On UV imaging following gel electrophoresis, WT DNA fluoresced as a single band at 
240bp. A single band at 195bp represented a DNA from a GP91phoxy/- homozygote, whilst 
a double band at 195bp and 240bp represented DNA from a heterozygous female. 
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4.2.6 Gel electrophoresis 
The products of the PCR were identified by electrophoresis on a 1.5% agarose gel 
containing 3µL of 10mg/ml ethidium bromide. Electrophoresis was performed at 110V for 
60 minutes with a 1000bp reference ladder. Gels were imaged using Gene Sys V1.4.0.0 
software and a Syngene Chemi XT4 imaging box. 
4.3 Glucocompetence testing 
4.3.1 Random capillary blood glucose measurements 
Mice were gently coaxed head first into syringe-like restraining devices, leaving their tail 
freely accessible. Their baseline blood glucose level was assessed by obtaining a drop of 
blood from a superficial tail incision. The capillary blood glucose (CBG) level was analysed 
using Accu-Chek glucose testing strips and glucometer. 
4.3.2 Glucose tolerance testing (GTT) 
Prior to the GTT, mice were habituated to the syringe-like restraining device in order to 
minimise stress during the test. Once the mice were relatively comfortable with being 
restrained in this way, they were fasted overnight with unrestricted access to drinking 
water. The following morning they were weighed and their baseline CBG was assessed in 
the same way as described above. Following this, the mice received an intraperitoneal (IP) 
injection of 1mg glucose per gram of bodyweight. CBG was then measured at 30, 60, 90 
and 120 minutes post injection using the same technique as for assessing baseline blood 
glucose. In between measurements, mice were placed back in their cage with free access 
to water but not chow.  
4.3.3 Insulin tolerance testing (ITT) 
As described above, mice were habituated to the restraining device prior to the test. Once 
relatively comfortable, mice were fasted for 4 hours with unrestricted access to drinking 
water. Following the fast, baseline CBG was measured as described above and the mice 
received an IP injection of insulin at a concentration of 0.75iu per kilogram of bodyweight. 
94 
 
Once again CBG was measured at 30, 60, 90 and 120 minutes and the mice had free access 
to water in between measurements. 
4.3.4 Plasma insulin measurement 
4.3.4.1 Blood collection 
In order to obtain blood samples of sufficient quantity for plasma insulin measurement, 
saphenous vein puncture was required, and this was performed by my colleague Dr 
Anshuman Sengupta. Following an overnight fast, mice were coaxed into the restraining 
device as described above. The right hindlimb was gently pulled out of the open end of the 
tube, allowing a hair removal cream to be applied to the surface. The cream was allowed 
to take effect for approximately 30 seconds, after which the hair was wiped away using a 
tissue paper, thus allowing visualisation of the distal saphenous vein. Vaseline was applied 
to the skin surface and a puncture to the vein made using a 14G needle. The blood was 
collected using capillary tubes, and stored in heparin-lined Microvette tubes. The blood 
samples were transferred in ice with minimal delay and centrifuged at 6000 revolutions 
per minute (rpm) for six minutes, after which plasma was removed and stored at -80°C.  
4.3.4.2 Enzyme linked immunosorbent assay (ELISA) 
Ready-made ELISA kits for mouse insulin (Crystal Chem) were used according to 
manufacturer’s instructions for a “low-range” assay (0.1-6.4ng/mL). This involved 
incubating 95µL of sample diluents with either duplicate serial dilutions of a mouse insulin 
standard (for a standard curve) or the plasma samples for two hours at 4°C in order to 
allow antibody binding. After five washes with 300µL of wash buffer, 100µL of an anti-
insulin enzyme conjugate was added to each well and incubated at room temperature for 
30 minutes. The wells were then washed seven times prior to adding 100µL of enzyme 
substrate solution. The plate was incubated in the dark for 40 minutes, following which the 
reaction was aborted by adding 100µL of a “stop” solution to each well. A Dynex MRX plate 
reader and Revelation v4.21 were used to perform colorimetric analysis at 450nm. The 
standard curve was appraised for linearity and correlation co-efficient (r2), the latter 
accepted when >0.99. Sample insulin concentrations were inferred from the standard 
curve and accepted only at a co-efficient of variation (CV) of <10% between duplicates.   
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4.4 Real time quantitative PCR 
This process was used to quantify the abundance of NOX2, human insulin receptor (hIR), 
murine insulin receptor (mIR), tumour necrosis factor α (TNFα), interleukin 1β (IL-1β) and 
vascular cell adhesion protein 1 (VCAM1) mRNA in the ESMIROxGP91phox mice. The 
experiment comprised three parts: 
4.4.1 RNA extraction 
The RNA was extracted from aortic and lung tissue. The organs were harvested from mice 
following euthanasia and transferred into individual 2ml micro-centrifuge tubes. These 
tubes were snap frozen in liquid nitrogen and then stored at -80°C. In order to proceed 
with RNA extraction the organs required homogenisation. This was achieved by adding a 
tissue lyser bead and 1ml of Trizol® to the micro-centrifuge tube, following which the 
samples were loaded into a tissue lyser machine and shaken in 3 cycles of 2 minutes at 
30Hz. Once this process had completed, the solid material and lyser bead were discarded, 
leaving behind a supernatant.  
The samples were centrifuged at 4°C at 10,000g and the supernatant transferred into fresh 
micro-centrifuge tubes. The samples were left to dissociate for 5 minutes at room 
temperature before 200µL of chloroform was added to each. The tubes were agitated for 
15 seconds in order to ensure adequate mixing, and the samples left at room temperature 
for 3 minutes. Following this, the samples were centrifuged at 12,000g and 4°C for 15 
minutes. Once again the supernatant was separated and 500µL of isopropanol added to 
each sample. Following gentle agitation the tubes were left at room temperature for 10 
minutes and then centrifuged at 12,000g for 10 minutes at 4°C. On this occasion the 
supernatant was discarded and the pellet re-suspended in 1ml of 75% ethanol. The 
samples were then centrifuged at 7500g for 5 minutes at 4°C. Following this the ethanol 
was removed and the pellets left to air dry for 10 minutes at room temperature. The final 
step in the RNA extraction was to dissolve the pellet in 20µL of RNAase free water and 
allow the samples to cool on ice for 20 minutes. 
The concentration of RNA in each sample was determined by placing a 2µL drop of the 
solution onto a NanoDrop® machine which would analyse the sample using ND-1000 
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V3.1.0 software to generate a concentration of RNA in ng/nL. This result was then divided 
into 2000 in order to give the volume of sample within which 2μg of RNA was contained. 
This volume of sample was then diluted with distilled water in order to create a total 
volume of 10μL, which could then be used for reverse transcription. 
4.4.2 Reverse transcription of RNA 
A mastermix was made using components within the High Capacity cDNA Reverse 
Transcription Kit in the quantities outlined in table 2.   
Component Volume (μL) 
Water 4.2 
Buffer 2 
Random primers 2 
Multiscribe® enzyme 1 
dNTPs 0.8 
Table 2 Constituents of the reverse transcription mastermix  
dNTP: deoxynucleotide triphosphate 
For each sample, 10µL of mastermix was added to 2µg of RNA in a PCR plate. The plate was 
then placed into a thermal cycler with a heated lid which then took the samples through 
the following cycle:  
 1. 25°C for 10 minutes  
 2.37°C for 2 hours  
 3. 85°C for 5 minutes  
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 4. 4°C for 30 minutes 
4.4.3 Quantitative Real-time PCR 
Two different probes were used for this experiment, based on which samples were being 
assessed and which RNA was being quantified. The rationale for this was based upon prior 
work in our lab which had demonstrated that the two probes were differentially effective 
depending on what was being quantified. In all cases, beta actin was used as a 
housekeeping control. Table 3 outlines which probe was used for the different 
quantifications: 
Transcript Probe 
hIR SYBR green 
NOX2 SYBR green 
mIR Taqman® 
TNFα Taqman® 
IL-1β Taqman® 
VCAM1 Taqman® 
Table 3 RT-qPCR probe selection 
SYBR green:  Synergy Brands (SYBR) Green probe; hIR: human insulin receptor; NOX2: NADPH oxidase 2; mIR: 
murine insulin receptor; TNFα: tumour necrosis factor α; IL-1β: interleukin 1β; VCAM1: vascular cell adhesion 
molecule 1. 
The cDNA samples produced as a result of the reverse transcription were diluted 1:20 into 
TE buffer for use with the SYBR green probe, but used neat with the Taqman® probe. The 
sample was then added to a mastermix containing the probe, primers and double distilled 
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water. The constituents of the mastermix for the two probes are outlined in tables 4 and 5, 
whilst the sequences for each primer are listed in tables 6 and 7. 
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Component Volume (μL) 
Water 8.5 
SYBR green 12.5 
Forward primer 1.5 
Reverse primer 1.5 
Table 4 Constituents of SYBR green mastermix 
Component Volume (μL) 
Water 8 
Taqman® mastermix 10 
Probe 1 
Table 5 Constituents of Taqman® mastermix 
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Gene Forward primer Reverse primer 
β actin CGT GAA AAG ATG ACC CAG 
ATCA 
 
TGG TAC GAC CAG AGG CAT 
ACAG 
hIR TGC CAC CAA CCC CTC TGT CGG AGG GTG GTT TCC ACTT 
NOX2 ACT CCT TGG GTC AGC ACT GG GTT CCT GTC CAG TTG TCT TCG 
Table 6 SYBR green primers 
Gene Assay number 
β actin Mm 00607939 
mIR Mm 01211875_m1 
IL-1β Mm00434228_m1 
VCAM1 Mm01320970_m1 
TNFα Mm00607939_s1 
Table 7 Taqman® primers 
The PCR was performed by a thermal cycler with each sample being analysed in triplicate. 
This yielded three threshold (Ct) readings per sample, the mean of which was then 
calculated. The difference in Ct between the gene of interest and β actin (ΔCt) was then 
used to calculate the relative quantity using the following formula: 
RQ = 2-ΔCt x 100. 
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4.5 Vascular repair 
The surgery described in this section was performed by Dr Nadira Yuldasheva. 
4.5.1 Arterial injury 
Mice were operated on under conditions of general anaesthesia. Induction of anaesthesia 
was achieved by placing the mouse to be operated on in an anaesthetic chamber, into 
which 5% inhaled isoflurane was introduced. Once the mouse had lost consciousness, it 
was placed onto a warmed operating table in a supine position and anaesthesia 
maintained using 1-2% isoflurane delivered via facemask. Prior to the start of the 
operation, appropriate anaesthesia was confirmed by loss of withdrawal reflexes in the 
paw. 
Veet® cream was used to remove hair from the hindlimb in order to allow clear 
visualisation of the skin surface. A small mid-thigh incision was made in order to gain 
access to the femoral canal, within which the femoral artery lies. Once identified, the 
femoral artery was separated from the neurovascular bundle and then loosely tied using 
an 8.0 suture and a proximal clamp. An arteriotomy was made in the profunda femoris, 
through which a 0.014 inch diameter angioplasty guide wire could be passed into the 
lumen of the femoral artery, aided by the application of 1% lignocaine in order to reduce 
vasospasm. The wire was advanced 2cm for three passes in order to achieve complete 
endothelial denudation. Following this, the wire was removed and the profunda femoris 
was ligated proximal to the arteriotomy via tightening of a suture. For control purposes, 
the contralateral artery underwent a sham procedure which did not involve the passage of 
a wire. Following surgery, the mice underwent a monitored recovery period during which 
they were checked daily until the end of the experiment. 
4.5.2 Assessment of re-endothelialisation 
Evans blue dye was used in order to identify areas of residual endothelial denudation, 
since it can only penetrate the subendothelial layer in these regions. As a result it stains 
areas of denudation blue, whilst leaving recovered areas unstained (see figure 7). The 
Evans blue dye (50µL of 5% in PBS) was injected into the mouse via the inferior vena cava 
under general anaesthesia four days after the vascular injury. Two minutes later, 4% 
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paraformaldehyde was injected into the left ventricle for the purposes of perfusion 
fixation. Once this had been achieved, as evidenced by muscle fasciculation, both femoral 
arteries were harvested and stored in 4% paraformaldehyde.  
The vessel was opened longitudinally under microscopy and a 5mm segment of artery 
was identified at a distance of 5mm from the proximal end (the aortic bifurcation) of 
the vessel. The total segment area and the area of remaining denudation (i.e. the portion 
stained blue) were quantified using ImagePro Plus 6.2 software. Subtraction of the blue-
stained area from the total segment area gave extent of endothelial regeneration, which 
could then be expressed as a percentage of recovery. 
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Figure 7 Vascular repair  
The above image demonstrates 10mm segments of both femoral arteries taken from a mouse following 
vascular injury and staining with Evans blue dye. The bottom vessel is the contralateral femoral artery which 
was not injured, and therefore remains unstained. The top vessel is the femoral artery which underwent 
vascular injury, with the segment of interest (measuring 5mm in length) highlighted. The areas of blue within 
the 5mm portion represent regions where the endothelium has failed to regenerate, whilst the areas of white 
within the 5mm portion represent re-endothelialisation. 
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4.6.3 Micro-osmotic pump insertion 
In order to investigate the effect of pharmacological NOX2 inhibition on vascular repair in 
the context of insulin resistance, experiments were performed whereby ESMIRO mice aged 
18-19 weeks were chronically exposed to a specific NOX2 inhibitor named GP91-ds tat. 
This molecule is a commercially available chimeric peptide which inhibits p47phox 
association with GP91phox, thereby preventing O2- production [72]. A scrambled ds-tat 
peptide was also administered to a cohort of equivalent-aged ESMIRO mice as a control. 
The GP91-ds tat or control scrambled peptide were delivered to the mice via a 
subcutaneously located micro-osmotic pump (Alzet, model 1002) which infused the drugs 
at a fixed rate over a 12 day period. 
Prior to insertion, the pump was incubated in sterile saline at 37°C overnight. The pump 
was then filled with a solution of either GP91-ds tat or scrambled-ds tat control peptide. 
Both molecules were dissolved into solution (the diluent was made up from 100ml distilled 
water, 0.9g sodium chloride and 57.5μL acetic acid), and 100μL of this solution loaded into 
the micro-osmotic pump. The pump was pre-programmed to deliver the drugs at a rate of 
0.25μL/hour, which equated to 10mg of GP91-ds tat or scrambled peptide per kg per day. 
In order to insert the pump, the mouse was placed under general anaesthesia as described 
in section 4.5.1. Once anesthetised, the mouse was placed in the prone position and given 
an IP injection of 0.25mg/kg of buprenorphine. The hair covering the scruff of the mouse 
was removed using an electric shaver, and an 8mm vertical incision made between the 
scapulae. Using sterile artery forceps, a small pocket was formed by spreading the 
subcutaneous connective tissue apart. The pump was then inserted into the pocket and 
the incision closed using 6.0 Vicryl sutures. 
Following insertion of the pumps, the mice were housed in normal conditions for one 
week, at which point they underwent arterial injury as described in section 4.5.1. The 
pump continued to infuse GP91-ds tat or scrambled peptide during the 5 day 
convalescence period, prior to the femoral artery being harvested and imaged as outlined 
in section 4.5.2. 
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4.6 Ischaemic revascularisation 
The surgery described in this section was performed by Dr Nadira Yuldasheva. 
4.6.1 Hindlimb ischaemia 
Two to three days prior to surgery, mice underwent hair removal under general 
anaesthesia, which was induced and maintained in the same manner as detailed in section 
4.5.1.  An electric shaver and Veet® cream was used in order to remove hair from both 
hindlimbs and the lower abdominal wall. The mice were then allowed to recover for long 
enough to allow the cutaneous inflammation to resolve, as this would otherwise cause a 
background signal on laser Doppler imaging. 
Surgery was carried out under general anaesthesia in the manner outlined above, but with 
the addition of an IP injection of buprenorphine (0.25mg/kg) for post-operative analgaesia. 
Once the subject was adequately anaesthetised and positioned, a mid-thigh incision was 
made in order to expose the femoral canal. Once the femoral artery had been identified 
and dissected, it was ligated proximally at the inguinal ligament and distally at the 
bifurcation of the saphenous and popliteal vessels. The intervening segment of artery was 
then excised and the skin closed. As with the vascular repair experiment, post-operatively 
the mice underwent a monitored recovery period where they were checked on a daily 
basis. 
4.6.2 Laser Doppler assessment of reperfusion 
Laser Doppler imaging was undertaken in order to confirm ischaemia 90 minutes post-
operatively, and then at 7 day intervals for 28 days in order to assess reperfusion. The 
imaging was performed under general anaesthesia, which was induced in the same 
manner as described in section 4.5.1. Once anaesthetised, the mouse was laid supine on a 
non-reflective, light absorbing mat and the snout was placed into a facemask which 
allowed delivery of 1-2% isoflurane as maintenance anaesthesia. Both hindlimbs were 
extended and supinated, with the dorsal aspects of the paws stuck down to the mat using 
a 1mm strip of double-sided adhesive tape. Once the mouse was in position, a laser 
Doppler imager (Moor Systems LDI2-HIR) was used to scan both hindlimbs simultaneously. 
Analysis of the data was performed by MoorLDI V5.3 software, which produced an image 
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with a range of colours indicative of the relative perfusion within the limbs (see figure 8). A 
region of interest which incorporated the area below the ankle was chosen in each 
hindlimb, and the colour within this area analysed by the software to produce an overall 
index of perfusion. By dividing the perfusion index of the ischaemic limb by that of the 
non-ischaemic limb, a relative perfusion index (RPI) was generated. Following the scan, the 
mouse was awoken and allowed to recover.  
As mentioned above, laser Doppler imaging was undertaken at 7-day intervals up until 28 
days post-operation. Following the day 28 scan, the mice were sacrificed and 4% 
paraformaldehyde used for perfusion fixation in the same manner as described in section 
4.5.2. The gastrocnemius muscle from the ischaemic and non-ischaemic limbs then were 
harvested and embedded in optimal cutting temperature compound (OCT), prior to being 
snap frozen in liquid nitrogen. These samples are currently being stored with a view to 
using them for capillary density quantification in future.  
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Figure 8 Hindlimb ischaemia 
Laser Doppler images demonstrating blood flow in the hindlimbs before (left) and after (right) ligation and 
excision of the femoral artery. 
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4.7 Circulating progenitor cell (CPC) enumeration 
4.7.1 Blood collection  
Blood collection was carried out by Dr Anshuman Sengupta 
150µL of blood was obtained following saphenous vein puncture in the same manner as 
described in section 4.3.4.1, and collected into Microvette tubes containing 50µL of 
heparin (1000 IU/mL). The blood samples were then transferred into 15ml centrifuge tubes 
containing 3mL of sterile 1:10 Pharmlyse™ red cell lysis buffer. The samples were 
transferred on ice from the animal facility to the laboratory, where thrombi were then 
removed using a 1ml pipette tip.  
4.7.2 Incubation with antibodies 
The samples were centrifuged at 300g and 18°C for 10 minutes, following which the 
supernatant was aspirated. The remaining pellet was then re-suspended in 1ml of FACS 
buffer and centrifuged at 300g for 10 minutes once again. The FACS buffer was made up of 
PBS with 0.5% (v/v) foetal calf serum (FCS) and 0.5% (m/v) bovine serum albumin (BSA). 
Once the supernatant had been discarded, the pellet was then re-suspended in 100µL of 
1:10 Fc block and refrigerated in the dark for 10 minutes.  
During this 10 minute incubation, two solutions were made up which contained 1:50 
dilutions of either the three antibodies or their isotype controls, with FACS buffer being the 
diluent. The antibodies and their attached fluorochomes are listed below: 
1. Stem cell antigen (Sca1)   Fluorescin isothiocyanate (FITC) 
2. Kinase insert domain receptor (KDR) R-phycoerythrin (PE) 
3. C-kit/CD117    Allophycocyanin (APC) 
   
Following this incubation, each sample was doubled in volume with the addition of 100µL 
of FACS buffer. The samples were then spilt into two halves, with one half receiving 10µL 
of antibody and the other half 10µL of isotype control. The mixtures were then 
refrigerated for 10 minutes to allow antibody binding. This was followed by a final 
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centrifugation step, after which the cell pellets were suspended in 500µL of fresh FACS 
buffer and transferred to the flow cytometer on ice.  
4.7.3 Fluorescence Activated Cell Sorting (FACS) 
A BD-LSR Fortessa flow cytometer was used for CPC enumeration. The lymphocyte gate 
was defined as shown in figure 9, and from this the number of Sca1+Flk1+ cells, c-kit+ cells 
and Sca1+c-kit+ cells were quantified within the first 100,000 events. The results from the 
isotype control samples were subtracted from the corresponding antibody samples in 
order to negate the effect of non-specific fluorescence. 
 
Figure 9 Definition of lymphocyte gate on flow cytometry 
Red portion of the graph represents lymphocytes. Portions of the graph which represent monocytes and 
granulocytes are labelled. 
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Figure 10 Definition of Sca+Flk1+ circulating progenitor cells (CPCs) 
Upper panel shows isotype control whilst lower panel shows antibody-labelled cells. Cells which co-express stem cell antigen 1 (Sca1) and 
foetal liver kinase 1 (Flk1) are seen in Q2.  
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Figure 11 Definition of cKit+ circulating progenitor cells (CPCs) 
Upper panel shows isotype control whilst lower panel shows antibody-labelled sample. Cells expressing c-kit are in the labelled region.  
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Figure 12 Definition of Sca1+c-kit+ cells circulating progenitor cells (CPCs) 
Upper panel shows isotype control whilst lower panel shows antibody-labelled sample. Cells co-expressing Sca1 and c-kit are in the quadrant 
labelled Q2-1.  
113 
 
4.8 Early outgrowth endothelial progenitor cell (EPC) culture 
4.8.1 Tissue harvest 
Blood, bone marrow and spleen tissue was harvested from each mouse under terminal 
general anaesthesia, induced and maintained in the same manner as described in section 
4.5.1. Once adequate anaesthesia had been confirmed, a midline laparotomy incision was 
made which allowed visualisation of the IVC. A 1ml insulin syringe containing 50µL of 
sterile sodium citrate was used to puncture the IVC and extract the full circulating volume 
of blood (typically approximately 1ml), which was mixed into 4ml of sterile, ice cold PBS. 
Following this, the spleen was removed and also placed into ice cold sterile PBS. The final 
step involved extraction of bone marrow from the femurs and tibiae. Having extracted the 
bones, cuts were made at the metaphyses and a needle and syringe containing sterile PBS 
used to flush out the marrow tissue. All samples were stored on ice during transit back to 
the cell culture laboratory. 
4.8.2 Mononuclear cell isolation 
Diluted blood was filtered into a 50mL centrifuge tube through a 70µm cell strainer. 
Spleens were mechanically minced in 70µm cell strainers using syringe plungers into 3mL 
of fresh sterile PBS and the filtrate injected through the cell strainer into a 50mL tube. The 
marrow was also minced and filtered in similar fashion. Each suspension was washed with 
2mL of PBS and the resulting cell suspensions were layered onto 5mL of Histopaque-1083, 
prior to density-mediated centrifugation at 400g for 30 minutes with a slow deceleration. 
Buffy layers were separated out and washed twice (for spleen and marrow) and three 
times (for blood) with 10mL of sterile PBS at 400g for 10 minutes.  
4.8.3 Cell seeding and incubation 
The cell pellets produced by the isolation steps were re-suspended in EPC growth medium, 
composed of EGM-2 basal medium supplemented with 20% FCS and an EGM-2 bullet kit. 
The pellets derived from blood and marrow tissue was re-suspended in 500µL media, 
whilst the spleen-derived pellet was re-suspended into 2ml. From each of these 
suspensions, 20µL was removed for cell counting purposes and mixed with an equal 
volume of trypan blue solution. The mixture was injected into a haemocytometer and the 
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number of cells counted under microscopy. Extrapolation of the count result estimated the 
cell concentration within solutions, which could then be seeded onto fibronectin-coated 
culture plates. The seeding densities varied depending on the cell origin; marrow samples 
were seeded at a density of 1x106 cells/well, blood samples at 5x106cells/well and spleen 
samples at 8x106 cells/well. Cells from all three tissue sources were seeded onto 24 well 
cell culture plates. EPC media was added to each of the wells and the plates incubated at 
37°C for 7 days. On day 4 the cells were washed twice with sterile PBS in order to remove 
non-adherent cells and fresh media was added. 
4.8.4 EPC imaging 
EPCs were identified based on their ability to import 1,1’-dioctadecy-3,3,3’,3’-
tetramethyllindocarbocyanine-labelled acetylated low-density lipoprotein (DiI-ac-LDL) 
and bind Ulex Europeaus lectin conjugated with fluorescein isothiocyanate (FITC). On 
day 7 the cells were washed twice with sterile PBS. DiI-ac-LDL was dissolved in EPC media 
and then added at a concentration of 10μg/mL. The cells were then incubated in the dark 
at room temperature for 3 hours. Following a further wash with sterile PBS, the cells were 
fixed using 4% paraformaldehyde. Ulex Eueopeaus lectin-FITC conjugate was then added, 
at a concentration of 10μg/mL in PBS, for one hour. 
Imaging was performed using an Olympus CKX-41 fluorescent microscope at x100 
magnification. Cell B software was used in order to take five images per well using phase 
contrast, red fluorescence (to identify DiI staining) and green fluorescence (to identify FITC 
staining). Image J software (v1.46r) was then used to create composite images in order to 
quantify the number of dual stained cells which represent EPCs [137] (see figure 13). 
4.8.5 Conditioned media 
In order to compare the functional effects of EPCs derived from mice of different 
genotypes, conditioned media was obtained following culture of these cells and used in 
assays of endothelial function (see section 4.11.2). In order to obtain conditioned media, 
spleen-derived EPCs were seeded onto a fibronectin-coated 6 well plate at a density of 30 
million cells per well, and incubated at 37°C. On day 4, following a wash with PBS, the EPC 
growth media was replaced with 1ml of basal EPC media containing 1% FCS. The cells were 
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then re-incubated for 24 hours, at which point the basal media was removed and 
centrifuged at 6000rpm for 6 minutes. The resulting pellet was discarded, and the 
supernatant frozen at -80°C for later use in the scratch wound assay. 
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Figure 13 Imaging and quantification of EPCs 
Representative images of EPCs derived from splenic tissue (x100 magnification). Top left = phase contrast 
image; top right = FITC-lectin; bottom left = DiI-acetylated-LDL; bottom right = composite image showing dual-
staining cells. Scale bar represents 100μm. 
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4.9 Isolation and Culture of Pulmonary Endothelial Cells (PECs) 
Murine pulmonary endothelial cells (PECs) were isolated and then used in functional and 
biochemical assays, including assessments of proliferation, migration and superoxide 
production. The method used to isolate and culture the cells was adapted from the 
technique described by Sobczak et al [208]. 
4.9.1 Lung harvest 
Mice were euthanised between the ages of 3-6 weeks via exposure to rising 
concentrations of CO2. Death was then confirmed using cervical dislocation. Following this, 
the lungs were carefully dissected out, stored in ice cold Hank’s buffered salt solution 
(HBSS), and transferred back to the cell culture facility. 
4.9.2 PEC isolation 
The lungs were transferred into sterile 10cm2 petri dishes. Within a 15ml centrifuge tube, 
10ml of a 1mg/ml solution of collagenase/dispase was made up, from which 100μL was 
added to the lungs. Two sterile scalpel blades were then used to mince the lung tissue, 
forming a homogenous mixture with the collagenase/dispase solution. The mixture was 
then added to the 10ml collagenase/dispase and the centrifuge tubes loaded onto a 
MACSmixTM rotator for 45 minutes at 37°C. Following this, the mixture was agitated gently 
using a 10ml syringe attached to a 14G cannula in order to create a single-cell suspension, 
and then injected through a 70μm cell strainer into a fresh 50ml centrifuge tube. In order 
to neutralise the collagenase/dispase, 5ml of PEC media (see section 4.9.5) was added. The 
resulting filtrate was centrifuged for 8 minutes at 400g, and the cell pellet then re-
suspended in 200μL of 0.1% PBS/BSA in preparation for the magnetic bead separation.  
4.9.3 Magnetic bead separation 
In order to obtain a pure sample of PECs, cell separation was carried out using magnetic 
beads with conjugated CD146. Having been resuspended in 200μL of 0.1% PBS/BSA, the 
cells were transferred to a fresh 1.5ml micro-centrifuge tube and 20μL of commercially 
acquired magnetic beads with conjugated CD146 (Miltenyi Biotec) added. The micro-
centrifuge tube was then loaded onto a MACSmixTM for 20 minutes and kept at 4°C. 
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Following this mixing step, 1ml of 0.1% PBS/BSA was added and the mixture centrifuged 
for 5 minutes at 400g. During this 5 minute period, the magnet used to separate the cells 
was set up, with a cell separation column placed above a 15ml centrifuge tube (see figure 
14). The cell separation column was then flushed through with 500μL of 0.1% PBS/BSA.   
 
 Figure 14 Apparatus used for magnetic bead separation of PECs 
 
Once the sample had completed its 5 minute centrifugation, the cell pellet was carefully 
re-suspended in 500μL of 0.1% PBS/BSA, avoiding the formation of any bubbles. The 
suspension was then pipetted into the cell separation column. The suspension would pass 
through the magnet, allowing sequestration of the endothelial cells which had conjugated 
to the magnetic beads, whilst filtering out the supernatant into the centrifuge tube below. 
Once the suspension had completely filtered through, 3 washes were performed by adding 
500μL of 0.1% PBS/BSA to the cell separation column. Following this, the cell separation 
column was removed from the magnet and placed on a fresh 15ml centrifuge tube, into 
which the contents of the column could be mechanically expelled. The tubes were then 
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centrifuged for 5 minutes at 400g in order pellet the cells, which were then re-suspended 
in 500μL of 0.1% PBS/BSA. The magnetic column separation was process was then carried 
out once more in order to maximise the purity of the sample. 
Following the completion of the magnetic column separation, the remaining cells were 
then re-suspended in 500μL of PEC media and plated onto gelatin coated T25 flasks, and 
the total volume was then made up to 5ml with fresh PEC media. The cells were incubated 
at 37°C with 5% CO2. The media was completely replaced 24 hours after isolation, 
following which the media was half changed on alternate days. The cells were allowed to 
grow until they reached confluence (see figure 15), at which point they were split into 
different plates for various assays (see section 4.11). 
 
Figure 15 A representative image of PECs at confluence following magnetic bead separation (x40 
magnification) 
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4.9.4 Determination of PEC purity 
Previous work in our laboratory, carried out by Drs Richard Cubbon and Anshuman 
Sengupta, has been done to confirm endothelial lineage of cultured PECs.  
Once the cells had become confluent, they were detached using 0.25% trypsin/EDTA (see 
section 4.10.3) and counted using trypan blue (see section 4.8.3). 15,000 cells were seeded 
onto 35mm imaging dishes and incubated at 37°C for 24 hours. Following 2 washes with 
sterile PBS, the cells were fixed by adding 1ml of 4% paraformaldehyde for 15 minutes. 
Following fixation, the cells were permebilised and blocked using a solution of 0.25% Triton 
X-100 and 1% BSA in PBS. They were then incubated for 2 hours at room temperature with 
10μg/ml of isolectin B4-Alex Fluor® 488 conjugate. Three washes with PBS were then 
performed, followed by application of 5μg/mL Hoechst 33342 in PBS for ten minutes at 
room temperature. A final wash with PBS was performed, followed by imaging using an 
A Zeiss LSM700 confocal microscope.  
4.9.5 PEC media 
PEC media was made in advance of the culture process with the following components: 
 400ml of basal MV2 growth medium 
 20ml of endothelial growth supplement 
 50ml of foetal bovine serum 
 10ml of antibiotic-antimycotic solution  
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4.10 Culture and transduction of human umbilical vein endothelial cells 
(HUVECs) 
Human umbilical vein endothelial cells were cultured and then transduced with an insulin 
receptor (or scrambled control) shRNA using commercially produced lentiviruses in order 
to knockdown the insulin receptor. This provided a complementary model of endothelial 
insulin resistance with which the effects of pharmacological NOX2 inhibition could be 
investigated. 
4.10.1 HUVEC culture 
Pooled donor samples of HUVECs were purchased commercially from PromoCell and 
stored as 1ml aliquots in liquid nitrogen. When required for experiments they were 
extracted from storage and transferred to the cell culture facility on ice, where they could 
then be defrosted rapidly in a water bath at 37°C. 
Once the cells had defrosted they were re-suspended in 9ml of HUVEC media (see section 
4.10.2), and the resulting 10ml split into halves and plated onto two 10cm2 petri dishes 
pre-coated with 0.1% gelatin. The total volume within each petri dish was made up to 10ml 
with fresh HUVEC media and the cells then incubated at 37°C with 5% CO2. The media was 
completely replaced 24 hours later and on alternate days thereafter. The cells were 
allowed to grow until 70% confluence prior to transduction. 
4.10.2 HUVEC culture media 
HUVEC media was made in advance of the culture process with the following components: 
 380ml of M199 basal media 
 100ml of fetal bovine serum 
 10ml of 1M HEPES buffer 
 5mls of antibiotic-antimycotic solution 
 10ml of sodium pyruvate solution 
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 2500 units of heparin 
 2.5ml of endothelial cell growth supplement 
4.10.3 Transduction of HUVECs with shRNA lentivirus 
In order to examine insulin resistance in HUVECs, a commercially acquired shRNA lentivirus 
was used to knockdown expression of the insulin receptor. All work involving the lentivirus 
and the transduced cells was carried out in a designated ‘Category 2’ viral laboratory with 
appropriate precautions taken. 
Based on results from pilot work done to assess the magnitude of IR knockdown with 
varying concentrations of the lentivirus (see section 5.3.1), a multiplicity of infection (MOI) 
of 15 was chosen for experimental work as this achieved approximately 50% knockdown of 
IR protein. The IR shRNA lentivirus virus was added to one dish of HUVECs, with the second 
dish of identical cells receiving a control lentivirus containing a scrambled shRNA at the 
same MOI. The cells were then incubated with the lentiviruses for 24 hours, at which point 
the 2 samples of cells were split into halves to form 4 cohorts of cells. The method used to 
split a sample of cells involved initially detaching them from their petri dishes using 0.25% 
trypsin/EDTA. Following aspiration of the media from the dish, the cells were washed with 
10ml of warm, sterile PBS and 2ml of trypsin/EDTA was then added. The cells were 
incubated with the trypsin/EDTA at 37°C for 1 minute. Cell detachment was confirmed 
using light microscopy and the trypsin then neutralised with 3ml of HUVEC media. The 
resulting 5ml mixture was then split evenly into two fresh 10cm2 petri dishes which had 
been pre-coated with 0.1% gelatin, and then topped up to a total volume of 10ml with the 
addition of 7.5ml of HUVEC media. Splitting the two dishes of HUVECs in this way produced 
4 cohorts of cells, which allowed paired samples of virally-transduced (IR or control shRNA) 
to be treated with a NOX2 antagonist or control.  
4.10.4 Pharmacological NOX2 inhibition 
In order to study the effects of pharmacological NOX2 inhibition in the setting of insulin 
resistance, HUVECs were treated with a specific NOX2 inhibitor named GP91-ds tat (see 
section 4.6.3). In vitro work from the paper describing the original use of this molecule [72] 
demonstrated that GP91-ds tat at a concentration of 50μM could completely block 
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angiotensin II-induced O2- production in aortic rings from rats, and so the same 
concentration was used for experiments in this project. In order to create a 50μM solution, 
a 10mM stock solution was formed by dissolving 29mg of GP91-ds tat into a 1ml of a 
solution made up from 100ml distilled water, 0.9g sodium chloride and 57.5μL acetic acid. 
This stock solution could then be diluted to the desired concentration using HUVEC growth 
media. The GP91-ds tat was supplied with a scrambled-ds tat peptide which was used as a 
control. This molecule has the same molecular weight as GP91-ds tat and so was 
reconstituted into a 50μM experimental solution in the same way.  
Once the 4 dishes of cells had become 70% confluent, GP91-ds tat was added to one dish 
of IR-knockdown cells and one dish of control lentivirus-treated cells, with the remaining 
dishes receiving the scrambled-ds tat control peptide. The resulting combinations of viral 
transduction and GP91-ds tat treatment is summarised in figure 16. The cells were 
incubated with the GP91-ds tat or scrambled control peptide for 24 hours, after which they 
were then used for the assays outlined in section 4.11. Lysates generated from the HUVECs 
were also used for Western Blotting in order to confirm effective IR knockdown (section 
4.12). 
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Figure 16. The four cohorts of HUVECs used to assess the effect of pharmacological NOX2 inhibition in insulin 
resistance 
Control: HUVECs transfected with control shRNA lentivirus; IR knockdown: HUVECs transfected with IR shRNA lentivirus 
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4.11 Endothelial cell functional assays 
Assays of cell proliferation, migration and superoxide quantification were carried out on 
PECs and lentiviral-transfected HUVECs in order to ascertain the effects of genetic and 
pharmacological NOX2 inhibition. The assays were carried out in an almost identical way 
for both types of cell, with the only difference pertaining to the number of cells seeded at 
the start of the experiment, and the concentration of gelatin used to coat the cell culture 
plates. These variations will be described in the relevant sections. 
4.11.1 Endothelial cell proliferation assay 
Proliferative capacity of PECs and HUVECs was assessed using 5-ethynyl-2’-deoxyuridine 
(EdU), a nucleoside analogue that incorporates into the DNA of replicating cells. The EdU 
was conjugated to an alkyne that can be detected with an Alexa Fluor® 647-conjugated 
azide, which allowed proliferating cells to be quantified by flow cytometry.  
Prior to performing the assay, the cells were detached from their respective cell culture 
plates using 0.25% trypsin/EDTA (see section 4.10.3), counted using trypan blue (see 
section 4.8.3) and then seeded onto a well of a 6 well plate at a density of 100,000 cells per 
well. In the case of PECs, the well was pre-coated with 2% gelatin, whereas for HUVECs 
0.1% gelatin was used. Fresh media was added to each well so that the volume totalled 
2ml and the cells were then incubated at 37°C for 48 hours, with a full media change 
performed at 24 hours. 
The assay was carried out using a commercially available Click-iT® kit (Life Technologies), 
and the constituents and required preparation of this kit is outlined in table 8. On the day 
of the assay, EdU diluted in growth media was added to each sample at a concentration of 
10μM, and the cells then incubated at 37°C for 4 hours. Following this, the cells were 
washed with sterile PBS and then detached from the cell culture plate using 0.25% 
trypsin/EDTA. Following neutralisation of the trypsin with growth media, the samples were 
centrifuged for 1 minute at 400rcf in order to pellet the cells. The supernatant was 
discarded and the cells then washed with 3ml of 1% BSA dissolved in PBS. Following this, 
the cells were once again centrifuged for 1 minute at 400rcf and the supernatant 
discarded. The pellet was then resuspended in 100μL of ‘Click-iT® fixative’ and incubated 
for 15 minutes at room temperature, protected from light. 
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Reagent Preparation 
EdU Reconstitute in DMSO 
AlexaFluor® azide Reconstitute in DMSO 
DMSO Used for reconstitution 
Click-iT® fixative Use neat 
Click-iT® saponin based 
permebilisation and wash reagent 
Diluted 1:10 in 1% BSA/PBS 
Copper sulphate Use neat 
Click-iT® EdU buffer additive Reconstitute in deionised water 
Dilute 1:10 for each use 
Table 8 Components of Click-iT® EdU assay kit 
EdU = 5-ethynyl-2’-deoxyuridine; DMSO = dimethyl sulfoxide; BSA = bovine serum albumin; PBS = phosphate 
buffered saline 
Following this brief incubation, the cells were once again washed with 3ml of 1% BSA in 
PBS and centrifuged for 1 minute at 400rcf. Once the supernatant had been discarded, the 
pellet was resuspended in 100μL of ‘Click-iT® saponin based permebilisation and wash 
reagent’ and incubated in the dark for 15 minutes at room temperature. During this 
incubation period, a ‘Click-iT® reaction cocktail’ was prepared as outlined in table 9. 
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Component Volume (μL) 
PBS 438 
Copper sulphate 10 
AlexaFluor® azide 2.5 
Click-iT® EdU buffer additive 50 
Total 500 
Table 9 Composition of ‘Click-iT® reaction cocktail’. Volumes are given per well 
Following the completion of the 15 minute incubation, 500μL of the ‘reaction cocktail’ was 
added to each sample and the cells then incubated for 30 minutes at room temperature, 
protected from light. The cells were then washed with 3ml of ‘Click-iT® saponin based 
permebilisation and wash reagent’ and centrifuged for 1 minute at 400rcf. The supernatant 
was discarded, the pellet resuspended in 500μL of ‘Click-iT® saponin based permebilisation 
and wash reagent’, and the samples transferred on ice to the flow cytometer. 
Flow cytometry 
A BD-LSR Fortessa flow cytometer was used in order to quantify the number of cells which 
had incorporated EdU, thereby providing a measure of the number of proliferative cells 
within the sample. In order to detect EdU with AlexaFluor 647, an excitation wavelength of 
633/635nm with a red emission filter was used. The first 10,000 cells were used for 
quantification purposes and the results expressed as a proportion of proliferative cells. 
Representative images of the quantification process are shown in figure 17. 
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Figure 17 Flow cytometric quantification of proliferating cells based on uptake of EdU 
The top panel shows which cells were used for quantification purposes, whilst the middle panel demonstrates 
the linear relationship between the height and width of the selected cells, indicating that these cells were 
individual as opposed to aggregated. The bottom panel shows the gating criteria used in order to quantify 
fluorescent (i.e. proliferating) cells, which are seen in the P2 segment. 
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4.11.2 Endothelial cell migration assay 
The ability of PECs and HUVECs to migrate was studied using an assay of scratch wound 
closure.  
Creation of a scratch wound 
The initial step involved detaching the cells from their respective cell culture plates using 
0.25% trypsin/EDTA, and counting them using trypan blue as described previosuly. The 
cells were then seeded onto wells in an Essen imagelock 96 well plate.  For PECs, 50,000 
cells were seeded onto each well of a plate that had been pre-coated with 2% gelatin, 
whilst for HUVECs 30,000 cells were seeded into each well of a plate that had been pre-
coated with 0.1% gelatin. This difference in cell seeding density resulted from prior 
optimisation experiments, and reflected the fact that HUVECs reach confluence quicker 
than PECs. In both cases 5 wells were used per sample, and growth media added so that 
each well contained a total of 300μL. The cells were then incubated at 37°C for 48 hours to 
allow them to reach confluence, with a full media change performed at 24 hours. 
Following the 48 hour incubation, the cells were washed with sterile PBS and then 
incubated for 4 hours with reduced-serum media. For PECs, serum-free media was used, 
whilst for HUVECs media with 1% serum was used. After the 4 hours had elapsed, 100μL of 
PBS was added to the empty wells of the plate and the cells then mechanically scratched 
using the WoundmakerTM 96-pin tool. This created a longitudinal scratch across the middle 
of each well. The cells were then gently washed with sterile PBS to remove any debris and 
100μL of full growth media then added.  
Analysis of scratch closure 
In order to assess the extent of wound closure, the cells were imaged straight after the 
scratch had been performed (t0), and once again following an 18 hour incubation at 37°C 
(t18). In both cases the imaging was done using an Olympus CKX-41 microscope with an 
attached camera. The Essen imagelock plates have a vertical marking line drawn onto the 
base of each well which perpendicularly bisected the scratch wound. Two images at x40 
magnification were taken per well, either side of this marking line. Olympus Cell F software 
was used to capture and store images which were then analysed using Image J. The area of 
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the wound at t0 and t18 was measured, and a ratio of these was used to calculate the 
extent of wound closure (see fig 18). 
Endothelial progenitor cell function 
The scratch wound assay was also used to compare the functional effects of murine EPCs 
derived from mice of different genotypes. For this experiment, untreated HUVECs were 
plated into the wells of a 96 well plate in the same way as described above. Following the 
creation of a wound, the cells were incubated in conditioned media obtained from EPCs 
(see section 4.8.5) rather than usual growth media, and then imaged 18 hours later as per 
the usual protocol.  
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Figure 18 Scratch wound analysis 
The upper panel shows HUVECs immediately after scratch, whilst the lower panel shows the same cells following 
an 18 hour incubation (x40 magnification). A ratio of the respective wound areas was used in order to calculate 
closure.  
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4.11.3 Superoxide quantification assay  
In order to assess the effect of genetic and pharmacological NOX2 inhibition on superoxide 
production, the cultured PECs and HUVECs were incubated with the compound 
dihydroethidium (DHE). In the presence of superoxide, DHE is oxidised to 2-
hydroxyethidium, which fluoresces red. Quantification of this fluorescence using a 
microplate plate reader allows indirect quantification of superoxide production.  
To carry out this assay, PECs and HUVECs were detached from their respective cells culture 
plates and counted, as described previously. In both cases the cells were plated onto 
uncoated wells of a 96 well plate, but the number of cells varied, with 50,000 cells/well of 
PECs and 30,000 cells/well of HUVECs. As with the scratch wound assay, this difference 
was a corollary of the fact that HUVECs tended to grow and reach confluence more rapidly 
than PECs. Four wells were used per sample and growth media added to each so that the 
volume in each well totalled 300μL. The cells were then incubated at 37°C for 48 hours 
with a full media change performed at 24 hours 
Following this incubation, the cells were washed twice with sterile PBS. For each sample, 
DHE was added to two of the four wells, whilst the remaining two were used as controls. 
DHE was dissolved into Krebs-HEPES buffer at a concentration of 25μM, and 100μL of this 
solution added to the relevant wells. The remaining control wells received 100μL of Krebs-
HEPES alone, and the cells were then incubated at 37°C for 20 minutes. Following this, the 
cells were washed twice with sterile PBS and 100μL of fresh Krebs-HEPES buffer then 
added to all wells. Upon completion of this step, the plate was protected from light and 
transferred to the microplate reader for measurement of fluorescence.  
Once the plate had been inserted into the microplate reader, SoftMax® Pro (v5.4.5; 
Molecular Devices) software was used to detect and quantify fluorescence at excitation 
and emission wavelengths of 500nm and 600nm respectively, at 10 second intervals for 3 
minutes. A mean of the fluorescence readings was then calculated and the measurement 
for the control cells subtracted from the DHE-labelled cells in order to give the final results. 
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4.12 Western blotting 
Western blotting was performed on lysates from transduced HUVECs in order to confirm 
effective IR knockdown. All western blots were performed in conjunction with Dr Romana 
Mughal. 
4.12.1 Sample preparation 
In order to produce lysates that could be used for Western Blotting, cells from each of the 
four cohorts of HUVECs (see figure 16) were seeded onto wells of a 6 well cell culture plate 
that had been pre-coated with 0.1% gelatin. These cells were then incubated at 37°C until 
they reached confluence (typically 4 days), with half media changes on alternate days.  
Once confluent, the cells were washed twice with ice-cold PBS to ensure arrest of cellular 
processes. The cells were then lysed via addition of 100μL of lysis buffer, composed of 
radio-immunoprecipitation assay (RIPA) buffer with added phosphatase 2&3 inhibitors. 
The lysis buffer was kept on the cells for 5 minutes, and the cells then harvested using cell 
scrapers. The samples were immediately stored at -80°C from where they could be used by 
Dr Mughal for protein quantification and Western Blotting.  
4.12.2 Protein quantification 
Cell lysates were gradually defrosted over a 30 minute period on ice and then centrifuged 
at 15,000g and 4°C for 10 minutes.  The resulting pellets were discarded, and the 
supernatants transferred into fresh microcentrifuge tubes where they could then be used 
in a bicinchoninic acid (BCA) assay for protein quantification. 
BCA assay 
An 8μL sample from each lysate was added to 56μL of distilled water to create a 1:8 
dilution. From these diluted samples, 25μL was added in duplicate to the wells of a 96 well 
plate, whilst nine standards of bovine serum albumin (BSA) of known concentrations were 
also added in duplicate to neighbouring wells in the same plate. The next step involved 
combining the two colorimetry reagents A (sodium carbonate, bicinchoninic acid and 
sodium tartrate in 0.1M sodium hydroxide) and B (4% cupric sulphate) from the BCA assay 
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kit in a 50:1 ratio, and then adding 200μL of the resulting mixture to each well. The plate 
was then covered and incubated at 37°C for 30 minutes. 
Following this incubation, colorimetric analysis was performed using a Dynex MRX TC 
microplate reader and Revelation software (version 4.21) at a wavelength of 562nm. A 
standard curve was constructed using the colorimetric measurements from the BSA 
standards, and this curve was appraised to ensure linearity and a correlation coefficient 
(r2)>0.99. Provided the standard curve was satisfactory, the protein concentrations of the 
samples could be inferred from their colorimetry results and, following a correction for the 
1:8 dilution, the protein concentration of the original lysates could be ascertained. 
4.12.3 Gel electrophoresis 
Using the calculated protein concentrations, a volume of each lysate containing 20μg of 
protein was added to 4μL of reducing agent and 10μL of sample buffer. Distilled water was 
then added to each sample so that the volume totalled 40μL. These samples were heated 
at 95°C for 5 minutes, and this time was used to fill a Criterion Cell tank (Bio-Rad) with 
500ml of running buffer, composed of 25mL of 2-(N-morpholino) ethanesulfonic 
acid/sodium dodecyl sulphate (MES SDS) running buffer and 475mL of de-ionised water.  
Following the completion of the 5 minute heating step, the samples were loaded into a 
pre-cast, commercially purchased 4-12% polyacrylamide gel along with 6μL of a protein 
reference ladder. The gel was subsequently placed into the Criterion Cell tank where 
electrophoresis could be performed at 100V for two hours. 
4.12.4 Transfer 
Following completion of the electrophoresis, the gels were removed and washed with 
deionised water. Two pieces of filter paper and a polyvinylidene fluoride (PDVF) membrane 
were then cut to match the size of the gel and the membrane soaked in methanol for 15 
seconds, water for 5 minutes and finally 1:10 transfer buffer (composed of 6.06g tris, 28.84 
glycine, 400ml methanol and 1600ml distilled water) for 2 minutes. Simultaneously, the 2 
pieces of filter paper as well as 2 sponges were also soaked in 1:10 transfer buffer. Once all 
of the components had been appropriately soaked, a ‘transfer sandwich’ was then made 
with the gel and membrane in the middle, flanked on each side by filter paper, which 
themselves were flanked by the sponges. This ‘transfer sandwich’ was loaded into a plastic 
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cassette which could then be placed into an electrophoresis tank containing 1:10 transfer 
buffer. Electrophoresis was then performed at 100V for 1 hour. 
4.12.5 Immunostaining 
Following the protein transfer, the membrane was separated from the ‘transfer sandwich’ 
and washed in a blocking solution containing 5% BSA in tris-buffered saline with Tween 
(TBST; 0.1%) for five minutes. A clean scalpel was then used to cut the membrane at the 
level corresponding to 75kDa from the reference ladder, thus allowing simultaneous 
immunostaining for the insulin receptor and β actin as a control. The two membranes were 
then incubated at room temperature for 1 hour in 15ml of TBST in order to block non-
specific binding. 
During this one hour period, the primary antibody was prepared in a BSA-TBST solution at 
a dilution outlined in table 10. Following removal of the 15ml of TBST, the membranes 
were then incubated with their respective primary antibody solutions overnight at 4°C. The 
following morning, the membranes were washed three times for five minutes each in 
TBST. At this stage, the secondary antibody was then prepared (see table 10) in 5% BSA-
TBST and the membrane then incubated in this solution for one hour at room 
temperature. 
Antibody type Targeted protein Dilution Manufacturer 
Primary Insulin receptor  1:1000 Cell signalling 
Primary β Actin 1:20,000 Cell signalling 
HRP-conjugated 
secondary 
Polyclonal goat 
anti-rabbit 
1:1000 Dako  
Table 10 Antibodies used in Western Blotting. 
HRP = horseradish peroxidase 
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Following this incubation, the membranes were once again washed in TBST three times for 
15 minutes each. 
4.12.6 Imaging 
Each membrane was placed onto cling film and uniformly covered with 1ml of Immobilon 
Western Chemiluminescent HRP Substrate (500uL peroxide solution, 500uL enhancer 
solution), before being imaged using the Syngene G imaging system.  
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4.13 Statistical analysis 
All continuous data sets are expressed as mean with standard error of mean (SEM) unless 
otherwise stated. Graphs and statistical analyses were performed using GraphPad Prism v6 
(2012). For the majority of analyses, two-tailed unpaired or paired Student’s t-tests were 
performed as appropriate. For analysis of body weights, GTT, ITT and ischaemic 
revascularisation data, area under the curve (AUC) was calculated. In all analyses, a p value 
of <0.05 was deemed statistically significant.  
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Chapter 5: Results 
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Chapter 5 Results 
5.1 IRKOxGP91phoxy/- 
5.1.1 Genotyping 
Example PCR gels for identifying IRKO and GP91 genotypes are displayed in figures 19 and 
20 respectively, with a 1000 base pair ladder on the left for reference. 
 
Figure 19. IRKO PCR 
IRKO gene cassette is denoted by a double band at 235 and 255 base pairs (e.g. 28), with a single band at 235 base pairs for 
wild-types (e.g. 23). 
 
Figure 20. GP91phox PCR 
WT mice are identified by the presence of an upper single band at 240 base pairs (e.g. 466), whilst GP91phoxy/- homozygote 
mice display a lower single band at 195 base pairs for (e.g. 467).  Double bands represent heterozygote females (e.g. 473). 
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5.1.2 Body weights 
No differences in bodyweight were identified between mice of WT, IRKO or 
IRKOxGP91phoxy/- genotypes (see figure 21). 
 
 
Figure 21 Total bodyweight 
Upper panel: Body weight at various time points; Lower panel: Area under curve analysis (N=5, 5, 3) 
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5.1.3 Glucocompetence testing 
Previously published data demonstrate that IRKO mice display no significant difference to 
WT littermates with respect to glucocompetence [120]. Data from the current study 
recapitulated these findings, with no differences seen in non-fasting blood glucose 
concentration (figure 22), glucose tolerance testing (figure 23) or insulin tolerance testing 
(figure 24). The same tests also demonstrated no significant difference between these 
mice and IRKOxGP91phoxy/- littermates, although a trend towards a reduced non-fasting 
blood glucose concentration was seen in the double cross mice. 
 
Figure 22 Non-fasting blood glucose concentration 
(N=6, 6, 4) 
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Figure 23 Glucose tolerance testing 
Upper panel: Blood glucose concentration following IP glucose injection. Lower panel: Area under curve analysis. (N=7, 6, 5)  
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Figure 24 Insulin tolerance testing 
Upper panel: Blood glucose concentration following IP insulin injection. Lower panel: Area under curve analysis. (N=7, 6, 4) 
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5.1.4 Vascular repair 
Assessment of vascular repair following endothelial denudation demonstrated no 
significant difference between WT, IRKO and IRKOxGP91phoxy/- mice. 
 
Figure 25 Vascular repair 
Endothelial regeneration following vascular injury (N=7, 5, 2) 
Experiments assessing vascular repair were halted prematurely after it was noted that 
IRKOxGP91phoxy/- mice were failing to recover optimally post-operatively. Further 
observation of mice from this colony revealed that the double cross mice were failing to 
thrive following invasive interventions, and on occasion developing granulomas (discussed 
in detail in section 6.1.4).  In view of these concerns, it was decided to curtail experiments 
on this colony and focus investigation on the ESMIROxGP91phoxy/- colony.  
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5.2 ESMIROxGP91phoxy/- 
5.2.1 Genotyping 
An example PCR gel for identifying mice with the ESMIRO genotype is displayed in figure 
26, with a 1000 base pair ladder on the left for reference.  For an example of a PCR gel for 
used to identify the GP91phox genotype, see figure 20.
 
Figure 26 ESMIRO PCR 
ESMIRO genotype is denoted by an extra band at 172bp (e.g. 480), whilst WT mice display only one band at 
approximately 350bp (e.g. 482). 
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5.2.2 Body weights 
No significant differences in bodyweight were identified between mice of WT, ESMIRO or 
ESMIROxGP91phoxy/- genotypes (see figure 27). 
 
 
Figure 27 Total body weight 
Upper panel: Body weight at between weaning & adulthood; Lower panel: Area under curve analysis (N=4, 4, 4) 
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5.2.3 Glucocompetence testing 
Previously published data demonstrate that there are no significant differences in 
glucocompetence between WT and ESMIRO mice [56], nor between ESMIRO and 
ESMIROxGP91phoxy/- littermates [123]. The current study recapitulated these findings, 
with no significant differences seen in non-fasting blood glucose (figure 28), glucose 
tolerance testing (figure 29), insulin tolerance testing (figure 30), or plasma insulin 
concentration (figure 31).  
 
Figure 28 Non-fasting glucose concentration 
(N=4, 7, 7) 
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Figure 29 Glucose tolerance testing 
Upper panel: Blood glucose concentration following IP glucose injection. Lower panel: Area under curve analysis. (N=5, 6, 4) 
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Figure 30 Insulin tolerance testing 
Upper panel: Blood glucose concentration following IP insulin injection. Lower panel: Area under curve analysis. (N=6, 6, 6) 
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Figure 31 Fasting plasma insulin concentration 
(N=9, 7) 
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5.2.4 Real-time quantitative PCR 
Real-time quantitative PCR (RT-qPCR) was performed on aortic and lung tissue in order to 
validate the expression of human insulin receptor (hIR) in ESMIRO and 
ESMIROxGP91phoxy/- mice, as well as to confirm successful knockdown of NOX2 in 
ESMIROxGP91phoxy/- mice. No manipulation to the native murine insulin receptor (mIR) 
was carried out, and expression was checked to ensure that there were no significant 
variations between genotypes. In view of previously published work suggesting that NOX2 
knockdown results in alterations in expression of pro-inflammatory cytokines (see section 
1.8), further RT-qPCR analyses were carried out to ascertain the expression of IL-1β, 
VCAM1 and TNFα. 
5.2.4.1 Validation of the genetic model 
As figure 32 illustrates, hIR was demonstrable in aortic and lung tissue from ESMIRO and 
ESMIROxGP91phoxy/- mice with no significant difference in expression, whilst being 
undetectable in WT littermates. 
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Figure 32 Expression of human insulin receptor (hIR) 
Quantified as a ratio relative to β actin expression. Top panel: hIR expression in aortic tissue (N= 10, 8, 10); 
bottom panel: hIR expression in lung tissue (N=7, 7, 8). 
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The absence of detectable NOX2 mRNA from aortic or lung tissue in ESMIROxGP91phoxy/- 
mice confirmed successful enzymatic knockdown (see figure 33). No significant difference 
was seen between WT and ESMIRO littermates with respect to NOX2 expression. 
 
 
Figure 33 Expression of NOX2 
Quantified as a ratio relative to β actin expression. Top panel: NOX2 expression in aortic tissue (N= 11, 7, 9); bottom panel: 
NOX2 expression in lung tissue (N=7, 5, 8). 
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No significant differences were seen with respect to aortic expression of mIR in the three 
genotypes of mice, as shown in figure 34. 
 
Figure 34 Expression of murine insulin receptor (mIR) in aortic tissue 
Quantified as a ratio relative to β actin expression (N= 4, 3, 3). 
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5.4.2.2 Assessing expression of pro-inflammatory cytokines 
A trend toward increased IL-1β expression in double cross mice when compared to WT and 
ESMIRO counterparts was demonstrated (0.0251 [0.0137] vs. 0.0164 [0.0102] vs. 0.0155 
[0.0075]), although this did not reach statistical significance (p=0.17 and 0.10 respectively; 
see figure 35).   
 
Figure 35 Expression of interleukin 1β (IL-1β) in aortic tissue 
Quantified as a ratio relative to β actin expression (N= 8). 
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No significant differences were demonstrated with regard to expression of TNF-α between 
the three genotypes of mice (figure 36). 
 
Figure 36 Expression of tumour necrosis factor α (TNF-α) in aortic tissue 
Quantified as a ratio relative to β actin expression (N= 8). 
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Similarly, no significant differences were demonstrated with regard to expression of 
VCAM1 between the 3 genotypes, although a trend towards reduced expression in ESMIRO 
mice was noted (figure 37). 
 
Figure 37 Expression of vascular cell adhesion molecule 1 (VCAM1) in aortic tissue 
Quantified as a ratio relative to β actin expression (N= 8, 8, 7). 
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5.2.4.3 Preliminary data assessing expression of NOX4  
In view of the findings regarding the effect of NOX2 knockdown on endothelial cell 
migration (see section 5.2.10.2), preliminary work was undertaken in order to ascertain the 
effect the of NOX2 knockdown on the expression of NOX4. As illustrated in figure 38, no 
significant difference was seen in NOX4 expression when comparing aortic samples from 
ESMIRO and ESMIROxGP91phox mice (0.328 [0.09] vs. 0.243 [0.06]; p=0.45). It must be 
borne in mind that, given the preliminary nature of these data, the sample sizes are small 
and thus these results are not conclusive. Potential avenues for further investigation into 
the concept of compensatory NOX4 expression following NOX2 knockdown are discussed 
in section 6.3.4. 
 
Figure 38 Expression of NOX4 in aortic tissue 
Quantified as a ratio relative to β actin expression (N= 3, 4). 
 
 
160 
 
5.2.5 Vascular repair 
As outlined in section 4.5, two sets of vascular injury experiments were carried out in order 
to investigate the effects of NOX2 inhibition in the context of insulin resistance; firstly, 
double-cross transgenic mice were compared to ESMIRO and WT littermates in order to 
assess the effect of genetic NOX2 knockdown. Subsequently, the effect of pharmacological 
NOX2 inhibition was investigated via implantation micro-osmotic pumps containing either 
GP91-ds tat or scrambled peptide into ESMIRO mice.  
Investigating the effect of genetic NOX2 knockdown 
Assessment of vascular repair following endothelial denudation demonstrated that 
ESMIROxGP91phoxy/- mice display significantly improved recovery compared to ESMIRO 
littermates (62% [4%] vs. 46% [3%]; p<0.01. See figure 39). Surprisingly, the WT mice from 
this colony displayed poorer recovery than expected based on historical comparisons or 
when compared to WT mice from the IRKOxGP91phox colony (43% [4%]). 
 
Figure 39 Vascular repair 
Endothelial regeneration following vascular injury (N=13, 9, 9) 
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Investigating the effect of pharmacological NOX2 inhibition 
Whereas genetic NOX2 inhibition in ESMIRO mice achieved a significant improvement in 
vascular repair, these findings were not recapitulated with pharmacological inhibition, 
which was shown to confer no significant improvement when compared to scrambled 
peptide (55.7 [6.1] vs 52.8 [4.8]; p=0.7. See figure 40).   
 
Figure 40 Vascular repair following pharmacological NOX2 inhibition 
Endothelial regeneration following vascular injury (N=5). 
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5.2.6 Ischaemic revascularisation 
In order to assess the effect of NOX2 inhibition on ischaemic revascularisation, the 
protocol of hindlimb ischaemia and laser Doppler imaging outlined in section 4.6 was 
carried out in WT, ESMIRO and ESMIROxGP91phox mice. Limb perfusion was assessed via 
Doppler imaging on days 0, 7, 14, 21 and 28. As figure 41 illustrates, no significant 
differences were seen between the three genotypes at any of these time points, or over 
the entire 28 day period (AUC analysis: WT 1.52 [0.18] vs. ESMIRO 1.59 [0.17] vs. 
ESMIROxGP91phoxy/- 1.38 [0.12]).  
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Figure 41 Ischaemic revascularisation 
Top panel: Time course of recovery following hindlimb ischaemia. Middle panel: Comparisons of relative perfusion index at 
each time point. Bottom panel: Area under the curve analysis (N= 6, 10, 12) 
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5.2.7 Circulating progenitor cell (CPC) enumeration 
Having observed a significant difference in vascular repair between ESMIROxGP91phoxy/- 
and ESMIRO mice, the focus of the project shifted to explore the potential mechanisms 
underpinning this finding. One of the postulated mechanisms for vascular repair is via 
release of bone marrow derived CPCs, which home to the site of injury and assist with 
repair either by direct incorporation, or by secreting paracrine factor to stimulate native 
ECs. To assess whether a differential CPC abundance might contribute to the differences 
observed in vascular repair, experiments of CPC enumeration using flow cytometry were 
carried out. For the current study, CPCs were denoted by co-expression of either Stem cell 
antigen 1 (Sca1) with Foetal liver kinase 1 (Flk1), or cKit with Sca1. 
As figure 42 illustrates, a significantly higher number of Sca1/Flk1 expressing CPCs were 
observed in blood from ESMIROxGP91phoxy/- mice compared to ESMIRO littermates (202.6 
[20.3] per 100,000 lymphocytes vs. 134.3[10.6]; p<0.01). In contrast, there was no 
significant difference with respect to ckit/Sca1 expressing CPCs (73.1 [9.9] vs. 49.1 [7.5]; 
p=0.08). No significant differences were observed between WT and ESMIRO littermates 
with respect to either type of CPC. 
  
165 
 
 
 
Figure 42 Enumeration of CPCs 
Top panel: Enumeration of Sca1/Flk1-expressing CPCs (N= 13, 16, 12); Bottom panel: Enumeration of cKit/Sca1-expressing 
CPCs (N= 12, 10, 14).  
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5.2.8 Early outgrowth endothelial progenitor cell (EPC) enumeration 
To complement the flow cytometry based method of progenitor cell quantification, early 
outgrowth endothelial cells (EPCs) were also cultured and quantified from blood, bone 
marrow and splenic tissue. As outlined in section 4.8.4, EPCs were identified by their ability 
to import DiI-ac-LDL and bind lectin-FITC.  
Blood-derived EPCs 
Blood-derived EPCs from transgenic mice were sparse, and no significant difference in their 
abundance was demonstrated between the two genotypes (ESMIRO 0.2 [0.1] EPCs/high 
powered field vs. ESMIROxGP91phoxy/- 0.04 [0.04] EPCs/HPF). However, a significantly 
higher number of blood-derived EPCs were observed from WT littermates (2.3 [0.8] 
EPCs/HPF); p<0.05 for both comparisons (see figure 43).  
Bone marrow-derived EPCs 
Bone marrow-derived EPCs were much more abundant than their blood-derived 
counterparts, and no significant differences were demonstrated between the three 
genotypes with regard to number (figure 44).  
Spleen-derived EPCs 
Of the three tissue sources, splenic tissue produced the highest number of EPCs for all 
genotypes. Interestingly, ESMIROxGP91phox mice demonstrated a significantly higher 
number of spleen-derived EPCs than WT littermates (85.7 [13.6] vs. 41.8 [6.6]; p=0.02), and 
a trend toward a higher number than ESMIRO littermates (85.7 [13.6] vs. 58.4 [6.9]; 
p=0.09. See figure 45). 
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Figure 43 Quantification of blood-derived EPCs 
HPF=High powered field; (N= 4, 5, 5) 
 
Figure 44 Quantification of bone marrow-derived EPCs  
HPF=High powered field; (N= 5, 7, 6) 
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Figure 45 Spleen-derived EPCs 
HPF=High powered field; (N= 5, 7, 6) 
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5.2.9 Early outgrowth endothelial progenitor cell function 
Function of EPCs was assessed via use of conditioned media in a HUVEC scratch wound 
assay. As figure 46 illustrates, no significant differences were demonstrated with respect to 
extent of wound closure when comparing conditioned media from the three genotypes of 
mice. 
 
Figure 46 HUVEC migration with EPC conditioned media 
CM = conditioned media; (N = 3, 2, 3). 
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5.2.10 Pulmonary endothelial cell functional assays 
The finding of a higher number of CPCs in ESMIROxGP91phox than ESMIRO mice (section 
5.2.7) provides a potential explanation for their notable difference in vascular repair 
(section 5.2.5). However, as outlined in section 1.5.3, there remains significant debate 
regarding the role and extent of contribution of CPCs to the process of re-
endothelialisation. In view of this, the current study also went on to assess for differences 
in EC function, as a means of identifying additional explanations for the in vivo findings.  
In order to ascertain the effects of genetic NOX2 inhibition on ECs in the context of insulin 
resistance, a number of assays were carried out on murine PECs.  
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5.2.10.1 Endothelial cell proliferation 
Increased EC proliferative capacity resulting from NOX2 inhibition was one of the 
postulated mechanisms for improved vascular repair. Proliferating cells were identified 
based upon their ability to incorporate EdU, and then quantified using flow cytometry. No 
significant differences were demonstrated between the three genotypes with respect to 
PEC proliferation (figure 47). 
 
Figure 47 PEC proliferation 
(N = 4, 4, 7) 
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5.2.10.2 Endothelial cell migration 
An alternative mechanism to explain the improved vascular repair noted following NOX2 
inhibition is via enhanced EC migration. The ability of ECs to migrate was assessed using a 
scratch wound assay, with a measurement made for the extent of wound closure in an 18 
hour time period.  
As illustrated in figure 48, PECs derived from ESMIRO mice displayed significantly reduced 
migration relative to WT PECs (28.1 [3.6] vs. 45.1 [3.8]; p=0.02). Genetic NOX2 knockdown 
rescued this impairment, with PECs derived from ESMIROxGP91 mice displaying 
significantly improved migration compared to ESMIRO (45.1 [5.1] vs. 28.1 [3.6]; p=0.04), 
thereby returning migratory capacity back to WT levels. 
 
Figure 48 PEC migration 
(N= 4, 5, 8)  
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5.2.10.3 Superoxide quantification 
Quantification of superoxide concentration was carried out on PECs and in order to assess 
the effect of genetic NOX2 inhibition on ROS production. Superoxide concentration was 
measured via a fluorescence-based assay using DHE. 
PECs derived from ESMIRO mice displayed a significantly higher concentration of 
superoxide than those derived from WT littermates (2.30 [0.26] vs. 1.32 [0.22]; p=0.02). 
Genetic knockdown of NOX2 resulted in a significantly lower superoxide concentration 
(1.38 [0.17] vs. 2.30 [0.26]; p<0.01), thereby normalising the level back to that of WT PECs 
(figure 49). These results recapitulate the findings from previous work published work by 
our laboratory group [123]. 
 
Figure 49 PEC superoxide concentration 
(N= 5, 8, 9)  
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5.3 Virally-transduced HUVECs 
In addition to examining the effect of genetic NOX2 inhibition in the context of insulin 
resistance using murine PECs, the current study also assessed the effect of 
pharmacological NOX2 inhibition using virally-transduced HUVECs and the NOX2 inhibitor 
GP91-ds tat. Prior to carrying out these experiments, pilot work was undertaken to 
optimise the concentration of the shRNA lentivirus to be used in order to achieve an 
approximate 50% knockdown of the IR. 
5.3.1 Optimisation experiments  
In order to identify the optimal dose of the shRNA lentivirus to apply to the HUVECs, dose-
response experiments were carried out using 5, 10 and 20 MOI. Western blotting using 
these doses demonstrated 20 MOI to generate approximately a 50% reduction in IR 
expression compared to control (see figure 50). 
 
Figure 50 Dose response curve illustrating differential insulin receptor expression with increasing concentrations of shRNA 
lentivirus 
MOI = multiplicity of infection. Expressed as a ratio of β actin (N=1). 
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In addition to assessing IR knockdown via western blotting, superoxide production was also 
assessed as a marker of insulin resistance following viral transduction. As figure 51 
illustrates, increasing doses of the shRNA lentivirus resulted in higher concentrations of 
superoxide, suggesting increasing levels of insulin resistance.   
 
Figure 51 Dose response curve illustrating differential superoxide concentration with increasing 
concentrations of shRNA lentivirus 
MOI = multiplicity of infection. Expressed as a ration of β actin (N=1). 
During these optimisation experiments, it was noted that HUVECs treated with either 
shRNA lentivirus at a concentration of 20 MOI seemed to grow poorly relative to the other 
cell samples. Therefore, as a compromise between effective IR knockdown and viral 
toxicity, an MOI of 15 was chosen for subsequent experiments. 
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5.3.2 Human umbilical vein endothelial cell functional assays 
5.3.2.1 Endothelial cell proliferation 
As illustrated in figure 52, no significant differences were seen between control and insulin 
resistant HUVECs with regard to proliferative capacity (37.2 [3.4] vs. 37.2 [2.4]; p=0.98). 
Furthermore, addition of the NOX2 inhibitor GP91-ds tat to either of these groups of 
HUVECs made no significant difference to proliferation. 
 
Figure 52 HUVEC proliferation in the setting of insulin resistance with or without NOX2 inhibition 
Control = HUVECs treated with scrambled shRNA; GP-tat = GP91-ds tat; Virus = HUVECs treated with IR shRNA 
lentivirus; (N=5). 
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5.3.2.2 Endothelial cell migration 
Insulin resistance conferred a significant impairment to the migratory capability of ECs, as 
demonstrated by comparing control and virally-transduced HUVECs (extent of wound 
closure 84.7% [4.7%] vs. 74.0% [3.7%]; p=0.02. See figure 53). Interestingly, this 
impairment was ameliorated by addition of GP91ds-tat to the insulin resistant HUVECs 
(83.5% [3.8%] vs. 74.0% [3.7%]; p=0.02), returning migration back to the level of control-
HUVECs. 
 
Figure 53 HUVEC migration in the setting of insulin resistance with or without NOX2 inhibition 
Control = HUVECs treated with scrambled shRNA; GP-tat = GP91-ds tat; Virus = HUVECs treated with IR shRNA 
lentivirus; (N=4). 
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5.3.2.3 Superoxide production 
Virally-transduced HUVECs demonstrated a significantly higher concentration of 
superoxide than their control counterparts (1.6 [0.3] vs. 1.3 [0.3]; p=0.03. See figure 54), in 
keeping with our understanding that insulin resistance is associated with oxidative stress 
(see section 1.2.4). Previously published work has demonstrated GP91-ds tat to be 
effective at suppressing superoxide production in insulin resistant cultured endothelial 
cells [123], and this finding was recapitulated in the current study. Treatment of the virally-
transduced HUVECs with GP91-ds tat was shown to significantly lower concentration of 
superoxide (1.6 [0.3] vs. 1.1 [0.2]; p=0.01), back to the level of the control cells. 
Interestingly, this experiment also showed that GP91-ds tat has no significant effect on 
superoxide concentration in the absence of insulin resistance (1.3 [0.3] vs. 1.0 [0.3]; p=0.2). 
 
Figure 54 HUVEC superoxide concentration in the setting of insulin resistance with or without NOX2 
inhibition 
Control = HUVECs treated with scrambled shRNA; GP-tat = GP91-ds tat; Virus = HUVECs treated with IR shRNA 
lentivirus; (N=5).  
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5.3.3 Western blotting 
Western blotting was carried out on transduced HUVECs in order to confirm successful 
shRNA lentiviral-mediated knockdown of the IR. A representative blot is shown in figure 
55, whilst a quantified analysis of IR expression is shown in figure 56. Taken together, 
these highlight a significant reduction in IR expression for the virally-transduced cells when 
compared to control samples (1.0 [0.1] vs. 0.5[0.1]; p=0.01). Importantly, the 
representative blot also demonstrates that GP91-ds tat has no significant effect on IR 
expression. 
 
Figure 55 A representative Western blot showing expression of the insulin receptor in HUVECs  
Control = HUVECs treated with scrambled shRNA; GP-tat = GP91-ds tat; Virus = HUVECs treated with IR shRNA 
lentivirus.  
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Figure 56 Insulin receptor expression in HUVECs 
Control = HUVECs treated with scrambled shRNA; Virus = HUVECs treated with IR shRNA lentivirus (N=4).   
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Chapter 6 Discussion  
In recent years, it has become accepted that insulin resistance is independently linked to 
cardiovascular disease [54]. One of the key, and most widely studied, aspects of this 
relationship is the way in which insulin resistance contributes to the initiation of 
atherosclerosis via endothelial dysfunction. However, equally importantly, it is thought 
that insulin resistance also interferes with repair mechanisms which would otherwise serve 
to mitigate against the progression and sequelae of cardiovascular disease. Key among 
these are the processes of vascular repair and angiogenesis; following injury to a blood 
vessel, appropriate vascular repair is essential in order to mediate endothelial healing, as a 
failure to do so leaves the damaged portion of vessel potentially more vulnerable to 
atherosclerotic plaque or local thrombus formation. Meanwhile, angiogenesis is the 
process of generating new blood vessels in adulthood, and is thus crucial for reperfusing 
tissues following an ischaemic vascular occlusion. A study published by our own laboratory 
group has demonstrated that IRKO mice, with haploinsufficiency of the IR at a whole-body 
level but unperturbed glucose homeostasis, display delayed vascular repair following 
denuding endothelial injury [12]. Furthermore, additional work from our laboratory has 
gone on to show that IRKO mice also have impaired ischaemic revascularisation following 
hindlimb ischaemia [130]. Taken together, these findings corroborate the theory that 
insulin resistance independently interferes with vascular repair and regeneration.  
A number of avenues have been explored with the aim of improving the diminished 
vascular repair and regeneration associated with insulin resistance. One of the areas which 
shows promise is via modulation of ROS. There is evidence in the literature to demonstrate 
that inhibiting production of NOX2-derived ROS can improve angiogenesis in the context of 
diabetes [170]. Furthermore, a study published by Sorrentino et al [209] demonstrated 
that the impaired reparative capacity of EPCs derived from individuals with T2DM can be 
reversed via siRNA silencing of the p47phox subunit of NOX2, suggesting that inhibition of 
ROS production by NOX2 can improve vascular repair in diabetes. However, whilst these 
papers suggest NOX2 inhibition may be a promising translational target to improve 
reparative processes in diabetes, the prospect of this strategy conferring the same benefits 
in insulin resistance per se remains untested. To this end, the current project aimed to 
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explore the effects of NOX2 inhibition on angiogenesis and vascular repair in murine 
models of whole-body and endothelial-specific insulin resistance.  
A number of interesting findings were generated as a result of this work. Firstly, genetic 
NOX2 knockdown was demonstrated to have no significant effect on post ischaemic re-
perfusion in the setting of endothelial-specific insulin resistance. However, in contrast, the 
knockdown of NOX2 was associated with a significant improvement in vascular repair 
following femoral artery wire injury in ESMIRO mice, and subsequent in vitro work 
provided two potential explanations: improved EC migration, and an increased abundance 
of CPCs.  
Interestingly, pharmacological NOX2 inhibition could not fully recapitulate these findings. 
Whilst treatment of insulin resistant HUVECs with the NOX2 inhibitor GP91-ds tat was 
associated with an improvement in cell migration, when the same inhibitor was used in 
vivo on ESMIRO mice, there was no significant improvement in vascular repair. 
Finally, whilst genetic NOX2 knockdown proved to be a viable, and in some ways beneficial, 
strategy in the context of endothelial-specific insulin resistance, the converse was true in 
the setting of whole-body insulin resistance. Double cross IRKOxGP91phoxy/- mice 
displayed a failure to thrive following invasive procedures that led to the premature 
cessation of experiments, and post mortem examination revealed the presence of 
presumed granulomas suggesting a possible immunodeficient state.  
Each of these findings will be explored in more detail in the following section. 
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6.1 Summary of key findings 
6.1.1 The effects of genetic NOX2 knockdown on angiogenesis in the context of 
endothelial-specific insulin resistance  
In vivo experiments carried out on the ESMIROxGP91phoxy/- colony of mice as part of the 
current project demonstrated that, in the context of endothelial-specific insulin resistance, 
NOX2 inhibition has no significant effect upon ischaemic revascularisation following 
hindlimb ischaemia. In fact, all three tested genotypes of mice displayed similar levels of 
perfusion within the ischaemic limb at all time points within the 28 day experimental 
protocol. When comparing the results obtained from ESMIRO and WT mice it is interesting 
to note that, when limited to the endothelium, this model of insulin resistance does not 
seem to confer any detriment to ischaemic revascularisation. This data contrasts with the 
aforementioned findings from IRKO mice, in which whole-body insulin resistance does 
indeed impair angiogenesis based upon use of the same in vivo assay. Combining the 
findings from the current study with previous work from our laboratory group, it seems 
that whilst the phenotypic aberration seen in ESMIRO mice is sufficient to impair 
endothelial function [123], unlike IRKO counterparts it is not significant enough to 
significantly affect reperfusion. This divergence between ESMIRO and IRKO mice has a 
precedent, as discussed earlier in section 1.1.2. Whilst the ESMIRO and IRKO murine 
models share a number of characteristics such as endothelial dysfunction and normal 
glucose homeostasis, it is notable that the ESMIRO mice display a milder phenotype as 
evidenced by their lack of hypertension.  
The initial hypothesis of ESMIROxGP91phoxy/- mice displaying enhanced post-ischaemic 
reperfusion relative to ESMIRO counterparts was predicated upon endothelial-specific 
insulin resistance having a detrimental effect on vascular regeneration following hindlimb 
ischaemia. Given that our findings in fact suggest no significant perturbation of ischaemic 
reperfusion in ESMIRO mice, and in the context of previously published work which 
demonstrates NOX2 knockdown to be detrimental in the absence of pathology [153, 167], 
it would perhaps be intuitive to expect ESMIROxGP91phoxy/- mice to suffer with 
diminished post-ischaemic reperfusion. However, as mentioned, analysis of our results 
show that ESMIROxGP91phoxy/- mice demonstrate no significant difference with regard to 
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ischaemic reperfusion compared to either WT or ESMIRO counterparts. Whilst it would 
appear that our findings are contradictory to those from the aforementioned papers, it is 
important to bear in mind that although ESMIRO mice do not have a significant aberration 
in post-ischaemic revascularisation, in contrast to the controls used in those studies they 
are not healthy mice, as illustrated by the presence of oxidative stress and endothelial 
dysfunction [56]. Referring back to the ‘redox window hypothesis’ (section 1.9), it is 
possible that whilst endothelial-specific insulin resistance is associated with oxidative 
stress, the ROS level remains within ‘redox window’ required for effective post-ischaemic 
reperfusion, resulting in an impairment which is too subtle to be detected by use of the 
hindlimb ischaemia experiment. Knockdown of NOX2 in ESMIRO mice may result in 
reduced ROS, but once again this may remain within the ‘redox window’, meaning that any 
adverse effect on post-ischaemic reperfusion is non-significant.   
An alternative explanation for the lack of differences demonstrated between the 
genotypes pertains to the method used for quantification. Laser Doppler analysis provides 
a functional assessment of reperfusion, but does not provide conclusive evidence 
regarding angiogenesis per se, for which capillary density is a better measure. In view of 
the equivocal results obtained with regard to ischaemic revascularisation, a decision was 
taken to prioritise pursuing other in vivo findings that were deemed to be of higher 
translational potential. As a result, an analysis of capillary density in the harvested 
ischaemic muscles has not been undertaken as part of this project, and it is possible that 
variations between the genotypes are more readily apparent when using this method of 
analysis. 
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6.1.2 The effects of genetic NOX2 knockdown on vascular repair in the context of 
endothelial-specific insulin resistance  
Whilst genetic NOX2 knockdown had no significant effect on post-ischaemic reperfusion in 
the setting of endothelial-specific insulin resistance, a significant improvement was 
demonstrated in vascular repair following endothelial denuding arterial injury. This was 
perhaps the key finding from the current project, and as a result a significant proportion of 
the in vitro assays were conducted in order to understand this observation. 
As discussed in section 1.5.2, our current understanding of vascular repair following 
endothelial injury is founded upon two mechanisms: proliferation and migration of ECs 
adjacent to the injured vessel segment which replace lost and damaged cells; and/or the 
recruitment of bone marrow derived progenitor cells which home to the site of injury and 
assist in repair, by either direct incorporation or paracrine stimulation of resident ECs. The 
findings from in vitro experiments investigating these mechanisms are expanded upon in 
the following sections. 
6.1.2.1 Endothelial cell migration 
In addition to being pivotal to vascular repair, the ability of ECs to migrate is also thought 
to be essential to other physiological and pathological processes, including angiogenesis 
and vascular graft healing [210]. Previous studies have employed a number of assays to 
investigate EC motility, including the use of a Boyden chamber which assesses the 
migration of quiescent ECs along a chemotactic gradient, traditionally generated with use 
of a specific chemoattractant [211, 212]. Whilst this assay is undoubtedly valuable in 
studying EC migration, it arguably models only one aspect of a three-step process; as well 
as chemotaxis to a gradient of pro-migratory mediators, EC migration is also thought to 
involve the steps of haptotaxis, which describes directional migration toward a gradient of 
immobilised ligands, and mechanotaxis which is the term given to directional migration 
generated by mechanical forces as a result of actin cytoskeletal reorganisation [164]. In 
view of this limitation of the Boyden chamber assay, the scratch wound assay was used to 
investigate the EC migration component of vascular repair in the current study, as we 
believe it may provide a more accurate representation of the process that occurs in vivo 
following an endothelial denudation injury. 
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The data obtained from PECs using the scratch wound assay appears to demonstrate 
insulin resistance diminishing EC migration, as attested to by the comparison between WT 
and ESMIRO mice. Interestingly, this apparent impairment is entirely abrogated by genetic 
NOX2 knockdown, since PECs from ESMIROxGP91phoxy/- mice display significantly 
enhanced migration when compared to their ESMIRO counterparts, returning migratory 
capacity back to WT levels. The concept that insulin resistance may impair EC migration 
has been mooted previously, and indeed insulin has been demonstrated to stimulate 
human microvascular endothelial cell migration via interaction with its receptor and 
increased Akt phosphorylation [213]. The cited paper also found that the observed 
enhancement in migration could be abrogated with use of a PI3K inhibitor, thereby 
implicating this specific signalling pathway. Interestingly, this paper made no direct 
reference to ROS as a potential mechanism to explain the migratory impairment associated 
with insulin resistance. Nonetheless, there exists a great deal of evidence highlighting the 
key role played by ROS in EC migration. As alluded to earlier, actin remodelling is an 
important component of the EC migratory process since it modulates cell shape and 
motility, as well as cell–cell contacts and cell contact with adhesion molecules [165]. ROS 
have emerged as a key regulator of actin remodelling, leading to the observation that 
NADPH oxidase activation and the ensuing superoxide production could modulate cell 
migration. Previous studies have demonstrated that migrating cells at wound margins 
produce increased quantities of ROS. Building on these observations, siRNA knockdown of 
NOX2 has been demonstrated to impair EC migration [214]. Furthermore, either NADPH 
oxidase inhibition or superoxide scavenging by an SOD mimetic can reduce both the speed 
and directionality of EC migration into a wound [215]. Interestingly, as well as ROS having 
the ability to modulate actin, there is also evidence in the literature to support the 
existence of a reciprocal relationship whereby actin can itself directly interact with 
components of NADPH oxidase such as p47phox to stabilise the enzyme, thus promoting 
ROS production [216]. 
The precise mechanisms by which ROS control actin reorganisation are complex, and 
incompletely understood. However, it is accepted that the actin cytoskeleton is affected 
profoundly by the prevailing redox environment [165], and based on this it would be 
intuitive to expect oxidative stress to be detrimental to actin remodelling, and thus by 
extension, EC migration. This concept has been corroborated in a study published by van 
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Aalst et al, the hypothesis for which was that the ability of oxidised low-density 
lipoproteins (oxLDL) to impair EC migration is secondary to increased ROS production 
[210]. The paper stated that oxidative stress diminished EC migration through excessive 
cytoskeletal disruption, suggested by the rounded appearance of the endothelial cells after 
exposure to inhibitory concentrations of oxLDL. Furthermore, SOD was shown to decrease 
oxLDL-induced reactive oxygen species production by ECs, which had the effect of 
preserving EC migration in the presence of oxLDL concentrations which alone would be 
inhibitory. Whilst the mechanism by which oxidative stress results in cytoskeletal 
disruption was not explored in this paper, the authors postulated that increased 
superoxide production may lead to formation of high levels of peroxynitrite, which has 
been reported to inhibit actin polymerization and impair neutrophil chemotaxis and 
fibroblast migration [217, 218]. The concept of oxidative stress inhibiting actin 
polymerisation had been discussed in a prior paper which examined the effect of ROS on 
glutathionylation of various proteins in T lymphocytes [219]. A variety of cytoskeletal 
proteins, including actin, were observed to be glutathionylated in the setting of oxidative 
stress. Importantly, glutathionylation has been demonstrated to reversibly inhibit actin 
polymerisation [220], thus linking oxidative stress, via disruption of mechanotaxis, to 
impaired EC motility. 
Accordingly, our observation that NOX2 knockdown rescues the diminished EC migration 
associated with endothelial-specific insulin resistance is in keeping with prior findings. It is 
possible that in the setting of endothelial-specific insulin resistance, downregulation of the 
PI3K signalling pathway combines with dysfunctional actin cytoskeletal remodelling 
secondary to oxidative stress to impair EC migration, and that inhibition of ROS production 
via NOX2 knockdown rescues this deficit by restoring the redox environment to 
physiological levels. 
6.1.2.2 Endothelial cell proliferation 
The findings from the experiments exploring EC migration provide a potential mechanism 
for the improved vascular repair seen in ESMIROxGP91phoxy/- mice relative to their 
ESMIRO counterparts. Another putative mechanism which warranted investigation was 
whether increased EC proliferation was a contributory factor, and this was assessed using 
an in vitro assay of EdU uptake. The experiment is based upon the principle that replicating 
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cells will incorporate EdU into their DNA, and if this is conjugated to a fluorophore, the 
proportion of replicating cells can be quantified using flow cytometry. The data obtained 
from the current study shows no significant differences between the PECs derived from 
the three genotypes of mice tested with respect to proliferation. In contrast to the assay of 
EC migration, insulin resistance did not appear to confer any functional deficit, with the 
proliferative capacity of ESMIRO PECs not differing significantly from WT PECs. Previous 
studies provide an insight into this finding, as it has been shown that exogenous insulin has 
no significant effect on the proliferation of human microvascular ECs [213]. Extrapolation 
of this observation suggests that insulin resistance may not influence EC proliferation. The 
role of NOX2-derived ROS in cell proliferation is not certain, but there are papers which 
suggest that, unlike NOX4-derived hydrogen peroxide which is pro-proliferative, 
superoxide generated by NOX2 instead prevents apoptosis and promotes survival [163]. 
With this in mind, our observation that NOX2 knockdown has no significant effect on 
endothelial cell proliferation is perhaps unsurprising.    
6.1.2.3 Circulating progenitor cells 
The concept of native ECs contributing to the process of re-endothelialisation via 
proliferation and migration is well accepted. In contrast, the hypothesis that bone marrow-
derived progenitor cells assist in repair via differentiation into ECs is more controversial, 
although the possibility of paracrine effects on local ECs remains more widely accepted 
[141]. In a paper published by our own laboratory group, impaired mobilisation of CPCs 
from the bone marrow was postulated as a mechanism underpinning the diminished 
vascular repair observed in IRKO mice relative to WT littermates [12]. This hypothesis was 
substantiated by the finding that transfusion of cKit+ CPCs from WT mice normalised the 
vascular repair of IRKO mice, whilst transfusion of cKit+ CPCs from other IRKO mice 
achieved partial restoration of re-endothelialisation. As a counterview, another group has 
published work which appears to demonstrate that vascular repair following carotid artery 
wire injury is solely mediated by the migration of ECs from adjacent healthy endothelium, 
with no demonstrable role for direct incorporation of CPCs [141]. Whilst the evidence 
provided in this paper is compelling and apparently contradictory to the mechanism 
postulated by Khan et al, it must be borne in mind that the mice used in this study were 
healthy and therefore presumably had a normally functioning endothelium. This contrasts 
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with the IRKO mice used by Khan et al, which have been demonstrated to display 
endothelial dysfunction [54]. Moreover, the conclusions of these studies are not mutually 
exclusive, since paracrine effects of CPCs were not excluded by Hagensen et al, and direct 
incorporation of infused cKit+ cells was not tested by Kahn et al. With this in mind, we felt 
it important to investigate the potential contribution of CPC abundance and function to the 
differences observed in vascular repair between ESMIRO and ESMIROxGP91phoxy/- mice. 
Quantification of CPCs was performed using flow cytometric detection of both Sca1+/ Flk1+ 
and cKit+/Sca1+ populations. When considering either population, although no statistically 
significant difference in CPC abundance is demonstrated between WT and ESMIRO mice, a 
trend toward reduced CPCs in ESMIRO mice is visible. Previously published data suggests 
that CPC mobilisation is dependent upon NO [159], and as discussed in section 1.6.4, as 
well as sequestering NO, an excess of ROS can lead to the uncoupling of eNOS, resulting in 
production of yet more superoxide at the expense of NO. Based on this, it is therefore 
possible that the oxidative stress associated with endothelial-specific insulin resistance 
compromises CPC mobilisation to some degree, resulting in fewer CPCs within the 
bloodstream. Knockdown of NOX2 in ESMIRO mice resulted in a significant increase in 
Sca1+/Flk1+ CPCs. These data suggests that by correcting the oxidative stress associated 
with endothelial-specific insulin resistance, NOX2 deletion overturns the deficit of CPCs in 
ESMIRO mice. Enhanced bioavailability of NO offers one potential explanation for this, 
although further studies would be required to test this hypothesis. The fact that there was 
no significant difference in the abundance of cKit+/Sca1+ expressing CPCs between ESMIRO 
and ESMIROxGP91phox mice may be a reflection of the fact that this population of cells 
differs from Sca1+/Flk1+ CPCs. 
An alternative explanation for the increased quantity of Sca1+/Flk1+ CPCs in the 
ESMIROxGP91phoxy/- mice, as well as the link between this and the improved re-
endothelialisation observed in this cohort of mice, pertains to the concept of vascular 
repair being an inflammatory process [221]. Recruited inflammatory cells play a critical role 
in the reparative process following vessel injury, and inflammatory reactions can influence 
proliferation and migration of ECs and smooth muscle cells (SMCs). As discussed in section 
1.8, NOX2 deletion has been previously associated with increased macrophage secretion of 
pro-inflammatory cytokines, such as IL-1β and TNF-α. Interestingly, the results of the 
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current study also demonstrate a trend toward increased IL-1β expression in the aortic 
tissue of ESMIROxGP91phoxy/-, and it is notable that this trend is seen in comparison to WT 
as well as ESMIRO counterparts. Given the uncertainty surrounding the identification and 
role of CPCs (section 1.5.3), it is possible that the increased quantity of Sca1+/Flk1+ we 
observed in the ESMIROxGP91phoxy/- mice actually represent inflammatory cells which can 
themselves augment vascular repair by stimulating resident ECs and SMCs [221]. Further 
weight behind this hypothesis comes from the observation of a significantly higher number 
of spleen-derived EPCs in ESMIROxGP91phoxy/- mice compared to WT counterparts, and a 
trend toward a higher number compared to ESMIRO. Whilst for the purposes of this 
project (based upon accepted definitions [137]), the uptake of DiI-ac-LDL and lectin-FITC 
denoted these cells as EPCs, it is known that these are in fact macrophage lineage cells, 
which could clearly influence tissue repair via paracrine mechanisms. This potentially 
correlates with the observation from previous studies of increased macrophage-
derived inflammatory cytokines in mice with NOX2 knockdown [193].  
Extrapolating the theory that the increased abundance of progenitor cells in 
ESMIROxGP91phoxy/- mice is a manifestation of increased inflammation leads to the 
possibility that the observed improvement in vascular repair in fact represents a 
prelude to increased atherosclerosis. The same inflammatory processes which 
augment vascular repair are known to be key to the development of stenotic lesions 
[221], and in a paper assessing the influence of NOX2 on abdominal aortic aneurysm 
progression, a trend toward increased atherosclerosis associated with NOX2 
knockdown was visible in a small sample of mice [194]. Since this is an area which is 
incompletely understood, it would be instructive to further investigate the relationship 
between NOX2 inhibition, inflammation and atherosclerosis. Possible avenues for 
exploration are discussed in section 6.3. 
6.1.3 Pharmacological NOX2 inhibition does not fully recapitulate the effects of 
genetic enzymatic knockdown 
The findings from experiments on ESMIROxGP91phoxy/- mice, which demonstrated that 
genetic knockdown of NOX2 can improve vascular repair and EC migration in the setting of 
endothelial-specific insulin resistance, were translationally encouraging. However, part of 
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the aim of this project was to appraise the potential applicability of NOX2 inhibition in a 
clinical setting. In this context, whilst genetic knockdown of NOX2 provides important 
insight as a proof of concept, in order to assess the translational potential of this strategy it 
was important to investigate whether we could recapitulate the positive findings using 
pharmacological NOX2 inhibition. As before, in vitro and in vivo experiments were carried 
out with the aim of acquiring both observational and mechanistic data. The drug GP91-ds 
tat was chosen as the pharmacotherapy for the current study since, unlike other ROS-
reducing agents, it is relatively specific to NOX2. Furthermore, previously published work 
by our laboratory group has demonstrated its efficacy in reversing oxidative stress-
associated endothelial dysfunction both in vitro and in vivo [123]. 
The in vitro work in this thesis was undertaken using HUVECs which had an approximate 
50% knockdown of the IR using lentivirus-introduced shRNA (or scrambled control). 
Reflecting the work undertaken on the PECs, assays of cell migration, proliferation and 
superoxide production were carried out on the transduced HUVECs following treatment 
with either GP91-ds tat or a scrambled peptide. Since the ischaemic revascularisation 
experiment in the ESMIROxGP91phoxy/- mice demonstrated no improvement following 
NOX2 knockdown, we elected to focus our in vivo work for this part of the project 
exclusively on vascular repair. Micro-osmotic pumps containing either GP91-ds tat or a 
scrambled peptide were subcutaneously inserted into ESMIRO mice, which then 
underwent the vascular repair experiment as described previously.  
6.1.3.1 In vitro findings 
The DHE assay for superoxide quantification demonstrated that HUVECs with knockdown 
of the IR produced a significantly higher concentration of superoxide than control 
specimens, in keeping with our understanding that insulin resistance is associated with 
oxidative stress [87]. Reassuringly, GP91-ds tat fully reversed the observed oxidative stress, 
returning superoxide concentration of insulin resistant HUVECs to control levels. The 
results from the scratch wound assay showed that this reversal of oxidative stress 
translated to an improvement in EC migration, as the functional deficit experienced by 
insulin resistant HUVECs was fully overturned via treatment with GP91-ds tat. Paralleling 
our findings from the PECs, no significant differences were observed with respect to 
proliferation. This finding suggests firstly, that the extent of insulin resistance associated 
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with a 50% knockdown of the IR is insufficient to alter the proliferative ability of ECs, and 
secondly, that NOX2 inhibition has no significant effect on EC proliferation.  
To summarise the in vitro findings, we demonstrated that insulin resistance is associated 
with oxidative stress and diminished EC migration. Treatment of the insulin resistant ECs 
with a NOX2 inhibitor can ameliorate the oxidative stress, which translates into improved 
migration. As with genetic knockdown of NOX2, the mechanism by which pharmacological 
NOX2 inhibition improves EC migration in the context of insulin resistance is presumed to 
be via modulation of actin remodelling, as discussed in section 6.1.2.1. 
6.1.3.2 In vivo findings 
Whilst the in vitro findings following pharmacological NOX2 inhibition correlate well with 
the in vitro results obtained following genetic NOX2 knockdown, the in vivo vascular repair 
results were conflicting. The data illustrate that in the setting of endothelial-specific insulin 
resistance, pharmacological NOX2 inhibition has no significant effect on vascular repair. 
The disparity between the in vitro and in vivo effects of GP91-ds tat, whereby improved EC 
migration is not translated into a corresponding improvement in vascular repair, is difficult 
to reconcile. This is particularly true in view of the fact that the aforementioned study by 
our laboratory group demonstrated that chronic infusion of GP91-ds tat can reverse the 
endothelial dysfunction observed in ESMIRO mice [123].  One possible explanation relates 
to the dose of the drug reaching the relevant tissues in the in vivo model. The in vitro 
experiments were conducted using GP91-ds tat at a concentration of 50μM. To this 
author’s knowledge, there are no published data that confirm the concentration of GP91-
ds tat achieved in the murine bloodstream following infusion via micro-osmotic pump, but 
it is highly likely that the concentration of the drug reaching the tissues is significantly 
lower. Based on our previous findings, it would appear that whilst the in vivo concentration 
being achieved is sufficient to improve vasomotor function of ESMIRO mice, it is 
insufficient to impact upon vascular repair.  
The inability of GP91-ds tat to improve vascular repair may also relate to the concept of 
the reparative process being driven by inflammation. It is plausible that pharmacological 
NOX2 inhibition fails to illicit the same pro-inflammatory effect as total genetic NOX2 
knockdown. Indeed, whilst there is evidence to show that IL-1β production is increased 
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following genetic NOX2 knockdown (discussed in section 6.1.2.3), a paper studying the role 
of NADPH Oxidase during hyperhomocysteinemia demonstrated that treatment of mice 
with GP91-ds tat actually reduced IL-1β production [222]. Thus, if the improved vascular 
repair in ESMIRO mice following genetic NOX2 knockdown is a consequence of a pro-
inflammatory state, it is perhaps understandable that pharmacological NOX2 inhibition, 
which appears incapable of generating such a reaction, fails to reproduce the same 
phenotype. 
6.1.4 Viability of the IRKOxGP91phoxy/- murine model 
The IRKO murine model, with haploinsufficiency of the IR at a whole-body level but 
without dysglycaemia, is one which has been extensively studied by our laboratory group. 
Previously published work demonstrates that aortic rings and ECs from IRKO mice display 
endothelial dysfunction, and that this dysfunction can be corrected via use of a SOD 
mimetic, implicating a role for oxidative stress in the pathological process [120]. 
Subsequent work has gone on to show that the endothelial dysfunction of IRKO mice is 
associated with delayed vascular repair following denuding endothelial injury [12]. As 
discussed at the beginning of this chapter, there is a body of evidence which supports the 
concept of NOX2 inhibition as a potential approach to rescue the impaired vascular repair 
associated with insulin resistance. In order to investigate this, we created a novel double 
transgenic murine model which combines haploinsufficiency of the IR with genetic 
knockdown of NOX2. 
Initial experiments comprised phenotypic characterisation of this new colony and 
demonstrated that the double cross (IRKOxGP91phoxy/-) mice grew appropriately, whilst 
not differing significantly from WT or IRKO counterparts with respect to glucose 
homeostasis. Following this, the focus shifted to in vivo studies to assess whether NOX2 
deletion could reverse the impaired vascular repair observed in IRKO mice. During these 
experiments, it became apparent that the double cross mice were failing to thrive 
following invasive procedures. Their recovery period tended to be longer than that of age-
matched mice of differing genotypes, and on occasion double cross mice would die 
following an ostensibly complication-free procedure.  Whilst post-mortem examination of 
these mice did not reveal a direct cause for the unexpectedly high mortality rates, a 
notable finding was the frequent presence of presumed granulomas. All experiments on 
195 
 
this colony of mice were halted prematurely in view of these observations, meaning that it 
was not possible to fully elucidate the effect NOX2 knockdown on vascular repair in the 
setting of whole-body insulin resistance. Furthermore, the planned experiment to 
investigate ischaemic revascularisation following hindlimb ischaemia was never started. 
Whilst the premature cessation of experiments mean that we have only limited data on 
this colony, the limited stress resistance of the double cross genotype is interesting, and 
the potential reasons underpinning it warrant further discussion.  
Historically, one of the concerns associated with inhibition of the action of NOX2 is the 
potentially detrimental effect on the innate immune system. As mentioned in section 
1.2.2, NOX2 was first discovered in phagocytes where it plays an important role in host 
defence mechanisms by producing a ‘respiratory burst’ of ROS in order to kill internalised 
bacteria. It is therefore intuitive to assume that a global NOX2 knockdown would leave the 
recipient vulnerable to invading pathogens, and indeed there is a recognised analogue of 
this in human disease, in the form of chronic granulomatous disease (CGD). Patients 
suffering with this primary immunodeficient condition are characterised by a significantly 
increased susceptibility to severe bacterial or fungal infections as a result of a mutation in 
one of four genes encoding the subunits of phagocytic NOX2 [223]. As the name implies, 
the condition is also associated with granulomatous complications secondary to excessive 
inflammation.  
Whilst genetic inhibition of NOX2 in mice with endothelial-specific insulin resistance 
seemed to be well tolerated, translating that into the setting of whole-body insulin 
resistance appeared to result in a phenotype which more closely mimics CGD. The fact that 
ESMIRO mice countenance NOX2 inhibition better than IRKO counterparts is interesting, 
and may reflect the milder phenotypic derangement associated with resistance to insulin 
in limited tissues, as opposed to global resistance. This distinction may be of importance 
with regard to application of NOX2 inhibition in clinical practice, since the IRKO murine 
model presumably provides a more accurate representation of patients with insulin 
resistance than does ESMIRO. Our observations from IRKOxGP91phoxy/- mice raise the 
possibility that complete NOX2 inhibition in insulin resistant patients may adversely affect 
the immune system to a degree that would negate any theoretical benefit derived from 
improved vascular repair. Nevertheless, it is worth bearing in mind that these detrimental 
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effects were only seen following genetic knockdown of NOX2 which, as discussed in the 
preceding section, appears to provide a more potent enzymatic inhibition than 
pharmacological blockade. It might therefore be interesting to observe whether IRKO mice 
tolerate chronic treatment with GP91-ds tat without adverse immunological consequences 
in the same way as their ESMIRO counterparts. Provided no concerns arose following 
chronic pharmacological NOX2 inhibition, an assessment could then be made of whether 
this is associated with improved vascular repair, with the caveat that no alteration was 
seen following GP91-ds tat treatment in ESMIRO mice.  
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6.1.3 Summary of mechanisms 
Pulling together the findings from the in vitro and in vivo experiments conducted as part of 
this project, we can surmise that pharmacological NOX2 inhibition can reverse the 
impaired EC migration associated with endothelial-specific insulin resistance in vitro, but is 
unable to augment vascular repair. Total NOX2 knockdown via genetic means can also 
reverse the impaired EC migration associated with endothelial-specific insulin resistance, 
with the additional benefit of improving vascular repair following a denuding wire injury.  
Based on our understanding from the existing literature, the improvement in EC migration 
following either pharmacological or genetic NOX2 inhibition most likely reflects 
modulation of the actin cytoskeleton, whereby the reduction in ROS corrects the oxidative 
stress associated with insulin resistance and results in a redox environment more 
conducive to effective actin remodelling. 
This observation is both interesting and encouraging. However, the findings from the 
current study hint at the complexity and highly nuanced nature of role of NOX2 in vascular 
biology, thus highlighting the need for circumspection when attempting to modulate it. 
The fact that the improved EC migration observed in vitro following pharmacological NOX2 
inhibition did not translate into a corresponding improvement in in vivo vascular repair is 
an indication that improved EC function may not be the sole mechanism underpinning the 
augmented re-endothelialisation demonstrated following NOX2 knockdown in ESMIRO 
mice. It is accepted that the inflammation which ensues following vascular injury is a 
critical factor in directing the subsequent reparative processes, and involves interaction 
between multiple cell types including ECs and SMCs [224]. Previously published work has 
demonstrated deletion of NOX2 to be associated with a pro-inflammatory state, and a 
number of observations from the present study serve to substantiate this. In particular, the 
trend towards increased IL-1β expression and the demonstration of increased CPC and 
splenic EPC abundance in ESMIROxGP91phoxy/- mice are potentially consistent with 
increased inflammation. Taken together, the augmented vascular repair observed in 
ESMIROxGP91phoxy/- mice may therefore be a corollary of a pro-inflammatory state 
facilitating improved re-endothelialisation following injury.  
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Whilst the identification of a mechanism to augment vascular repair in the setting of 
endothelial-specific insulin resistance is promising, it is important to note that the post-
injury inflammation which initially benefits re-endothelialisation may ultimately also 
stimulate atherosclerosis and vessel stenosis [224]. As a result, the hypothesis that an 
improvement in re-endothelialisation following NOX2 deletion is mediated via an 
inflammatory response portends a potentially significant hurdle to the translation of NOX2 
inhibition from bench to bedside. The contrasting effects of pharmacological and genetic 
NOX2 inhibition on ESMIRO mice in vivo suggests that a significant blockade of NOX2 
function is required in order to augment vascular repair. However, the concept that 
improved vascular repair may be a harbinger of a pro-atherosclerotic state means that 
significant caution will need to be exercised in recreating the level of NOX2 inhibition seen 
following genetic knockdown with a pharmacological agent.  
Accentuating these concerns are the insights gleaned from experiments in the 
IRKOxGP91phoxy/- colony of mice, which highlight the potential of complete NOX2 
knockdown in the setting of whole-body insulin resistance to compromise immune 
function, leading to phenotype analogous to the immunodeficient condition CGD. 
It is clear that more work needs to be undertaken before NOX2 modulation can be 
considered a viable therapeutic intervention, and a few suggestions that arose from work 
in the current project are discussed in section 6.3. 
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6.2 General limitations 
Whilst the methods and techniques employed during this project have been honed and 
refined by previous studies, as well as optimised for the current study, there are inherent 
limitations which need to be borne in mind when appraising data and drawing conclusions.  
6.2.1 Fidelity of animal insulin resistance models to the human disease state 
As research into the area of human insulin resistance grows, it becomes ever more 
apparent that it is a complex, multi-level pathological state. Rather than dysfunction of a 
single component in a signalling axis, insulin resistance is likely acquired as a result of 
modification of signalling pathways at various levels due to myriad co-existing pathological 
factors including, but not confined to, inflammation, lipotoxicity and hyperglycaemia.  The 
IRKO and ESMIRO murine models used in this project attempt to model insulin resistance 
via haploinsufficiency of the IR, or overexpression of a mutated form of the IR in the 
endothelium, respectively. These comparatively blunt measures cannot fully recapitulate 
the nuances of the human disease process. Furthermore the ESMIRO mouse, with its 
endothelial-specific insulin resistance, has no true correlate in human pathology. 
Accordingly, some caution needs to be exercised when extrapolating findings from these 
models to clinical settings. Nevertheless, whilst conceding that these murine models 
cannot truly recreate human insulin resistance, the following points provide justification 
for the reliance on them during this project. Firstly, both IRKO and ESMIRO mice have been 
demonstrated to faithfully mimic aspects of the vascular dysfunction observed in insulin 
resistant humans [54, 56]. Secondly, the experiments carried out using virally transduced 
HUVECs recapitulated the key findings from the PEC assays, lending credence to the 
robustness of the transgenic model. Thirdly, the inclusion of transgenic mice, as opposed 
to exclusively using human cells, allowed in vivo work to be carried out alongside in vitro 
experimentation, granting a better understanding of the therapeutic effects of NOX2 
inhibition. And finally, the in vivo experiments carried out in the current study clearly could 
not be performed in humans, whilst use of larger mammals would introduce additional 
logistical hurdles such as longer breeding cycles and increased time taken to reach 
maturation.  
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6.2.2 Models of vascular disease 
Accepting that the models of insulin resistance utilised in this project are a simplification of 
the human disease process, in a similar vein it must be also be appreciated that the in vivo 
experiments used to model vascular diseases are approximations rather than true 
representations of clinical pathology. The hindlimb ischaemia model is widely used to 
assess ischaemic revascularisation, and when combined with laser Doppler imaging it 
allows for functional data to be collected at varied times from the same mouse, thus 
obviating the need to sacrifice mice at different time points to allow analysis. However, 
whereas human peripheral vascular disease usually progresses chronically, allowing for the 
development of collateral vessels prior to possible arterial occlusion, in this model the 
ischaemia is truly acute in a way that is rarely seen in clinical practice.  
The vascular repair experiment, which provided pivotal data for the current study, also 
bears similar limitations. The assay provides an insight into the process of re-
endothelialisation which occurs following arterial injury, caused either by vascular disease 
or stent deployment. In order to allow reproducibility the injury to the endothelium is 
linear and discrete in nature, which may not reflect diverse range of insults that the 
endothelial lining in a diseased human artery may be subject to. Furthermore, the fact that 
the extent of repair is analysed four days following the injury does not allow for any 
assessment of longer-term recovery. 
6.2.3 Choice of endothelial cells for in vitro assays 
As discussed in section 6.1, the observation that genetic NOX2 knockdown improves 
vascular repair in the context of endothelial-specific insulin resistance was one of the most 
exciting of the current project, and a large proportion of the subsequent in vitro work was 
performed in order to understand the mechanisms underpinning this finding. Assays 
exploring EC function were pivotal in providing mechanistic insight, and so the selection of 
ECs used bears further scrutiny. 
The in vivo finding of improved vascular repair was based upon experiments using the 
femoral artery, which forms part of the macrovascular circulation. Ideally, the in vitro work 
that followed wound focus on ECs derived from other macrovascular arterial vessels, such 
as the aorta. For the current project, the ECs used were PECs and HUVECs; cells 
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predominantly from the microvascular and venous circulations respectively. It could be 
argued that this is a significant disparity, since these circulatory systems are exposed to 
differing haemodynamic pressures. As a result, the ECs are likely to display a cellular and 
molecular heterogeneity which may influence vascular function and repair [225]. However, 
whilst accepting the caveat that the ECs used are not fully representative of the 
endothelium used in the vascular repair experiment, we feel that the selected cohorts of 
cells share enough overlap to provide mechanistic insight. Our laboratory has extensive 
experience culturing PECs, and previous unpublished work has shown that this subset of 
cells tend to reflect aberrations in macrovascular endothelial dysfunction. Meanwhile, 
HUVECs are widely used by many groups and are thought to provide a robust model of 
endothelial cell function [226, 227]. 
As well as the need to use suitable surrogates for macrovascular arterial ECs, pragmatic 
considerations also influenced our selection of cells for in vitro experimentation. It is not 
feasible to obtain a sufficient quantity of ECs from aortic tissue alone for all of the assays 
performed in this project. Whilst an option could have been to pool together the aortae 
from multiple mice for each experimental sample, this would have necessitated the use of 
a prohibitive number of animals and we deemed the benefit of using macrovascular ECs as 
insufficient justification for such use of resources. 
6.2.4 Sample size   
One of the limitations inherent in the current study is the relatively small sample sizes used 
for a number of the experiments. Whilst statistical power calculations were used to 
determine the minimum sample sizes for the key measures of vascular repair and 
ischaemic revascularisation, additional ethical considerations were taken into account 
when deciding on the sample size for experiments such as PEC assays or progenitor cell 
quantification, since these represent hypothesis-generating mechanistic work. As is 
necessary when conducting animal research, during this project we made a concerted 
effort to balance the need for a representative sample size with the desire to minimise 
animal usage. Whilst it would be ideal to use large cohorts in each experimental group in 
order to provide more conclusive data, a pragmatic approach is required when deciding 
how many replicates are needed in order to answer an exploratory scientific question. This 
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represents a different approach to clinical trials, where sample size for all experiments are 
traditionally determined by use of statistical power calculations.  
In addition to ethical issues, resource considerations also had a role in shaping 
experimental planning, since funds and time available for this project were finite and the 
development and optimisation of assays undertaken prior to data acquisition required 
significant investment. 
Overall, a number of the mechanistic experiments undertaken in this project were 
designed to be exploratory, rather than to provide definitive conclusions. When viewed in 
that context, and taking into account the ethical and resource considerations outlined 
above, we feel that the sample sizes used represent a satisfactory compromise which 
allows the generation of data which can form the basis for future work. 
6.2.5 Mechanistic insight 
The current project has highlighted a number of interesting findings which warrant further 
exploration in future studies. Whilst great effort has been made during this project to 
elucidate the mechanisms underpinning the changes observed following NOX2 inhibition in 
insulin resistance, it is important to recognise that there remain a number of important 
unanswered questions. Part of this is attributable to time constraints that are inevitably 
associated with fixed-term research posts. This has necessarily meant that certain 
experiments have been prioritised based on our current understanding, whilst other 
avenues which may have proven more fruitful have been left unexplored. In recognition of 
this, the following section outlines additional experiments which may aid in developing a 
deeper mechanistic insight into the observations discussed in this thesis. 
An additional limiting factor which needs to be recognised is our currently limited 
knowledge on the function of NOX2, and its interaction with other NOX isoforms. A more 
intimate understanding of the workings of these enzymes would facilitate a more nuanced 
modulation of ROS production. In lieu of this, we have had to employ the relatively crude 
approaches of total genetic knockdown or single dose pharmacological inhibition. For the 
purposes of examining downstream and compensatory effects, it would be useful to be 
able to make more subtle alterations to NOX2 function.  
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6.3 Future directions 
As discussed in section 6.1, the current project has identified a number of interesting 
findings which could potentially lead on to clinically useful developments. However, 
further work is required in order to fully understand our own observations, as well as the 
nature and extent of the effects of NOX2 inhibition in the context of insulin resistance in 
general. In this section, we outline a number of potential directions for future studies to 
build upon the work described in this thesis. 
6.3.1 Endothelial cell migration and actin remodelling 
The current study demonstrates that endothelium-specific insulin resistance significantly 
diminishes EC migration, and that this impairment can be fully reversed via either genetic 
or pharmacological NOX2 inhibition. Based on existing literature, we postulate that these 
findings are a corollary of changes in the redox environment affecting actin cytoskeletal 
remodelling, and further experiments would be useful to explore this theory in more 
detail. As an initial step, fluorescently labelled phalloidin could be used to provide an 
insight into actin filament arrangement, allowing comparisons to be made between ECs 
with differing levels of oxidative stress. By carrying out this assay in the PECs and HUVECs 
used elsewhere in this project, the effects of insulin resistance and NOX2 inhibition on EC 
migration could be examined. 
Whilst staining actin with fluorescently labelled phalloidin provides useful information into 
gross filament arrangement, the technique is limited by the fact that direct fluorescent 
labelling of actin inhibits its function and dynamics. As a result, an alternative approach 
such as use of a novel live cell-compatible probe is required for studying the dynamics of 
actin within living cells [228]. Such a technique could potentially be used in an in vivo 
model, and could ultimately provide a detailed understanding into the effects of NOX2 
inhibition on EC migration following vascular injury. 
6.3.2 NOX2 inhibition, inflammation and vascular repair 
Whilst enhanced EC migration may provide a mechanism for the improved vascular repair 
noted in ESMIROxGP91phoxy/- mice compared to ESMIRO counterparts, results from 
experiments studying IL-1β expression and CPC quantity suggest that increased 
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inflammation following NOX2 knockdown may also be a contributory factor. It is important 
to recognise that our RT-qPCR experiments assessing the expression of pro-inflammatory 
cytokines were incomplete due to time constraints, and so completion of these would be 
the next step. Based upon the trend visible from the experiment in the current study, as 
well as previously published work [193], we feel that it is highly probable that tissues from 
ESMIROxGP91phoxy/- mice will display significantly higher quantities of IL-1β than either 
WT or ESMIRO littermates.  
As already alluded to, one of the key questions to arise from this project is the relative 
contribution of increased inflammation to the improved vascular repair observed in 
ESMIROxGP91phoxy/- mice. An interesting way to dissect this out would be to combine 
vascular repair experiments in ESMIROxGP91phoxy/- mice with administration of the drug 
canakinumab, a monoclonal antibody targeted at IL-1β [229]. The use of canakinumab 
would isolate and remove the effect of IL-1β in the reparative process, thus providing 
evidence of the role of inflammation in re-endothelialisation following NOX2 inhibition. 
6.3.3 The effect of NOX2 inhibition on atherosclerosis 
One of the concerns identified from work in the present study is that the increased 
inflammation associated with NOX2 knockdown may ultimately lead to a corresponding 
increase in atherosclerosis. Indeed, it is possible that the improved vascular repair seen in 
the ESMIROxGP91phoxy/- mice is actually a prequel to a pro-atherosclerotic state. Clearly, 
before pharmacological NOX2 inhibition can be used as a therapeutic intervention, more 
work is required to confirm or refute this hypothesis since a pro-atherosclerotic tendency 
would severely limit the applicability of this strategy in clinical practice. One way to 
investigate this would be to cross ESMIROxGP91phoxy/- with ApoE-/- mice to create triple-
cross progeny. A comparison could then be made between ESMIROxApoE-/- and 
ESMIROxGP91phoxy/-xApoE-/- mice with regard to atherosclerotic burden via en face 
analysis of different portions of the aorta, as published by Gage et al [13]. 
6.3.4 The effect of NOX2 inhibition on other NOX isoforms 
One aspect of NOX2 inhibition that hasn’t been fully addressed in the present study is the 
effect on other NOX isoforms, and in particular NOX4. Previously published work has 
demonstrated that NOX4 expression is increased in response to NOX2 knockdown [214], 
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and this may have a significant bearing on the findings from this project. As discussed in 
section 1.2.2, NOX4 differs from NOX2 in both structure and product, with hydrogen 
peroxide being the predominant ROS generated by this isoform of NADPH oxidase. Further 
differentiating NOX4 from other isoforms is the possibility that NOX4-derived ROS have a 
protective effect within the vasculature. A recently published paper demonstrated that 
NOX4-/- diabetic ApoE-/- mice suffered with increased atherosclerosis compared to diabetic 
ApoE-/- counterparts, and that NOX4 overexpression in human aortic ECs results in reduced 
expression of profibrotic markers [230]. Extrapolating from these findings, it is plausible 
that the benefit seen following NOX2 knockdown with regard to EC migration and/or 
vascular repair are influenced to some extent by an increase in the expression of NOX4, 
and therefore the abundance of hydrogen peroxide. Whilst preliminary data comparing 
NOX4 expression in ESMIRO and ESMIROxGP91phox mice was obtained (see section 
5.2.4.3), the sample sizes were small and the results therefore not conclusive. Therefore, in 
order to investigate the hypothesis of NOX2 knockdown leading to compensatory NOX4 
overexpression, the first step would be to undertake further RT-qPCR, followed by an 
assessment of hydrogen peroxide production as a marker of activity. Whilst not 
demonstrated in our preliminary data, based on the aforementioned papers, we would 
perhaps expect increased NOX4 expression following genetic NOX2 knockdown. It would 
be particularly interesting to examine whether this is also true following pharmacological 
NOX2 inhibition, which could be achieved by analysis of lysates obtained from the 
experiments on transduced HUVECs. 
If increased NOX4 mRNA is associated with both genetic knockdown and pharmacological 
inhibition of NOX2, the next step would be an assessment of the contribution of elevated 
hydrogen peroxide levels to EC migration and ultimately in vivo vascular repair. A potential 
strategy to enable this would be the creation of murine model which combined 
endothelial-specific insulin resistance with genetic knockdown of both NOX2 and NOX4.  
6.3.5 Pharmacological NOX2 inhibition in whole-body insulin resistance 
As discussed in section 6.1.4, when combining genetic NOX2 knockdown with whole-body 
insulin resistance, the resulting mice had a phenotype which mimicked the 
immunodeficient condition CGD. Since the IRKO mouse represents arguably a more 
accurate representation of human insulin resistance than its ESMIRO counterpart, this 
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observation is concerning as it suggests that NOX2 inhibition in insulin resistant patients 
may result in compromised immune function. However, this apprehension needs to be 
balanced against the knowledge that genetic NOX2 knockdown appears to provide a 
significantly more potent enzymatic inhibition than can be achieved by pharmacological 
means. Therefore, it would be instructive to implant micro-osmotic pumps containing 
GP91-ds tat into IRKO mice in order to observe the effect of chronic pharmacological NOX2 
inhibition in the context of whole-body insulin resistance, with a particular focus on 
immunodeficient sequelae. Provided the mice proved healthy and viable, vascular repair 
experiments could then be performed to investigate whether pharmacological NOX2 
inhibition can rescue the impaired re-endothelialisation associated with the IRKO genotype 
[12]. 
6.3.6 The extent of superoxide production suppression achieved by 
pharmacological NOX2 inhibition 
One of the reasons postulated for the beneficial effect of pharmacological NOX2 inhibition 
on EC cell migration in vitro failing to translate into improved vascular repair is a failure to 
reach the required dose of GP91-ds tat in vivo. As discussed in section 6.1.2, it is unlikely 
that the concentration of GP91ds-tat reaching the relevant tissues in the vascular repair 
experiment reached the 50μM used in the in vitro assays. The ideal way to address this 
uncertainty in future would be to accurately assess the extent of superoxide production 
being achieved in vivo, and then adjust the dose of GP91-ds tat accordingly to ensure 
sufficient enzymatic inhibition. One possible method to achieve this is to harvest aortae 
from mice following chronic in vivo exposure to different doses of GP91-ds tat, and then 
perform a DHE assay on the explanted tissue. However, whilst the DHE assay used in the 
current study is a useful and widely used tool for superoxide quantification, it must be 
recognised that all existing techniques for identification of oxidative stress have 
limitations. The main limitation of the DHE assay is the fact that DHE oxidation yields at 
least two fluorescent products, which have varying specificities for superoxide. In order to 
improve the accuracy of the assay, high performance liquid chromatography (HPLC) could 
be used to isolate the fluorescent product of interest, allowing a more representative 
assessment of the level of NOX2 inhibition being achieved.  
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6.5 Concluding remarks 
Whilst great advances have been made regarding the prevention and treatment of 
cardiovascular disease (CVD) amongst the general population, the incidence and mortality 
rate of CVD among patients with diabetes mellitus remain concerningly high [4]. Our lack 
of effective treatments for the insulin resistant syndrome which underpins diabetes 
mellitus, as opposed to simply the hyperglycaemia which results from it, is accepted as one 
of the likely contributory factors to this observation. As such, there is an impetus to 
explore new avenues through which novel therapeutic agents to treat insulin resistance-
associated vascular disease can be developed. One area that has provided promising 
results is the modulation of ROS in order to improve vascular repair and regeneration, 
processes which have been demonstrated to be impaired in the setting of insulin 
resistance. At the outset of this project, the aim was to study the effect of inhibiting the 
production of NOX2-derived ROS on angiogenesis and vascular repair in models of insulin 
resistance, with the ultimate goal of assisting with the translation of a potentially 
promising concept into clinical utility. 
A number of the findings from the present study are encouraging and, whilst being novel, 
also correlate with insights and hypotheses borne of previous work. Key among these are 
the observations that, firstly, in the setting of endothelial insulin resistance, a 
normalisation of the redox state via NOX2 inhibition significantly improves EC migration, 
and secondly, that this translates into augmented vascular repair provided that NOX2 
inhibition is complete. These beneficial effects provide hope that NOX2 inhibition may 
potentially become a useful tool in the treatment of insulin resistant patients; however this 
project has also served to highlight pitfalls that need to be investigated before this 
potential can be harnessed and utilised. Our findings corroborate existing concerns relating 
to NOX2 inhibition and compromised immune function, as well as supporting to some 
extent the notion that inhibition of NOX2 runs the risk of inciting a pro-inflammatory state. 
Based upon our findings, and those in the existing literature, NOX2 remains a potentially 
suitable target for therapeutic intervention. However, what is required is an ability to 
carefully modulate its activity to a degree which augments endothelial function, whilst not 
curtailing immune responses or promoting inflammation. In order to achieve this, 
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regulation of NOX2 function would ideally be controlled both spatially and temporally, 
whereby the inhibition of ROS production is specific to the vasculature at the exclusion of 
immune cells, and would be of a sufficient duration to improve vascular repair but not so 
prolonged as to generate a sustained inflammatory response. Such nuanced manipulation 
of NOX2 is not currently possible and in order to expedite it, a greater understanding of 
the roles and interactions of NOX2 is required. It is hoped that the work carried out in this 
project can be built upon in order to facilitate that understanding and ultimately generate 
therapeutic agents which can benefit many patients in future.  
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